var title_f25_61_26576="SPECT scan in brain death";
var content_f25_61_26576=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F76427&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F76427&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 528px\">",
"   <div class=\"ttl\">",
"    Two-planar imaging with HMPAO-Tc99m",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 508px; height: 364px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The top figures show anterior posterior and lateral views of a normal scan with uptake in the brain. The bottom figures (same sequence) show lack of brain perfusion and the \"empty light bulb\" and \"hot nose\" signs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of G Bryan Young, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_61_26576=[""].join("\n");
var outline_f25_61_26576=null;
var title_f25_61_26577="Follicular thyroid cancer";
var content_f25_61_26577=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F75526&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F75526&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Follicular thyroid cancer: Appearance on surgical histology",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Surgical specimen demonstrating thyroid epithelium with follicular differentiation extending through the capsule of the tumor and invading a blood vessel. Vascular invasion carries a worse prognosis than tumor capsule penetration alone.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephanie L. Lee.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_61_26577=[""].join("\n");
var outline_f25_61_26577=null;
var title_f25_61_26578="Gentian violet: Pediatric drug information";
var content_f25_61_26578=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Gentian violet: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?40/5/41042?source=see_link\">",
"    see \"Gentian violet: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/19/3380?source=see_link\">",
"    see \"Gentian violet: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1047568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibacterial, Topical",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antifungal Agent, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1047563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/5/41042?source=see_link\">",
"      see \"Gentian violet: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Oral candidiasis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants: Apply to affected area (under tongue or on lesion) twice daily; solutions diluted to 0.25% to 0.5% may be less irritating.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adults: Apply to affected area once or twice daily; solutions diluted to 0.25% to 0.5% may be less irritating. Do not swallow.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F176028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical: 1% (59 mL); 2% (60 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F176015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1047571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Apply to lesions with cotton; do not apply to ulcerative lesions on the face. Keep affected area dry and exposed to air.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1047570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of cutaneous or mucocutaneous infections caused by",
"     <i>",
"      Candida albicans",
"     </i>",
"     and other superficial skin infections refractory to topical nystatin, clotrimazole, miconazole, or econazole",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6052748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Gentian violet may be confused with gentamicin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F176044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Necrotic skin reactions, staining, vesicle formation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Esophagitis, gastrointestinal irritation, ulceration of mucous membranes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Hemorrhagic cystitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Burning, irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Keratoconjunctivitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Epistaxis, laryngitis, laryngeal obstruction, tracheitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic contact dermatitis, sensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1047573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to gentian violet; ulcerated areas; patients with porphyria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1047562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May result in staining of the skin when applied to granulation tissue; tracheitis may result from swallowing gentian violet solution, laryngeal obstruction following frequent or prolonged use",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F176024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1047561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical antiseptic/germicide effective against some vegetative gram-positive bacteria, particularly",
"     <i>",
"      Staphylococcus",
"     </i>",
"     species, and some yeast; it is much less effective against gram-negative bacteria and is ineffective against acid-fast bacteria",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1047566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/19/3380?source=see_link\">",
"      see \"Gentian violet: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Drug stains skin and clothing purple; proper hygiene and skin care need to be used to prevent spread of infection and reinfection",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1047574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     0.25% or 0.5% solution is less irritating than a 1% to 2% solution and is reported to be as effective",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13333 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-12D3B89698-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_61_26578=[""].join("\n");
var outline_f25_61_26578=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047568\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047563\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176028\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176015\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047571\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047570\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6052748\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176044\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047573\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047562\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299399\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176024\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047561\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047566\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047574\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13333\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13333|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/5/41042?source=related_link\">",
"      Gentian violet: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/19/3380?source=related_link\">",
"      Gentian violet: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_61_26579="Elbow ligaments and capsule";
var content_f25_61_26579=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F72889&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F72889&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Elbow ligaments",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 333px; height: 565px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The capsule and ligaments give stability to the elbow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pring ME, Wenger DR, Rang M. Elbow: Proximal radius and ulna. In: Rang's Children's Fractures, 3rd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_61_26579=[""].join("\n");
var outline_f25_61_26579=null;
var title_f25_61_26580="Nafarelin: Drug information";
var content_f25_61_26580=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nafarelin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/37/18005?source=see_link\">",
"    see \"Nafarelin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F199096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Synarel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F199097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Synarel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F199127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Gonadotropin Releasing Hormone Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F199099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Endometriosis:",
"     </b>",
"     Intranasal: Females: 1 spray (200 mcg) in 1 nostril each morning and the other nostril each evening starting on days 2-4 of menstrual cycle (total: 2 sprays/day). Dose may be increased to 2 sprays (400 mcg; 1 spray in each nostril) in the morning and evening if amenorrhea is not achieved (total: 4 sprays [800 mcg]/day). Total duration of therapy should not exceed 6 months due to decreases in bone mineral density; retreatment is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F199114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Central precocious puberty:",
"     </b>",
"     Intranasal:  Males/Females: 2 sprays (400 mcg) into each nostril in the morning and 2 sprays (400 mcg) into each nostril in the evening (total: 8 sprays [1600 mcg]/day). If inadequate suppression, may increase dose to 3 sprays (600 mcg) into alternating nostrils 3 times/day (total: 9 sprays [1800 mcg]/day).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F199100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F199083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Synarel&reg;: 2 mg/mL (8 mL) [contains benzalkonium chloride; 200 mcg/spray; 60 metered sprays]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F199070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F803173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nasal spray: Do not use topical nasal decongestant for at least 2 hours after nafarelin use. Allow ~30 seconds to elapse between sprays. Sneezing during or immediately after dosing should be avoided (may decrease drug absorption).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F199084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of endometriosis, including pain and reduction of lesions; treatment of central precocious puberty (CPP; gonadotropin-dependent precocious puberty) in children of both sexes",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F199133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Nafarelin may be confused with Anafranil&reg;, enalapril",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F199125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Adverse events may be more frequent in the first 6 weeks of treatment due to stimulation of the pituitary-gonadal axis. Sensitivity reactions included chest pain, pruritus, shortness of breath, rash.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      CPP:",
"     </b>",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Emotional lability (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Acne (10%), seborrhea (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast enlargement (8%; transient), vaginal bleeding (8%), hot flashes (3%; transient), vaginal discharge (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Pubic hair increased (5%; transient), body odor (4%), sensitivity reactions (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Endometriosis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Central nervous system: Headache, emotional lability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Dermatologic: Acne",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hot flashes (90%), hyperphosphatemia, hypertriglyceridemia, hypocalcemia, libido decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Genitourinary:  Vaginal dryness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hematologic: Leukopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cardiovascular: Edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Central nervous system: Depression, insomnia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Dermatologic: Hirsutism, seborrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast size reduced, cholesterol increased, hyperlipidemia, libido increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Gastrointestinal: Weight gain/loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Bone mineral density decreased, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Respiratory: Nasal irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Arthralgia, breast engorgement, chloasma, eye pain, lactation, maculopapular rash, palpitation, paresthesia, sensitivity reactions, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Postmarketing and/or case reports (any indication): ALT increased, AST increased, liver injury, pituitary apoplexy, pituitary gland changes, seizures",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F199087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to gonadotropin-releasing hormone (GnRH), GnRH-agonist analogs, or any component of the formulation; undiagnosed abnormal vaginal bleeding; pregnancy; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F199074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ovarian cysts: May occur within the  first 2 months of therapy and may occur more commonly in women with polycystic ovarian disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pituitary apoplexy: Rare cases of pituitary apoplexy (frequently secondary to pituitary adenoma) have been observed with GnRH agonist administration (onset from 1 hour to usually &lt;2 weeks); may present as sudden headache, vomiting, visual or mental status changes, and infrequently cardiovascular collapse; immediate medical attention required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CPP use: When used for the treatment of CPP, some signs of puberty (eg vaginal bleeding, breast enlargement) may occur but should resolve within the first 2 months of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Decreased bone mineral density: Use with caution in patients with risk factors for decreased bone mineral density; may pose an additional risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F199078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Luteinizing Hormone-Releasing Hormone Analogs may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F199080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2929271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Major fetal abnormalities have been reported in some animal studies; a dose-related increase in fetal mortality and decrease in fetal weight was also observed. Ovulation is inhibited and menstruation is stopped when used appropriately for the treatment of endometriosis, however contraception is not assured. Nonhormonal contraception is recommended. Pregnancy should be excluded prior to initiating treatment. There is no evidence that pregnancy rates are enhanced or adversely affected by use.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F199102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F199089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Synarel Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/mL (8 mL): $1477.32",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2929987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     CPP: Bone mineral density, GnRH testing (blood LH and FSH levels), measurement of bone age, Tanner staging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endometriosis: Menstruation, vaginal bleeding or spotting which persists after 2 months of treatment",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F199090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Nasanyl (JP);",
"     </li>",
"     <li>",
"      Nasarel (IN);",
"     </li>",
"     <li>",
"      Synarel (AU, BE, BF, BG, BJ, BR, CI, CZ, DE, ES, ET, FR, GB, GH, GM, GN, GR, HN, HU, IE, KE, LR, LU, MA, ML, MR, MU, MW, MX, NE, NG, NL, PL, PT, RU, SC, SD, SG, SL, SN, TN, TR, TW, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Synarela (DK, FI, NO, SE);",
"     </li>",
"     <li>",
"      Synrelin (AR);",
"     </li>",
"     <li>",
"      Synrelina (CH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F199073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potent synthetic decapeptide analogue of gonadotropin-releasing hormone (GnRH; LHRH) which is approximately 200 times more potent than GnRH in terms of pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Effects on the pituitary gland and sex hormones are dependent upon its length of administration. After acute administration, an initial stimulation of the release of LH and FSH from the pituitary is observed; an increase in androgens and estrogens subsequently follows. Continued administration of nafarelin, however, suppresses gonadotrope responsiveness to endogenous GnRH resulting in reduced secretion of LH and FSH and, secondarily, decreased ovarian and testicular steroid production.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F199086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: 80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Degraded by peptidase; forms metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~1% to 6%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~3 hours; Metabolites: ~86 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 10-45 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (44% to 55%, ~3% as unchanged drug); feces (19% to 44%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Hornstein MD, Yuzpe AA, Burry K, et al, &ldquo;Retreatment With Nafarelin for Recurrent Endometriosis Symptoms: Efficacy, Safety and Bone Mineral Density,&rdquo;",
"      <i>",
"       Fertil Steril",
"      </i>",
"      , 1997, 67(6):1013-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/61/26580/abstract-text/9176437/pubmed\" id=\"9176437\" target=\"_blank\">",
"        9176437",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tahara M, Matsuoka T, Yokoi T, et al, &ldquo;Treatment of Endometriosis With a Decreasing Dosage of a Gonadotropin-Releasing Hormone Agonist (Nafarelin): A Pilot Study With Low-Dose Agonist Therapy (&ldquo;Draw-Back&rdquo; Therapy),&rdquo;",
"      <i>",
"       Fertil Steril",
"      </i>",
"      , 2000, 73(4):799-804.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/61/26580/abstract-text/10731543/pubmed\" id=\"10731543\" target=\"_blank\">",
"        10731543",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9673 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-24348CF07F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_61_26580=[""].join("\n");
var outline_f25_61_26580=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199096\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199097\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199127\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199099\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199114\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199100\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199083\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199070\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F803173\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199084\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199133\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199125\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199087\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199074\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299735\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199078\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199080\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2929271\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199102\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199089\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2929987\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199090\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199073\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199086\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9673\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9673|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/37/18005?source=related_link\">",
"      Nafarelin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_61_26581="Atrial activation after maze or radial procedure";
var content_f25_61_26581=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Schematic representation of atrial activation in sinus rhythm and after the maze procedure or the radial approach",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 391px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal activation sequence of the left atrium is maintained with the radial approach while it is altered with the Maze procedure. Thick lines represent the surgical incisions and the solid areas represent parts of the atria surgically isolated or excised; dashed lines represent normal conduction pathways between the atrial appendages, the interatrial septum, and the crista terminalis. Arrows indicate the activation sequence.",
"    <div class=\"footnotes\">",
"     AVN: atrioventricular node; SAN: sinoatrial node; RAA: right atrial appendage; LAA: left atrial appendage; SVC: superior vena cava; IVC: inferior vena cava; PVs: pulmonary veins.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from the Society of Thoracic Surgeons. Netta T, Cox R, Schuessler RB, et al. Ann Thorac Surg 1999; 67:27.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_61_26581=[""].join("\n");
var outline_f25_61_26581=null;
var title_f25_61_26582="Conglomerate shadows PA";
var content_f25_61_26582=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F72316&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F72316&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Large opacities in pneumoconiosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 365px; height: 350px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFeAW0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5WoroLfwtfz42KCTx0NWl8GX+7azRq3HBzn+VAHK4pcV3Vl8ONWvH2wFXbjhUY/yFbtr8E/Es+z90yBu7QSYH/jtAHlO2jbXtkHwA150DPeQJ6/uZP8Ktr+zxqxzu1W2X/tg9AHg+KMV7037O+pjga3Z5xnmF6o3/AMANctkDJqNlMMkfIknH14oA8j8PW4ude02FlDCS5jQgjOcsBXp194cijnQfZYh8o48sep9ql0L4ValpWu6ffXF3bPFa3CSsqq4LhWBIGR7V6Hf2CzTb1QgEBQGHP+eaAPNh4ehjQFrePj0UUyPRYmcgQJ17LXoSaOzLypzwBmrdnouxxgEsQBgZPNAHC2HhpJBk2qsBnOE612Oj+FSwVLe0QL0MmwBR+NdxpGgJAA14Pk6iIEgk47+ldLaWwVVOwCMfcUdBxQBg6F4Yt9NRzcJFJM3UICABxW4kcSoEjiVAOwGKsmMDcrZK443kn88/1qC4uYbcjzJMDpg0ANMIJ+UADrUEkAzkqCc54+tFxqdpDt8yXbn/AGT60faomXMTq/rjvzQBE0e3GF7jnNNCLkYHUZPWpGdGDYJBFRYJK/gCOxoASSLAPAyRnPPpVGS0JyGcH8Kv5BI4OCAc1TuCVb7xzn0oAqf2buKzFzvQ5U7enGOPw4q+kX7kjnj1zipASbfaPvHofSmQsASCxLAGgB4h5OfXOakTBHGevfigNu5J/HmlQnIyeOvH1oAXaQM7fwHPepkhUMTt5JySB1pgkBYgYJzUc93FCDvY8dcdqAL8UeV4B5xzVSSMpKxVAM9xwear2OqfaYmbytq/w/PkkVBba00s/lyQLtPQ+bknr2xQBo+RDLxNErHHJ6dulcvrPhKC4kZ7RhH8w2q5OG4HQj39a7FYwwDICARn2/GiW13QbQp9m9DQB5DqfhiSzlYzRbc5A9D06Gq0Wjt3Udc4xXrMkTPG8UyB0P3lbvWVqGi7WaS2UmEH7uSxH4+lAHER6FDJGVaNTk8A9etWtP8ADOL6F1XKKwJBB45/OustLWPBynPqa07O3WKYFcenAoA+Qvinbi28e6xGowBMCB9VBrk8V658ZfCWu3vxB1K503RdSu7aURssttaSSITsUHlQR1FcSvgbxU5wvhrWzn/pwl/+JoA5kClArql+H3i48jwvrf8A4Ay//E1NF8OPGMgyvhfWMeptHH9KAOQxxSFfSu2X4Y+NCCR4Z1QfWEiph8KvGpOP+EcvwfdR/jQBwNFd83wo8aY/5F67H12/41w1zA9vNJFIpWRGKsp6gg4IoAiooooA+8dG8H6TpBD28CM+eHZcnH49K1DptiJTIbS2LkjkxDJqczBmIQ5GeTigcYHJHvQBJEwhT90iRqeMKoXj8KkEuerZx255qAck/h0oXaOT/KgCcy9gecdAeae0hXjPtVPzFOSuMjuB0phvY1HLcng4H0oA0BIGXkA57U0BcdMVSW6jPTI4z0zUu8HGCD3+lAEN9pltcgkopbP0P51hXnhxN7GMsoB/u5HX1ro9/TsfpQZTuPTB9KAOQbRnR87NxIx3q9YaYLRg4T94emM/JxW+SuRkA+nFN+Uk8Y6daAKMUGDvndcE9O9R32qW9oApcBueSDVuZVfAYgc4FZlzpwky4KZHouT0oA5zxb4yk09Ehsot1xLnLOMbV9fr6Vy1pd6tfXDOZ53P3mXeTj0xVLxL4cv5NUuriUajKr8gKmFAA45Fc/e3v9lkQCaZHx0II2/jQB6QHvI1UzNI5HUHJ/z1qxF+8bK5hkPzFlzxz6V55Br99GkcsUxeN+RkEqexzXQad4n+0FVuYgjY5ZFyBz6ZoA6y1v5orkQzAurNgSc8itcPnHJ+b26VzNncLMxZcNGTyQMd+4rcgOY0BORgYx6UAWsjjPAHqKzruSRJRhSQTwcZq4Ccjj8MVVvTIjjYwHPcUAILoCNHwcDrx0pLOdpZZGPAGeD61HEGMBZsfiM1LafeIfA/DHNAF+JyRx15qTftAJ5wKhQ54XO3nPbNRTqzLgce5BoASWd5JNiDBJ5xniop4N6E3DMeM+UCfXuanVo4E2jlu5I5PNZt/rNrGr7SZJV/hA/nQA/ZJj90xClR0GMD61wmqz3lpqEmx2Vd2SST+laF14wlMDQxeRAScbihO0fWvNfGN219dm4t7mW44CuOSc880AeueE/E026O0uZy+8kq53Z6dP0rvorjcnLkN/MY/wA/lXyLpkji6jd9+I2Dcg8Ef1r0FfFurCSAxxSCJQBwrZxj1zQB9ALKkxIcKcdiOaeI0BJPy5/EV5j4V8TatczyJdwKYsEo8ikdunWu80q8+1wZmQxkZHy8igB95ZiMmWLJUn5gDkD6DtUUeOF68ZxyOcithEKqf4h79DSi3iVy2ACecAUAZ8Vm8uBhgv0NaNvp6IBgEn1qVCq5xjFK0nAJ6YoAeIIlA3dgOtSrt7DoMVVD525PP0oM4GTuG0ccL3oAt5GOcU7bleccfWqYuEPIBz3z0qdJAec9aAJSqjGPXJIFfAfixQniPVVHQXcwH/fZr77aQY7fhXwN4zG3xXrI9L2cf+RGoAw2pKU0lAH34JAGP1705ZzjGeePwqnuYsccDPp1oyemewoAttKcDik3sTwvvVVmO30OM54qRCCoPUmgBHmlW4WP7O7QMufODLhT/dIJz9CAe+ccZcF3H8M05mBAAFMkcIDnOSKAH7gznZj39qe8p6EfKc9KrrhcY56+lIxJ7fXigC0k5UAcZqVWYg5XHPaqUa5IOOM/nUzvtHAB44oAn3YweuOtQSTnIB4xzzVK8mPlFYzgkdfT35rDgv47EwW/mmQkYywGT6k47k8k96AOjDnICjnoT6daf8xXjistL9XUHayjOOBmrSSHYcsOe/GRQBH5bOSGk29eQtUn0e3mZjcItxjkB4xWuAjHnrjrjGaeQqhgRj3oAxru1sre3CrYWuOyiJazI9PtoUe4ttPtIwWyQYvm61qapcQReX5snzMflDcbqijVpgJFPycgY9KAK8RjLZWNVJPp71cjRVjDKB154pnkqJCMc98dqV/3JQc9snigCZDwNoxxnmqN4f3uOBwAeParcbDjbmqt1GHbKkbsjsKAHWwDRnIyD7c0kQHmEnqR07UsCsqHAOc0qJiQtyMdRQBbjIG4AYH0pCd27IAx1x25pFOHIyMdqGBYFAckjPTFAFWdoij79oXHPvWKdPt4bjzposKT0XqTk9fXtWhdxYuYySCqt+RqK8ga8LJtJA9MZx9aAKUWlaXdCWJCybgNxwAf51Vt/B1s843TI67cA+SOalgjtrO+RHfDMMFeprqrKNPLARcx4zwaAMvTPClhbRxxyokiKMktGvzEjritWLT9Mi/5dIzgkjKD060y5mEBwYycn+dQC8h8r998gBznIFAGxHBaxAmK3iTHogpVnOCEC+vFV3ZfIbY2DjOSMAfjWfHfRxBn8wzAfKRFhvftQBvw3DZKnOe4NWI5ASccHtzXPW+pwXMg8tDkcjeBxz/+qrXnSbgw4HYUAbG8AHgYzzgU1Z+2PQVUSUORkjd6UxnwowenUUASF5muMl08jYPl2kPuz1znGMe341Mc4JXAPoKpu/Q8jI9aWGQkAMSOccd/SgC2jEHJHU/lV2N8dgMjv3NZ77QQwzknGDU8TBV5wT6mgDQByOMZ9TXxh4x8GeI5PFOsSQ6DqbxPezMjrbMQymRsEHHQ19ilg2VO7BBHFSKAAFG4DjHOaAPhpvBHifBP/CP6pj/r1f8AwqM+DvEgP/IB1T/wFf8Awr7twMjI5p0ZAX5QfyoA5Uy9gTnOKeXwc5zVNX7Hg9c1Mjgk/Mc+lAFnecg4/wD109Wwoyeg7VXD5Yc56c/5FKHx0br1oAs7yBnNK7Dc2f17Hiq4f5c9/c+1NZ8Eg46djQBOX9B1pV+bGOnNVw/IJ61PHnPPUnmgCwDhTjhfTvVa5lCnLnk9MfWpZZCEGOcHgZ6Vi6rfRWwLTDzH7Ip5xnv6fSgCbUpTJal0IAXBLlgoH1PTFcLqOtadagEo9xMOpjI2Dj16/l+dWvEeoTX+hXAZj5cZV0RTg8Hnjv681xmnWst9fwwWbbsrllfuO+KAOyttek1CBVj3hSAQABjp+ddHpCIIsyBi2OprM0PSfJthAqEHPIH+NbEMM8M6CJU8sA5DsOKANWVIyjZJUYz8prkNd8TXWmXNwsRZkiTeVZQQQAD+tdVPIGiZHkQFwR15P+c1Qv7SFtNmt5mZ0KN1YZII5HHagDh9N8X6Trtz5brJZ3mc4k2+WxzgBcnOfat201HekvlugCnClOmaw5PA9mbl5bZ2hP8AdXDBcnjA6j61t6fozQQKZrgSyZI3FsBueuMelAGjpN28qt5vLZ5PHX3p95ZJe3lncCa4je2csvlyYV8jlWXow6e4I4I5yyCKOMt5ZVTxnnvmrNqrRBYmJI65J9aALKqPl5x9KQlcgkHr3pEY4Hp29qQ/w4agBVCngE0qgBiR64FImeMEcdRmnY+bjAPPFADgMnIxz/KnRzxvbiWM/KeRkY7+n50gYjvjHelupgtsRuwMckEUAY19e28Um6Rsvu6Z4rDutSnvG8uwfEgPyqAAD+NaX9mtK6ts81QTjnjr1PtUkNtcWZEdlGm52y7E/c56CgBlnpbi2glufLSQbSTI6j61oXWsWunhFjLSyN8uIV3gHFZptLma+M17cxBBgIA+7Gfw/WrNpDJvliK7QmCGJHJIoAdPr8AAUW07ScEblxn8u9RW94s5VnCIh4PH4dTV2W3y/UkYzu/z9aijClX8xRhegz7UAcf8QtQY+TExaVWDcAewrjbC8a0YNA7w45K55A969T1nSLLVkkkZSkincSpwOOK4/VPCHmJNNb3ihR1jPHIHc+lAHReHNTnKyTaiqMvRZFUZx1ySOtdLa3aPloJFkQgnAIyK4Ke3vbTRYEmVjtGcj7vaotE1K4S4LGRVGCAOB3/zxQB6pHMHAJPNLNOscKyOGI3KpCqWyWYAcDtzye3WsDTdVEwCt8rDHXjdzWrBcbz82OtAFyXbjPI/lTkcFcjioi2TwP1qIEjODxnoaALqOOSWHPY4zirEbjJyfYGszeduM4HepUm6gn5s9ev40AaKuM/LT1kHB6nnHNUBOCT8wHrT/NI5B5z60AaAnxkn8fanxzjHLYrKNwMnnHT+dKlwOctn6UAYu84Xn071OkmD2zVVecg8jPSpcn0wD6k0ATb+QAcDrkU5HzwTUROcY6D3NSR88nPp+lAEm8kHJz3PNK7kljkgjqetR9vyoV8hvlYEfLz/AEoAnj5ZfmGB175q0SVXcTz2596rwDPTOOv1pt/dCFAF5Y9D/WgCO6v/AC8oGBlHJ7gVzmoneJHkPJ+brjNOuLhzPujVnfceBn5uac9osv727ODzuiJOevegDL0cyX9yLeFAVBGWYYGO4zXSaD4Vs9JmaWBmLH35xg8dKl0dCXARMKD1JrfiAQZY7QB0PWgCpJKiSEnjpz0qnI8DSAecA+cgZGOaS71TT5NQS0jctcMcAZ4YgHP5Yry7xl4n1zQ7idYohbxH5Q6ruDEr13Y7UAelXqrJdKpVSyrkoGwx98GqGuXirGYmuYRMwbBZwOeMc14lZ+Mb4TiS4upyFbd945J+vpWtqXijTrkTeYLl3IAWUyEhTjrjjFAHe2xvkjTzJldi2N0cmec98V1FlMzwJl1ZlzuJFeGWuszrcGWwunMh5KjIJHoPxrvtC8Y+VBBFfuscxYI4J+6c9/woA7EQxyTNInHTgnFWWjyq727dB6Vh2+v6deStHazr5gfDAbgD6YOMHpWys67yRymBj5utAD4wAMDlTxzTcZYfXHNTRjK5BznB6mo2OB17+tACAkqVp4O8nPQetNXPPP4805T68Z7UASDIOep6VV1KLzLcqxPXOAferY+779Kg1MOtqzxnBoAqW7GCIlGwh6c8n8KWW6lXaCQAw+YkDisC68TWNh98l5R8xjUE89OvSuL8U+LLm7mjW3Zo0b+ESHA5PagDvJ9Ys41laTYrIAdpIyR/SrnhvVoNSR1AIIAxk/eGP8BXmWq6xY2tn5Mk0bGdUbgktjPIx6/lWX4Y8aS2OoSmCLELFRh23FQM8CgD2+a/S3Kqyjyt2Ad3Q4rPu9Xt0uoIfKkkZlJLKwOOO9YreImurCF2AWVwHZhxgY4FYWpam32tYrdhGwwcqeMY9aAPQrW5tTkecULDkNio7zRBdNutJkKE5bYRj8q5/R5XlOHyFPG5sjJrrl220RZAcHrk8k0AZ+qiS3hZQCEXjHYYPFc8bCC6lMjuschP8BHPPOR9a3NQvLu43RCHzouRggjjPr61kh7ByQzrbXL8eXlmwQfWgBDaXIdmWVTGhwSp59M1sabdncsczAuAAG/pVC3ee1wrZMf/AD0BOG61bMayDfEACOvPX/CgDdV2yuCuM8knnpxikdiFxnkcGorOXdGMg7gO5OakfPPfj8RQAxpAFJxknpzQrkf72Oe1V3Ygkcke9IzbcknnGBzQBaE+Ac9eaUTkDk4BOMVQ871BHXA9KRpzjA47j86AL8kh6qw6+tRxzsGYDp65796qGXjnI5x160xJFHJJ57k0AWo+BjB9aTcfMUHAXpye+aaDuDZHPpzQmGA3YyCCOvWgCyDnqOffNPXPGQfzqMFcqR6fWpQTtxtPUfjxQAoOeMcU+P2700fdOOtSxgnljzQBPH8qsCBxnof845rMuEe4kYJkbW6mtF2zkKcDBzio3QhQB8qt6560AZM8CQkiGLM395etVJDDbHztRna3BOdpBLN26VZ1bUo7RDHbgNddPMPO3msKGzW7nhku7rzSxOVI4zn7o9uaAOj0PWUuWP2azeCLjLucsfwxxW/5XmRmQFvqCSawbaI2I/dgqjYJ4rSe/CYjUSNxkttPH1oA4nxXHJFKbiPMLRn76feHHOD2615Z4h1WbVJYrcTvcIzA7Wzg8enrXa/Ei71bVo2gtbVvJVw+/aQSACDkj6159oemC5uSt1eCCQjKtjoe3PagBt/4a8lSYbmDCglvnJHAzjp1rNkspYEAcYB6Ek8/T869BttK03TrUy6lZS3R5RxO7ruPUEBSOP8A69SWES3wujaWgMECfKoViyOe4zzxjrQB5vqEskIiCK0Ui5+YZBzUsOpNMqiZTuQ72dckt9fWvULuy0/XLCOyksof7VjYgKcoxyQMk/zq7a/D/TrdShDMMbRJyfrmgDznTdSllVBC3KPuJBO7Of0r0/wvq4uIwszN5gAGCxPPqKwrLwXFHrAhjYPHu+VoyQQMnj3rptL8Py2c6vGFk3dRjGB2oA7GEnyVznJ6c9qQ4yOlK2YoIwBgqoGOfSoQfujnHvQBKD8uBjvnmnDAORyPbNNBG0kDH0p2cgEduwyKAJBwxzkehp8m2RPLYZBGKj5znJzjoasIMgD19qAPP/FHg93tpH05PnHzeXk5YcdK8nutNv2vHtmgNs5YqXlY5GDyQK+no4wSA3T6dOa8++JGn/vd6RNuk5jdR918/wBRQB5JfeH5bGYJdJJcSMF2su7Bz3BPWt/wb4It5xPJeyurhA0ar179RWncwPZ6bCLvfczOA3mlj+755UHPXrW94DEsdlciclFXhXOBuGDigBq+FZpYIk8ySEBQuGbOQBxxVq28LW9q5mlfz3Lcb1ICjHTjqeKdc30sUtqkhVhxnDYbkcd615zciBJIsyKNu45OVOORQAyCJpJ5W2RbRgKgzgADpWnGJzBInlFsjBIOc1VshGXdmZ1JORuXgjjkVqWtwrOwi3Djrg80AZVzbypFmTIJGO/rXDa3YhpxKjMoR9v3jyc16tPhwAzZXv2rntZ0a3n5g3I/PCjOD64oAxdNvkt4lS4JaMj+Ik4+vrWtC8U+17dgBgYAzzXI6ha3trI0UsbyIOd4QkDk/r7VN4fvboyA8pGpXgqSG55AGfSgDuotyqARgjFTt/qwazbZyxMskm5mxkdAvsBnp+tXs4iHXjigCvONuDk85wOahkJxhSTxnJqec/uyOOKrSEjr25oAjLcc+/UZqMOS20owA7460rE4JA6ZpGLBuckDgUANkbBwRkdsGmqwYsTke2ahnfAJPPHFRrIR0OBigDcOSMg4bHce9OjAGDnjimgjnODj2p8a4IzjcQBQBJkjbyf8+9SK3XBPr+lNX5go/AcU8FeMdDxkDrQA9fu455qyvfbnA64quFyOAOParKABeBnPtQA7bkkdumcYrP1actE0MbADrkg8kHj+VW7iQCMqp5A54rEvJgFbZH8w5yR05oA5lpN00v2hz8mcI4wCfrTrVruS8t47eEshYElVLYJPc9BWh/Yi6gYpL9pECncgT7xORx9OK3bC3RZwEjaNFIARBjI96AL8dtuSITzEsqgNGBgf5+lXWVIrGUxQFwR0XcST2qSGADDfLjA5PBH41UuPE+mWl7HbSK7SMSAVUbeh6nPt6UAeX+LZpLbzVt0nZCQBKrkhmx8yntmvPbuyvRiTypCpxhthG3jv/jXa+M/Et6yuNNt7Owtw+FkijPmE88ls+x6AV5NdXMguizyOzjGWY5zkUAdr9rmlSQXF1GDEucvIOMYBIBP6Dmlg8SzWE0jxywuJAVLIzDGcc4/CuEuZWkIB6j86ZI5MfHGOMUAek6Bq1r/wkvnz3aRJKGA+U5HOQOP5mvS7DVC9tPHbzQXAZMrxkjPr+lfNCKQVZT1/Q1qaHq1xpt8JYJGQjhtvcdxQB71ompB7iNZ12y+cFPlg4PP1JAroQCLjCcDOBjNeMWHi9kuYP9EWZd6kuBh+vbnBPPevY9KkV4beVXLCUBxkdAQODQBpXGcgYwNufrVcAA85BHep526EYPbiq+CMEAfjQA4ngZ4yO4p24Fvb1pmRjt+ApxHNAEgOCcHI9anj9TyTVWM5bjBqVWIYd+aANCBWyCTz+XeuX+Jeox2Giec6BxGysVK5BG4DB710kMhxkgEY/wAmvIPjZJdTxhFyIV/hzgZ3UAcp411xp7yOOyaNYWjSQMCRgkdBz2qmNduLLSXhhu3dX2qcDjPfHvWTHZtfRxnnMYA6c/SllieOAAKCOoGOpoAdPf3j3AkeeZiACCSew4rW0vxPrIkYrdXCR8Yw5GTjk5rkILmXzBCSdoJ/Ct97O4NjJdRAsEXJyQOMHmgDs4PGepIyxtdeYTkNI67vTjmuji8b7tw/0cKF5YbgT0968WtLgxsVA9/ariTOkWbsDhjtUjk5xzQB7vZ+L9PntlaacRy5IIwWC8+3tWkNVtLuFX06dJpsDAU/Mx6cA14JaEvbh4SzEk5X9a1tM1K5gMYeKPyUYuFxz16k5oA9Snlu5pmSRcKuASR15qvPp8anZapsAHucHPuai0vxUr26w3UAZQQBJjJ6+pOa1NyTxme0+ZSAD69aAKllPJCSsgIOO/U1twuHCMDlcf5FZkypcoI8bWHO7GCParViGjjWJuo6ce1AFpkzuJ9+fwqjKQWYeh/OrsxIDDqT/hVFwD2+oxQBX3HDZP1ODSb9y7X5Xpk0sikDPUEEdKr7mA46Z5oAjnOd2MnnrjrUUQGOuPrzTyTknC4/nzUSsBk4BzQB04IIbABzg+lOjwByeO3FRgYznG2pF55AHvx70AS4IIJX88cU5RkdKbgHp0p6Y4z0z27UATRjgDAzjuKnf5QTzkcY61CgwAc/yp8mGyoHOMUAUJSXmKry3pjIpq2yxMWJDSZ54A2n2q4kW1yVX5++cc1Dqk9rp6GaZv3ig/IMYP19aAIxaPNukkPkRt1c9OvaprPUoEne3hUOUPMki4B+lebeIfFk995cZyGLER7QNg9B/Kun8GalbrpYOoJsYng8E/ligDU1BZ7x2ktZS7oARu789u1cf4hia3MM0KqGkXLjP1B+ld5Y3VrMxS1RQXA4XGTTda8Iwat5LSKUVRu3KQDu9D60AfPPi27e6u2QL5bxHbgNngDA+tYVxE8tss/lDg7S3PPFeu+Mfh9bWf7+wndzuJYsV+UYz0ArkILKO0ureSRopHziSEqrKUx78f1zQBxBK7WLp7Cpre0mmZoUikckZGF46eteha1Jpf2dIrOztfnyVkEKq3A74AqzZ2b3Fs0uqSxRxMRsiRlG8Dr8o6AfhnmgDzU6ddW8LSyW0gjDbcleh/yKks9LurppEt4HkkC7iEGcDNevjQrfUtSs9O0kJsiBaaH5QSvqxI65Hb1qaSzl0zVEsooEggicLJs25kPBIz6e1AHC+EtDmuZlhdMNFywPUYPavYNFt/skXmMVABG3H8VXNAtLGOJpEtIElKn59g3Yye9VZ7aSSZBGWZF5OCOBmgDVLlwGAHzDvURm4HAz1xj/AOvUhRQgwTwBioAozwT170AO3jaOMg8DI/rT1fIwMH3FQFCQAeR1698U7GCSefTpQBOJOncY9KkDHPAGQOP8/hVcDIwOlSxD6Hn8qALsIJxgDkdfxrjPiFosuqwxpCqqwbJJPBA7YrsbdgeDuOOOD71V1a0S9Uow+bHynPINAHl1j4Uj8xF+0yJKAB8sWNuPXJ5/SofFPhaGxsdi3qxyghxuhwrE/wAOQTz716TZaUqsjPEXUdQOM+9L4o8PWN7pjuzyLLkMN3IHH064/lQB4ra+ELmeEO8kYjYgSSCPcUGOB171N42kk/suPTYYEiSAqu4IAzYXqTn8a7XS9OFhY3A8h5Eib92p+bcMDnArI8RGKXULf7VawodnzqF56defwoA88s9FvZkdo4gVjXJc9F/Wq89neLN5ZClk5wOO1emPYxW989jGstvbsm84YHnAPOOKmutGtm1BpbWMAEAt8qkbce/OeKAPP7ZrnT7IPHAyPN8rOy5wM9quRWcisjPLEm7kjqQOvr1NekS2cX9gqGWCUK2TGmCcgjr6daxtU8PafLH9p837JO5woSRChYHuvUZoAz9E1Cxt7aWG7MwZSvlsBx1Oc5qxaaq0Ya4siyRA4wRjPuBWHDoN0bqczBpIQwx5TA5GTzjrW1JAhhhWNNlvGAGPBJI7n9KAO50m7j1K1SRdokA5wMnpWpbNleQOvy5rh9KuI7XYbcEE4zniu002VLmNXXuM49KALc5LLnb07CqjjvgYPtVpvmBHOarS9NoJ49KAKU+S2QBjsMVCMDPH5U6f7x64J74ppOI9uOD9KAK05GCSMDqT0xVJZmYlolLL6nAH61MV8z53UkDOB6e/vSKQSc7s0AdccHIP6DFOTgdyOOnakcblySPzpyHCjnnjvQA8DKgHJ7c05FywDE+lCkcj1xT4cZPP4UATR5wcZ9P0qQDBO3OBxzSIPl56Z/pT1YKpY8Z9aAG3EwtUZmB3EHiuD8TNNLIWJPlsOv412V1IXDb/ALrDHuK56fTbi8cwxyBYQS2/0Ge9AHDzacsckEkYlnk8wFREP4s//qrpLXw5eT2arc5treL5mhJHmODz1HSuo0y0t9Et99vGZHkOGlz+vTpxUF7HLIsl357p8wbcZRGq89CSMY5oAi0zWls4QtrC/lw/wEAHA98/5wa1tG8U/aZXheN0dxlEJXd0OeleZeJfGFvbylrVvtM6Y3PbvtjPXgEr1+grnE+IOsRs0um+TaxrywjQMxGD/EwJ/LFAHs2u3NpqFkXJMNrNjEksix/kSfSvJDDpOnyu0utW8p8w4Ef7w4wRnsp6jj61zV3fz3YiluLx5w/zN5z5wfWqjCCTaXba4+8RyPY4xQB3dn4e8P3ryKdbJ6yIkaAnoM45qrO9jbiK30u6vZZVmKSElQxTjAxj13f1rmTdOyQiDZlRt3Y4Oc9R+NRabP8AZtWVpmKsW+ZgcEA9/egD6Q8IaLp9pbQ3SXTT3O0K77hwQenA69jmqfi6KEX8RWaAsTkiRgP1ry+51XVfDt9Zw6RqhFrcMWLDa4Zsj1FasOtzajrCHVp08pwJCrqFwMjpigDsdLucXKLEylMY3cH24xVmB3kuV25Bxz061yNnqNn9td7W4ktlV/l3Dhxk/p0611ukSs8vO04H3h0PvQBoSE9cj+lQktjqfpUr9uxqEkjJ7Z/HpQAw8g/MSMYzSngndz7UoOFJwR70ZBxg5PXrQA4Y7EgU5CeMn8qZn5cZGaep5xkD2oAsxMflHQj396lLDdwNxHrjrVdHGfUZ6596kWQF8jHXigCld308eoxRqp8thkljxXLeLPEOoQyQrZy4jX5XIA9Dmuq1a5W2ki3Lu3sBw2OaqWGmWWrSK97cxgA5IVh70AeQa74m1u28gfbWOxVbZx1YdfyIqLw5qOpXvnNJqixtETIPO2tkgZON3XpXpnjDwbpk0z3UV0EyBlCwwSBxivCDL/pZVNyHnOT1GPpQB1t5441vzcT3kFyrDBd7ePH4EKDTLzx3dX9nHBMkIWMnYNpXGcc9fauHW6LyMpGQzeuMVeuLF4GDKm5SARjn86AO/sPEkVtCpaXzWDBcALgj1OMGukRNO1yz3ieAzt0SMgM5Ddh3/CvGUjd5fkDKzHJ9Bz0rXguZIZFiVQHU8SA5zz1oA9NhtmjjKRJKrxHGH4wPb/69Wp4Rr1skDl4mjAAdQBnHr696t+Ar9bqwMd1ei5KAExk7inJ4B61tX2noEWSwYGHqyZ5oA4OSwm0+RVk2ygdGH3enPNdXoJEUC8Bd3JGcnGBTrZBJ8suCnAAz2p6RmFgVbKe556UAXXKk8E8+h9qikbIOMgfzoikyCCeM9c9vyps5PJJGMHv0oAqMQD0qBiGByMLnqakldtvBznPeo3JaMAN19+lAFSViSxHXt6VXDPk4Jz+FSuNqkCQueAScc478Co8ksSDnPvQB1743EAjOf605TkAsSOg601hxwD+FKn3QAM46fSgCVMZxjg+p4FTxDjr15696gRjgEjt1NWIR0GCBx1oAsbRtHPXgVVmkUOVzwBwaslsIx55HXv0qvHGMlpF3dcA8UALBCJvnlJAGcr3NXYhGzCNF+ToB2qJD5kjc8Y+bPamzajEitHBuJzgkZ59fpQBmeLddtdAs0G0XMxLBYxIcA5/i7nr0/lXjmt+Jb3ULmWK4uZBG7blCOVSE56Bf69a9T8RxaZc6VPBJ8m8lt/zfKxI715FqeizW0jvMjMEO5WTOSAeuPQ+tAGRbWhvE2hsZ5LbuoHrVUKbdmljUnHyknkH2xVyyvBDODboolwAu4enpWleQXDzl43klaVPNKR5JJPX3PpQBXs9Jhm06C9cxeW26J13kOSOfw6gU6b7LaEQtYb4+AZGc5Jx1/A+nXFWNBtZbi9SQ2sqRIAXQucEhefoT/WoX07WprssI3tQzs6eY+zt9PQUAZ092mmX80Cr5qOMCUMRuBA4/DkVPdPbzQLLHaykrwzNJy/6Vsp4UvtcuT5M8DzOCWUbxgjjIyo4r0bwh4VFroV1aajsukYEDZlRjjjJweooA4vw7cabfCASQFbm2KyIWkIB5GQP8Kt6tJpssuTOplZzlXyMDdnn6V2cXgu0gliktrYRhOmXbgkj86o+JdBguWIHlqwY8g9R+VAHI2VhNchmS5hMbH7vmZ/i9Ow4r0fwpDJBbuJmVyMbSmcVy+iaQ1nL5RQPGxIGGP4f0/Ku100eXEy7dvAoAnclm7e3NV891GPQ5qdyCD3bjgZyaqs31B9e2KAB9xDANjIwCT7UpYFmPcZFMLEoSemKdkHOeO+fWgCTqxAHGPU0vXHPH6UxWPJPT0p4HAGf/AK/NADuO3Bz606DO/IGRuHBY0nIK4BH4+9OibDEENyeO+KAKfjOGV/Dl00LBXUKwwSO/I49q870mDUXkTybiMKAS2SR9ckivXZFSS32SfMhGDk9RXH2CC0YwxbZJIxtJJ4JNAD7Tw9qOqxoz3MPkKu3JYgg46jiuJ8R/DRrVJbiCeNpOWJLnGccYGK9Muru+TTykTK0oAzg4Xp2rjvDmp6s9zdJIzysXDGJ1IK8envQB49q2kXNg2xolD4BJUk/zqmPt9oB880fXoxGa+g/FukXl1YG5s4VRiuJNuTnvzkdBivNrm1e3LwmIRrGS7uS3z8DGPb/GgDl4ri4g01ju3vNwrlsbRnnH8qrqZVhjkDyA845OPwrtXOn3OkCK6gNzcw5IkdjwCRwcHPeqH/CMm/sTdadK5bccQvnGM87T7e9AGdoWo3dlMrxNiQlSpJ6YNdfZ6vfXd0s8N80RTBcGUhXIPIA75zXIvpV3aTqJYmwSNpGWUHPqK2NLuDvZJgSdw2dRgen8qAPV9NvI76JWbYlyAN25uD9KnC4JHGfc4rirAtbRo0kcis6qRyRXVaZfRzKsUhJlAwDz0xQBYKKJScDaRiicAryR0z1qRiASjt8xyQM84/yaZK2VOCBx/nNAGdIGAOW4571AM55PBPrzU0x5bjGeKqFhu5z15zQBHKNzEJ6/pUIL7m2444qyWGD3weOvrUeGycg5oA6tzgcZ9c8+tKq/OWOenHJ6fSmyD7zA8LzyevP605ZACnX8sUAWEAyOpPrU0I+UemQarqclc9euQDVmHAwPfrQBPtBG38MYPp/jShDuJJycZPtTkBxgcEEZqHVJjBbkLwzZ7dKAMfxLqTW8Tx2jY29Tg/McdKg0Vxc22542SXaQQAfXrzULSMZOegOW3DI7dafqbGaFYbKVgUJIWMkEjPtQBHq0sVqkayxq0RyCMHjnqTWTqVit1cRtbJNcN91GGVjCk4wx7Y54rQhsCxiN5M1wyE/KCdoG7OG/vduf51uRym2VFcxRBmBVCOOuOB6ZoA4+P4f6bZM7aiTct5YJCkoiHvyDk/pVnSfDsVo0cME4ktioO5TsZV5yB611k8LuGCqD035yRg+gzTHWztrPzTcQxbVH31xn6f8A1qAOV8QabafZt+jx4VJAjSRMwJOOc571iXCXRtJk1ZpHQKTHIg+bp1J7nnFdIviTSNPjLyzxXTSH5ysJVenufatHSb7S/EdxBaxW0BEpOVldmwNpzjBHpQByHhW6ZL2ZoIpBPECvQjcpxwfT8K9WsJUubdXCqq4+7txzXm2qTy6Z4gnS3htkZJNvmwQkhhxjqxx3ruxvmtd1vOwHJwowcUAaMse5dqE9eAa57U9Ny4lcOWPGAMjFIL9YbnypbuYlj8hbPr/+vms/xBrcbSCC1mPnp2bPzc9qAGW0C286k7jhs45J/St9AoQ7D8vpiue0RpJJcyKeDlsg/wCfat1XyqnoT29KABic5B+pqvkrk9BnFTO20DNRMfT60ANPIIPTHAxSjOct29PwpuDg44I6Uu4knvjk8fSgCXaRnnr+FOT3Y/j9ajU9ST+NOXIPzHr9aAJ1HAJJPtinR/KWwSQSeueKjHUA8c806MhTx/I0ASXMkhhdEIHH3sZrg9cvNXsdSilijjMUowUMQPzf1rv12yFeeeMg5qLUNPhubbyXHz4yrn+E0Aec3vi3WLECEQwSS4XIaHJyQPftXPx+NNS03WpZmsLRpti7gYnGPlHXDe9dJe6Xdmd5FUTx7+hDcED25NcrqMklneSTXa+W0jBTDtPzFRgMSe3fNAHZQ/Eq4vLSaK809YrZ4D5ewMC7HjBJzx+FYqJBrETTRTyjPEkIJfAGPTt07Vx6z3Op3+JUAjXlFLEbfb+VXZbXytRcJMYkPRUP07/jQB062mlQXUqyz+a4BwdjKcZ9Dj/Peug0jTrNIUa3hKQSqR5gzkDP3WGe9cTDfSQReRqDK3lsVQyKWZeT0P5fnVceJL3Tb6RoLlzFuyEfJjxnj6UAehRWMWnPJFHAuXHDnoc+35Vm6toUfkefbiOCUKDtwdpOf0zUumeI7HVNPSS/uo7KdvutyQW5zjv2pt75ixNHDM84YAh2UlTz/KgDGS9njCwXav5mAUDg9PY+la2mNgBlkYtnnr1q3awwXdqkd5lmYDOcgjjt+lNNi1nOpTLRE/K3IzxQB0Mb+bD5hGGHHApkhO1iB7GnQAKgT0+tEinBwOKAKE3DY9jyOoqnIhz357AVcmXO7HGO+KpsGDZY8dASPegCLfgsuTmo1nwMp9CeeabPn95zg8e2OtVowMHIB5784oA7ZnL5Zcc4weveo9+CE+XJ9OaitSdzIxHUkD1p8qEOrfTp/n6UAXoT8oOOcc8VdgHzDnt2PtVC3ADgjJGM/TrV+IEtluB0oAtI2PTAHSqt2fORh6rwcZxU0p2R4HU9fyqBYzJJg/L6kUAYF5ps5mYJJ+7PU+gxnPX9Kns0SFVjsoMyAFWfaNzcjv8AWt9wrZRIwVxwuOKzNX8rR7FrjY0hYErGo5PPQnsKAMG5uIbRHkuArbG+cuMbBnqDXG6x4tiN9H5AMxAwERBhjuOPmJz6cgVQ8U6pc607PIVjiiLAQKu0Lnrn34FYNlGsVtMypFNPwQdoJXnoO9AG9e+M72dFihItkjwWEORjnpnriq9/Jb6gLaLTlJeOMecH4HmHkkHNcvGJzvQ43lhnHX6frRBcSwurKVDZAJUdetAG/b6ZJNaPF5eHaXcr8EdD39/T2qxK8um6IgaT5zII1lUYKjGfX9farGgeKrGwiS2vYJJoyCrMqjcTj69Ks67Dpd7p9sI7qGFppQMlD0C//W70ATeE4bx4gHf7ZvbOQcMvA657V7J5aWke7cdpGNoHQV5jpN5a2TxpEoKnaAAVO4ADJ4Oetdxe30U1qsrI4O75eOOgwcA+9AGB44vmWBhYKqyqSGdhxjIrzTTb++bVDvj81lfJBHHXNeo32nxXFkf7SERijYDIOSRnpmud1nybJHh0qNSky7fMwAceoP8AnigCxF4wj82O1gg3S52sw6Z9K7OAMIVZuG2gkehNeY+BtGm/ttpH3LsGCMkg8kjjOM5HWvUWJCgY6cetAEbnhe/pUeCSOBz/ACp7dATj0qPO4rkD2oAQBiGyO/WlCjnGBjPWkwO2M/pijGWzg5OeMdqAHknOf0qRRgZKj1JHao8kN8wA9OKcnbK8nIx6UAS5zgjGfpTl+UEnAHFRDOMEHOetSIPmBxgjpQBON2OBgY79alZWdR0yBwAM0xTgAEdh2qaJ8Z3AY9+1AHIzreWmtzSiIfZ2USBTxzjB/kTXM+OrY3ttNdW+390xK5UHnHT616jM0X7tpUGQ+M7fUdK5u5utNEGyXIRuWQoMMPXk9qAPGrDz2ljaJS6upDYXoR7VoapPbuxjt1yWXLOBjYR+OfXNeuPY6NdaXdwWNpBDPPGcssQVjkcdO54rhtQ8FJJDvs5MED95wM+9AHE3F4XWNWJJHABPfPuay7lyxRH3BiSVbOcc962NQ8K6pHcpHBCzFidu5cZ549qoal4fu9NZZNSiZFfBwCCCfTigDLM8oRl2BSpHOeetdF4S8QHRrh5zuIYDdGy7lfHqM+9YNxcRqI28kDA7c57c06AqWBAO0gcHg0AeyeH9Zs9bGbQGO6Ay0bKOeuSp7jrXUW8QMW6bBz2K8V4r4Zmmkuoo7bdCqfMzAfdGDXsulXgurWNJCBOFAGP4gB6+tADnUo3qOcHFI7kqSB9OOTU0wznpjP61CAdjDb09qAKk2MEkA5/WqTqu8O5OQMY7davzJuHQg96z7lDwOMZ5oAoXB3zMcfK3bHFZ9yx80hRgD6VfuGCOzNkduaxpgXkJLH16UAdzCBvUn7oPPvzV5lyuBnAHfBrP8xQjYz+PFXYZN0SEnOVAPFAFiAnC57dzgVqwDoR9ayYScHuewrXtgcjHA74xQA64RmkAXI9Tj2pw2r8uMe3FT9QSDk9/pWL4l1caRZl0BNy6kRnGQvvQBY1S8j09JTnfdFGKpwdpwMZrirm9mup531WWUxsMBFUYU59f6dqx08STT3hF5JIgYH94MZ98jite8ktruSBrS4VoQBnkYyO2fXrxQBi3MGnXU7wsHiHGDtGc54zWDeadDpYvFnga4jZvkdHHGCeemfeugmUx3RWRW2bvv46DPv8AWp4dJubwyNET9lmbZvJBQc5+vB9KAPPGmtF58o5b+JsD8vWrmiaNFqdylswkVpcKhyAAev5V6Ro3geztbiGaKKSdwyl3nC/LzztXH09ah1nUbiK+B0vZB5bYxEoJbtn9celAHnF74dvLOSRVVZJVYruQhhkd+O1dV4I8F2c1w93rdxJ+5XzTEpA3cfxZ9qwp59SaR0JdLgSHI+6DkV3nw9s7meKUXKN++xks2SFA4/A5oA6i20fQTZi7gt0UAlBjGT/nNO1y5jt4DFGG3uDtCqME+lWdWt4tJ05C8oihUli7uq847k457VwyeJrHUy8bXUZkSbO1FLnBAGRgetAFnUplCRPdvvjMZJUkYJ9/8K5+We3uQotoyjKCN54BJOfy6VoeLtS06yit7Yw3kkoJzjauenJPP8qxtFv3l1SNobSGC383Y5kO95PmHygf+zY7UAd14StUht4mwN78kjoT7V0EuAc5/HpWdZXDq5XYgTd0AxWgSGUEHt0JoAjyDjpxUDcvzzke1SL+f5daaTlgc8Y4oAYy8nPbg9OKUjJPp+FAG1c4AzQRkc9ec8jNACgA7ueDwKeOoznBPfFN6kkkDPTmnLwQQcEnIoAfgcDj9KkUA8FuM1EjA8jofX60qkkgE8HpzQBaBXjk57YqTcqgBjxwM8cVVQ9MEjIzz3qxExyN2MbevTFAD1EDoyTq20jnA68da831DVdPuo5p2P8ApETMPLbCkEcY2nrXpEaeY21icg9M9vWvJPGuirHr955zCKKchopARjO0AjPbmgCo+sRQXAntLiVW2YIJ4B65xggn8a6hNcW3QXXmRTPIWMiRsP3YAGAf1ryPX4X0S9NpFIZGB37s5ABA4qwuowzWm+6yXkzuMLBSCvT+dAHrI8TW+pXHkwhIlbAzJjcoJGSOuen61R1e3tQ+JjFNBtP+tAwcnG4V51a61ZWrh7ZJvNXPMjhuv4DvWnoOs/2hItu8zeahJCNgKRnOATx+fFAEGq6HZmB7lNlu/HlogDBz3/Dj9a517G6gkU3kbxxngE/d/MdK9ctIobpY47tDLaOQo8sAbeTnB7/hV2fTLUJIIn+1QlArGTBIA6cUAcP4akSJYQhRmHy7SoLEYPQ9etdfZy+X5WWCsvKjI/PHas278Pz2rwXNiGeJFyQCuQeap/bhbwhpGzM5+QlxkHGelAHocFzHdRks374feAI6YqYgbe3Ncj4duhHcKZWO587hwN2a7NkK8jggEYzQBnzDHHPQ5xWdOwGe/pyK1ZuBjkZyOtZlwduefagDB1KUmZUbrkZ796g2Bjlhzj2NLqqkOZMkjjgEU+JsoCPlJ65oA6KRtxIBGNwByeTnJ6enFaFk20GMkdsZqhbKWmkY4OTjr2q/AhVhyQw7AmgDQiQA8Z6Cta1ADr659c1k27Mw+Y/meSK2bVT5gbn354oAtEhY2ZyMDkk/SvMvGN5ML6Yuu4NghgeAox7V3mvXAgt0jGMyEk89h2rjdftor6CUDcJSpKHdjn0/HFAHFSLHdM+6TZJg7gWyCOOBgdaz4be8+1oulyIJmYL6qRnqwx29a2dE0q41S8MUSCJbdS0rOOB7fU+ldjbwQWMC2tpCRExO4k/MTnqT7elAFbwnJCbpY9TQfbIycOT+7c5H3c8n8a2Lpbua/dIrlF3PlD0AOeQf/wBVQpp6m0hD3CxneNpdipfnoPzrBu9ejtdV8iLN0yShd+4/uSCRgZ6igDo31NtLt5GkuW83Kj5dpIA69RWBq2qxo8Tm5iHm4KoBjaTnhhWZr88Jdfsd/JLGqAeYrAqxB+bgVzl34ktlMUccDS7ecq2M9RwfxoA2NU8Spfana+fC8k6hTgKBuG0ZyCK7jwlqdxdzS/6u3tVChF2jccL098AfyrzbT5JdYvPNCxQoiqjFycgAcH9K7XR9UtrPUhYReXcT7M71fnO3v+GeKAH/ABY1dIdPgtiVmkuCy43fdAH/ANcVwngLbJeXF1HEFFkjTMC2N+MfL+tbnj8ylUkeOVXuDJHHGDuGAqgn8c/pWNorzaZo2p28duWa6jaMOGwMFcZHfjP6UAT6y39stFqAcBSWIRT9w54zgdK6DSNPhuNRg814hNFn+PkjPB/WsT4fqym5tmG5/vJg529jkVt6TbsdYuFcgSrkKA2c8/8A1s0AddHEsPAkU8465qwflClTnOPwqsIimCWY5P8Ak1OWHH09elACK2VwSMYz16VGxx8wIz0o3Z7Hn3pjNtOeMemaAF9ST7dfalyN7dz65pnHIBwAM9aQ/fbJ49z0oAeOpwcdehp4Jzjj6UzOM4I+tOUjA4A59etAD9x6NjPqOO9ND4PHSgEEHJH54xTc4zg8/XrQBOrcAdO3XNSqSZBljyBgZHy9faoAeAAABx3qaNuR+fWgDStyWXJbb/n9a5fxtoL6pp8jK6Dyj5pEnoB8w49v5V0ULgY5HX1qS6jV4HV/uMCrYPYjmgDwPxxpz3OplWvbdioAAQn5BgdeK5g6XH9llZbmIFJNpTOCOmD9P8K9G1+C0XULgXkSPcWp2GNWOWzjB/EYpdH8MaZr1nKQgiucu0cjSEhuBhSPbmgDzi5002sMVzKsjLIcI54ViOvHtVmzkeK5A8wrH2HT0/yK7dtKi0pDbXUccjoTkFslhkZwO3UCszWTazxiMackG0/eEpYr7enrQA3RNW8i7eIFt6HCndlSMk88V6Xp2rRXsYt5zDFJtUo2cAk9RmvLiH+wmKGdCCQGViRtwc4OPqfxqGTUriykiN4hliOAAHwRx+lAHo2oKdPIbOMjGCx4HvXL6vYDULl7q2jMlwFBJDfI4Azxx16VFpfiNxGE1J3urZsYcyFni4PQHt7dK2zbNF5UtrLut2G9QjZXkd/f27UAUfDjSy3eHU4i5JPb0r0S3lEtuD2HbPNYU9sLW1M2xRcDLOFPbFWtBn853Gc7ge/egC3cDcx+YfnWVenJxjufSta7BzksQuD8u7rWPdKScjGM8kmgDHuogwPHHcdagiiOzC9q0JBtyCQc89feqzBs8NgH3xQB0lqwbjqR1ySa0IVGRgZ4BrMsmJIwSBgHI7VrRkIud+B2JoAtwR5AAWtm1HTPfvg9Kw4XO4c9a37MfImOAeeBQBznjN1cSIHIkh24Az0wKwtAkkuLmUqWjt0Yq8pJwx4+Ue/NbXi6ye5vFEcjR7wSz7SQoAPX1z0xXPzXdscw2m6ERDe1sgJK+p56g+tAHUT7LyFYbBWt9u4YyR2HX17Vi6gq6DD52rzkM8jGMxktn3/3s460smvWeiWb3TzLJd7cAHPyg9z7dOMVx8/iFNYu5ZLpzLCWIAcsVBz1AH6UAVtY8SvO0ZWSUmLJRi5OAcc/X3rBj1O9gJebexLechlJIVT9fXFLfaVNvkltySg4YZwCC314rEayvfOkS6SREAIZihAAHQD8aAKsNzIEZg6gmRSUBO1seoqzbypOzKIWjlDBy6E/Mfp6daSO0CskBjzJLtCuT2Pt+NSTabez3aw28UyPnCrtPORwfx60AdPo+u6dYaU4lhdJ3yQuWJJwACRjHUf55qXwPfwXXicLFZyvPKOGD4HAGc5Hsau6d4asNLtEfXZd80ke1I2jYbTtznIOccEdK2fAen2FiEvtyLJM+AzA4VMfXvjrQBo+MNOsx9kVkmdYg5kUk4ycYJx+FYGo/Z4ZpVit/KgWEKPMc4BOD05PWuv8TgXUUtxDxGq7pG5IAHb1z/WuJXT90lxPrN8ttGFL7ZUbdjj+Hr3HOPpQA7TLsPe25gURrISrsoK8Zxya6Dw1CI9XutyqBggHH8W7jnuK4248TaLpyQQ6ZDNqLI2d0waNSc9hnJ/E10/hnXLjVXjkW0tbcL80jruIHPAGT1oA7GWLZIc9c5A/GmFjx7e9I1yXIKqpUdwDUgAZR64B6UAVy2OMn2FMYk54OfansoLEknP160xsYzkjPbHWgB2cADPboaaT1ADYGaOOT29fwpjHGQBjFAD1Y4I5oIdxtVihJ64yetIAN7YOAMnPJpy/dORn9O9AHP8Ahz/hI21O7fWWh/s9N8UICbZGYOMPwPu7c9+pHFdGNpJ60HJAGc9ulRgdOcHPpQBOCOCR9KkRgXA/U96hGMKRjIOAKcrneB37GgC7Gfl61eiZXTBG7ArNg4JB/wD1VYjkKqp470Ac74w8Nx3d4t/Gu1jjzeT820YH6D9K5uCCfTmeWzgmiLKW3MxAVhjJ/lXpmo5n0yURthtpIwOQcV4X4j1LUrf5WctsJD71+Y9O3UUAdLrtxMba3up4hcsCVYKPm5I5BHLdMmsO3v42k2gFXgLghxlXAPr2qpoWvXcqNHLOHgHQbSx3HpgZ6daZf6Jcq099Yq5WMkkuCEY5GQM9OtAFe/vIkaWWKHJZj0yQBn36/jVDU9ZXU5WYw4jSNYx2xjr9ec1m397cSSlbmL7K0fYAgNyecHrWU95JtCcEEYzjmgDRuboIyNE6nbxkEgfSt/w34nksLmJbuV5LJc+ZCjHDkrgEDpkcHP4VxEYZ5grECMnp61KAB8obAAJXAoA99+1xXOLmCQSwMBtlGcNxV3TxscSoBhzjA7HjmvIPB3iH7JL9hupvLsZmyzHJMbY6j26Zr1vRZN9wyYKgZ+U5z9aANq6jyWx3BIrJul4PYZ/rW7KoKAn3Hfk1j3QA3c9z/OgDCuflbOBketVSSzHGPXHNWr23cyBvNO3dkjByfbOen+c1TkJEjbCefSgDpbU/MMYIHscE1rREYAXG7A61h2e0yJj/ABretxuXP8PB6UAXIFUFeuT04PNbtngCMZz8vv6VkWq8DGATWxajpwOmOaAM/wAQROdKm8sZk6g46V5L4vv7LQIJJhJINSkQmFckHHTLe38/zr2jUZEgs7iaUKY40LNu4B46e1fJvje9nvdfvbi5dWlkkILIuFxgAAewGKAKkuvXOoTyy3t1IJGHJOcP0GMdun0q7YarlyvyxKM7mAJrmNg2g5HUip42KgYGVHb0oA6rTdVYXZBf5UTncC24D1z2rT03V7i/1JdkCMc/Ogztk5JIIz9awPDWi3muXccVojvvbBIHHX68da9IsdIi0SeCyVITLvMcjFfmTrnkH35PsfagDX8O6RomtXFrNd2bQvAQfkYlCwxwR0wOOtdgdEhn1Q3c8sUkqjIZI9oAxgDrxXm95riW8K22lKiQ7g5bGecnnue3Ste48630dZmuEdmSNygYj5SDgDn9KAL2p+GJdV1FljvkhG4hMMZNuAeMZA68fjUV9apY2IXUb2COztmUS3Cws2844A9fwH4VzdvG+nfv5Vilmnx8oJIJK9+eMH9al1rU7aKxh+3o013bKPKVohs3MueRnt0/DNAG14414+F7ea1sYUdXUZ84E5OAeB04ry6bUJL/AFO/maaYRmMyYZy+7oACc9OldD4w8/Ume/uAqSMixyK2ewA4H5fia5WERI3KAjBXOevT9KAEsIVe6iHzqDk8jgc9a7zwdL9nuZLZfuMpbJH3jkdPwrn9DjEMckkixbmB27k6HcOavwNJFc20wiBSG4DM5XA2bhQB6bpw3LnBGeefqf8AP41fbgDn9DWdZXiyxxvGuN/b05xWgynGRj1oAjHUHOTnnAqJuOB+meDSlgrZIBI6ZHSmuc4zge4A5oAYDtUjkdximk5OB0+lLyQffnAxSZxnGOe9AAQBnsM9waep2pjPv3qNjxjGM+1Lngnjqfx5oAk3Y6kg/wD16Qk7u3X8qYCQRwcEY6cUrKTnGAB9PWgCSNid2CPXJB/lT4i4RN5y+0bioIBPsOeKiRhx6CnGNWG103oeMMMigC7CfXv3NTfMAd3H0qCLkAd/UirEJzjgjPtQAsBIV0djhgVIGeB61458SbQR3U0cEpM8LYkR88qQCCpr2kw/uZQq5LKcY+leU/E2N3v7d5IgEkTdlF5GAM5P5UAeTR3cltKUVnQ7ju5IIGa6TTfF19bhULrIidUlGVY8dRnviqGv26PdCTYkTxjYQi8SEY+bk96yZCEkUou1c52j69PegDpNavn1i3/0i1t/nG5WiQhk+Ynjnp1rnJNImVQ6gvDxubHQe3rXT6DbyatbSmAlGiAGVAxkn5R7HNa9ra3Mc+1bREgQIsqlNm49N3Pf1oA89+xSjaMEjG7p0HvUZjZSACN2eg54r0fxLpVrLClxprCJxw8TjKfUEdB7VwGqvNHM6SJ5ci4Xbj24oAzpiyOQpO7+IV7T8JNYbUbWWK6kZ7u2GOhJMZwASe+DkflXiBB7813vw21FtLvmusZ3fIwx1HFAHvrqGhBOffNZV1Hy/wAxyTz9K20AkgVoyCrLlSO4rNu4wGHTvxQBz93GBWdKm2Q4JH4Vt3UYbIxketUTEAxwAB7igCTTZC6IVBA6+mea6SzA67Rzj3rjvD0xaKMnJBFddZ/cyM54+lAGza/e/TArYtgPQZ6fjWTaZO3I9DWxbgKPm4AHU0Acv8Qp2Gli2Vcq5y3uccD+tfPHjbTGtrszKv8ACA4IHGcYPH1xX0H4xkE2lvKB+8Rjj2ODXiPiGOdnkS5XcXz3BAPp6UAefBdzEFeAOorpdA8LvqSJdXT/AGeyOSHwCXII4AyPfnpUcXhy5FyWmXFplgrhgd2ACV+vzD8xWvL5c1uwiEiShtqR8bQvpjselAGvpWq/2ReSjTYlhjRT5b4G7g9PpxWdceIZrW9llnkVnmG5gyhgSef5/wAqzojHbkw3srOZAQFjwdrZH9M1j6g1vGGK7zNnhSPugGgDf0S4/wBPjMqEqxB3JhiB3A9/y5r0iw0pr+28uKSWOBm3R5w2TtO1cZyMcn8K8P0pJ570eWTliFOB68V0dl4kvNAYC2mcshyqsQwzjqaAOj1uc2Sw20caCRACrFAobaOvvVDXJZLu2iijTeNgkfPrgAnPTH+Fc5f6zdatqX2q7KOZG5G0DGB2x0q/Jc2UrERCVX2KsY4xnaOcf/qoA7XVyn/CNwySQ7ZFjOQTw442n65H8q4mNxOWlniAbDLsAwMYGMfjXTyySy6PHZqXDyxF1B43Yxjp0PX9KxodPutyTzwsJJOAMcHGMnNAGjoei3Gq/Z3tWPlebmSNxnfyNw/HqPTA+lWdeN1aiVHhSG2Mnlgg8nByOh9RW9pMAW5Z7RWVDGZJQ+FBO4cL6DHNc3JYteXxEjHY0u4kY+7u5PtQB3/hybztNtyQGBUDIHv1rbGcE5PpgjvWV4et1gshDG29IWKhvXnNazA8HHYYoAglJ4yPp+tRtk/MMkdMGnEDoT+GBRsyBgdc9KAI8cHjnHXFJk4xjj6U4Yxj2xmkbHOf0FACEnAGOec560mccbeQfzpTjJ6k9cUZXJ7856UAKARxtJOe9KSVBzz7Y96TAH4npjpzSHCg+vrjpzQA5ByD696fkA9B6GmqMnn+lOVTwDkmgC0jbYx357c1ZibjgD8qqRkBRnhTx9KmjIXPWgDRUkAnHzY6EV538WmX7LYlz5cnzhCo4IwpIPsK7yzt4YHuJIYkjlmO+VwoBc4AyT9BXJfFfSZb/wAPJLbR75IHd25xhCvzfyFAHkt5Ztf+XCZU3RnsvJUnOc+xNZts1pb3TQzWjXSrkMW+Urz1H5frSJI4gSUHY9uckgdBkfnya6zUtIttb8Iwa9aqftVrkXYGAGG7APuen50AUdGkhhfzlbZaygM8cYyVwxAKj612lxPbT2G+aR2VigDqMbAeMkZ5/wDrV5npt15Mz7lXY4PAA+TPY9wK07LU9tpcwSxqYZAMk9Rj6e4FAG/dSojqqLGAqg5KgE57nmud8SWlvcwyPMAJgBsZB2x71nQa0I5FhG4w9CDjgf7J5xWvc3MF7HA8YKoBtZuOTjse3FAHn86NDIysoyOf/r103h1nht1AADN8w+p9aludMi1HU0tbdHLyEcZUYAGSR+GTVlLGSyvGt5VBP8Dg8EetAHu/hK5WfSI0wMxp1Axn/Jq5dJntnB/SuZ8IXiwXVraZwZFOQfrXW3i4jzgcEdfrQBgXQODwPT9azJAN3Az9K17xdz4OfrWdcxKWAPb1oA5nwpcho0IIPHTOa72wbgHLY4ryDwVeYdQMAccZr1rSW3IpJHIHfmgDorPJK59Mdua2CCkEjByBjABAwOOfesyyUl1HXoK0p+bRxwep5oA8j1/UZrPUruN8tAzHcMAnpkHFc9b6SdYvmigdU2pve4Yq21PQD1OfrWt4tQpfMsSrIbjAAHViOPz6frW1pVguhWhti7ypIWbLjo5ABHsuBQBBdafaW9tKghTyVjKxq4U7QcZYH+8cDn+leb69ZLpKCS4myLhmESxKDuGevbA/nXpd5fQwq9xJG4CnAQnHmdOOnSvKfG181/qDgsjYPRDlRz0H/wBagDBuriNI2kjLeYzHk4GB7is6GKSUtKwJXOWbHFSfZpRMwUFsDJHXFPRG8zYche4oA1TcraWiCGCKN5Iwdwzux6/WsmSU3EuC3JGAcVfvZnjVVViDHGsZDY4I6VmLhWVmOMj+GgB0aCGYecQrDt1rr/DWk6bfzHzrqRBnIfb8oA7H3rk9MtJdQvljjKglv42wAO5J7Cun0+WW3tXtbOQM0kigsmGLYH3enP4UAemvbaNo2gqBcG4u9hXczLu4wSAR0Ht1Ncy+uG4mRVUooGEJxkDAPI9OKs2HhrXNRt7SS3gUosj+Z5hAzkDP8q3G+H17czA318iQdGS37/iR/SgDl7K6lbV4FXaWkc7vmHPTp+tat5ewKREGE0zkjbblXK8926flmujtfAem2j5jEzEt8zyuCxHoMAACtuPw/Y2qK8Fui8EcDGPwoAyPDQdbJU2OoODtYg9zW02dhwOfenRxJCuEVcDpQxHPSgCoRz83H48UhGfb6461M/XPG761GSMdcetADEztXdye+PWkbrwPwzzTlbIGM/U/SmnG04y3WgBjD73GT+ApMcjAx6GnnOctyfrSE8YOetAAcgA59/5Um3CnjpQ5AxzxxQXJAy3OOB0oAVTheeBx2p4zxk9vzqNevPGBke9PjyxAHPTIoAsxEZOOSD+OauQhSpAGDVFG5B3YIq1A5ABfP1BoA0oArMeBntWF40bZZ/NzFtYvtAORgVrpMOSpGCOlYXiXUxFYXJuEVo9u0gnkg+lAHhUpE+pXEcjCO2mZzgYwozkY9O1S6VrU1kGtbNTJbO2JYiMh1yOMevvW7qdtpT2krWUim+ZiwjkYbOoOAcc8Z/SuH1ae8tnZPMVY2z/qj0/woA6O9s9Igf7cbkwpwzQDa7Me46461ylxfLISFwqjjGBmqUcxJ8pydp6ZNR4CsQRwePcUAWbqMRyAwuCh5Hb86bBeSWrBkOGByOARSFlZNpJYAD0qOJGADcbc4waAPRvC8kVxH9oCoZycFdw3IPp1H16dq6240uG5hV8IuFJHA+XuTXlehX81heJdWuFlUHIbkdOcjHSvVYdbtL2xje1AHmnY4U524AJB+uaAKvgycnxE/mqwlQkgenOB+letXI3o+DgY3Dp6151otsp1lpEULKFO4E9RkV6UgDqvcZINAHOXaEk9h2/wrMnBXG5eec9K6O5gwGz1HHFYN8AkvLAZ5oA8N8IXRWeMFhyRXuvh91dEG7ccA+lfM2iXZimQ5PUcZr3PwHqnnKqSdyuMnpQB6xp+N6YOMcjmr8p/c4ByCCMfhWdpb5ZeDt21N9rYsiYz8x4HfigDhxYrJOuoEbjaudig+q4P86j8QajcHDRmEQW6FizNwB3PrxiuovYEtLWWIfKrZAwT09c14f8AEPXpLWWTSonkR85nOcZBwQn9T+HpQBR1bxVLe37q5/dgEQgnAUY647nPNZaSkF2l2SxkhjyR371gTFHkJBO715rTs5Fjx9ojBB5YHI47GgDee/W7sI0hiMMbyBTHE2CSMc5x7VJpkGmvfyTtcy208WDHlVcMfVumeayptUQ24tYVyQCyOCVxznP15xVB7nPlJETvb7zEnHWgBuu3VxczxrJdxXIhXYhj5AXJ9h61V063kupxCY3fdxsQfMT2wK2/DPhy+1vUlg06B5cFfMbHyp7se1e9+DPAdh4fCXIjMt9twZSSRnBzgfjQBwvh74b3F1FBFcSNaw4DyKD8+4r06YH6969L0DwvpuhwLHaQ52nhmwW6fhW9hYgMD/OKgkl7d+/PTigCSVwinnp71Xd843FaiklyxGd2PQ1DI+AePu56UASPL69Paq8kxI5PA6CmO+eDwPWo2b5iTkk88UANlfJ9D161AXPbPNPc4yQKiOTkjI9aAImYgZyPTrRubGAaQk7vftxxSYyOpJ9c9qAEyc598USdyPvd6D1x2B659qSQjnIxjpQAh3NnkHGeaXd9en9aZnkgjkfpS8ZOeg6kmgAfIP3sGmqfw545xTyevUg/WoyAV4GPzoATdtAYE4PWpFck9c8Y4qFQ4OByOwz1pNrM2MED0zQBcjb5sk8e9TrMPLPIHOePWs/5wSu05GOaEEjrggg5+lAGmZipdl4AGcA9fauS8Vztq2i3bKxiktgXwDySBnHvXUpE25gAeR1rB1LT5jdyFI2aFh80eTjGOooA8Zmne3lWNkZRId25u/NRS3MV1LM0ilnJJYAgbua6zxV4buxExcFIw26Nskhskfkea4wI8F35TxMJADwQeelAGXfwqsxkg6dcHtzULnfErDt1961LuMN5jhcLu6A9altbSLymmdHkCgFoV+XIz60AUNIs3vLhYkZVDDBLHAX6mtqXRjHlcqyqCTsYHjHWhJVSGNrRBEmOApPB71rJG0tsJpHCsF5XnJyv9eaAOemgMEhMRAXGQSc9qm0fWG0+9ZhtlRhsIPyhh17e9QapJ5bEIfmbkY9KynYZGM+2KAPffA199tupGXlNmVbdwTn/APXXpqLtQ8jBORXhnwe1Eu8djKWLsTIhJ7A4I/ma95hHmW6nH3uetAGdeqQXwQSa4bxDK8V2qggDB49K9CvIwRgDHy/nXmvi3cl+g5UbT0PXn3oA+brB9rD/ABr1DwNqDR3MPzEcqM5968ntWw45rtvCNwRew5ORuGfbmgD6j8PyBwhzu3Jx+Wa3PJDAEKCVbcOtct4UlDwwnjbtHy/hXYQoShOOvtQByHxBvl0rSpL1xuVFPy56nHH64r5g16efUb972Te3mcszZP617n8ZtUSezbSYZMSJi4lwpJK9AP1z+VeI3GWRlXJRgR6cYoAz45htYPGDjnk4NMnmcuHYkM3TnjHpUd3HtkPlklB90461r+G/D15r8yJGkiwDrKVO0c8jPTNAFawhuL64H2KOSSVMHCgnuBn+Veq+A/hdPdM154gHlhyGWJWIPvu44rrPAvgiy0lI5YkU5U/MQSWOR6mvQoVWNMcZ9PWgCHSNJsNGtFh062jgiGM7Bgn3J7mrLynrg8DnmomlyCST+vFV5Hyev0OKAHySZAwD65qsz569P5UO5PJYH/PSojnBySR/KgBSRk4HP1qu7ZGOfzpxOZDyeM0yTg85bPUnigCN2J/wprNg4YnJ7/jQxOBjGffvzUZbJ65H55+lADJeSRwSD1zTMgLucEEDPygn8scmnSMf14HtTd3/AOv0oAiUq6hlDYKg/MMH8u1AA7enAz7UrDByOPpSRhSQBzgZPFAAv4e5zmh1xn5fw9Pelx0PryOKaScncTk+1AETZ6g9OcY5IpVBx9O3rS9ckfgKTPPH5elADjz+vBoAwMjPr1pDIB936UmW3NngZoAeOmOQPWpEC56HjHNRBzj6cYweKXzCpwWGOBmgCzHjcDjDEYyP8/SpIl4AwMfj6VTRyWH165qzFJxjPH0oAuwkA5PP+RV6NEJ+dR+NZaPjJyce5q5FI2eMigC7cadY30fl3FurDPHJHNcZ4h+G0OoQP9jkUSDJjMmQV9sjPH1rs4puR1FWo5cjqc0AfNPiLwVrWiTFri1laDq08aEpnOPSsyOFkCzgFdpCtz19eK+rSwddrgMD1UjOa5TVPh/4evYpljs/s8snPmROwwfXGcUAfP5S0UO8ELDLjMW4kDOckH8KiuZZ1ifYGMfDBvYD1rttY+HN5pcqi2u3uMnkmEqAMHrya4DW7S9tFzLFNHAvG0g4xjsfTigDOuplly/XnA5ziqW0yHahBJNMdtrOqt8vHNXtEhLTlyQeowaAO98ARm1v8oWUxpkYzxyK+hdJmFxaBxypJH5f/XzXhfh6L7LZy3KgeY6EqfX0/WvY/Aauvhu0DrhmDMQ2c8saANa7U4YD7vvXknjm4Meq7csMZxg9ea9eulO0nAyeRjNeI/E2Qx61GEBPynP50AfPMZwa6Pw7Psu4sn+IfzrmhWhpspSZDx1FAH1r4DmEllHgj7q/yrvrPBiUd8+ntXkPwqvfOs0U9Qi9Poa9bsjiJMjBPP1oA8K+KSBfGV08oAQkLux0BjA4+leb30P2WSaDgyDPJHTn/Cva/jJp6m3W+SP514ZgM/Kf8Dj868R1USEoQMYGOep/z/SgCno+lz6vfpawBueWIXO0etfRHhPw4tpHFG6rCiKMxom0dqxvg54Uex0ptR1GERXN3zGjD5lj4Iz6Z5OPpXqOxY4wFGMevegBiKI02hQqjoAMAU2RgBgECmO+B6YPrUJkHzd/TAoAczHnHTrUJ5bn/wDVSMeOB271Dnng9unpQBIcenHXpTGZQBk859OelMLcD8ulRkjb0x9enSgCR2GSTjkdhUZbg9+OPrSMw7A8+30pjktuxwfpz0oAHJHTgY9KiyAc/wBPenOcg+/BNRMnJI6ng5oARwCxHc8DioyBwSeeB0zmlfIUDAyev503vjgg4PI96AG87VwBjHcUDkBcdvT2ppODgenNHQ5x09f/ANdAClmQZKlhgDI6g0kp+Y/j0FM75PBP+FOYY4OMjjOOtADTjHUdT2xTR97npTnwR8x6f4Uwkg5x160AOPIyMCl+6e2M46VEDnheD2NSEd8Zx7UAA9hz9OlO7Yxnj0pnAznH5VIvJHAAoAchA7fpT1J4PHHWowoJB60q5VQcAnk4/CgC1G+BgAVZibLHoD6VQUjHIwSMleuKnjJDYPNAGiJMouPxqwkvOTgCqCtkAHHJ5NSqwK9B/KgDSR+Scce4qVZh0BG4gcYrMjcbtvAHarKtuUEDHqDQBYdY58b1XPHOK5zxF4StdYsZoGVF3IVUhfutg4OK2wx3KRwSPwq1A+W7HigD5I8XeGr3w5q8lndRFhkFZNpCuMA5FS6fG25TGFOOAoGD/nrX0z418M2viTRpoJI1E4UtDLtGVbHH/wCqvnibRrrR9Ylsr5CNvIY8Z96AO0SMpYwRDIklbG0Ajv8Ar1r2jRIhb2dvEucKuBxXk3hOP7bq4d1DrDwp9Wz3H+elew2gK7VABAwKAJLo4jBIPcYxXz/8WJimvRhCANrHp717/d/LCTjIye2a+cPi1Pu8S4x91SOnvQB4rUsLbXB96ioBwaAPe/g1qALqjEngcAexr6B09swx8cHg8Yr5H+F2pta6io5IOBwPY19T6JLusl4APDZA9QP/AK1AFTxfZx32kyxSL8vIbgZ27SCf8+leK+HPDJv/ABdLb6hDm1gHIGPmPGP55r3fUuQd3OevvxWVZ6VBaXO5FXe2SXwMnNAGzEqou1RjAx7YpkrcZHQev1oZhzweBVWZhnHOetABIwZvQDpUbk7Tj16UwvnAPrTCw+YAYA4oAUsBkLgdOKiLHcOefpQDngE9qjfHy/TP86AFZj0I/WmljgcjH9aOAwx0xz+VNO0KOue3tQAsjYO49Peg52npn2pGGSfXFRuDuJHXvkflQA0ucDuPT0qN5dm3OeuOvFMLBmYkZxTQRkkrznH60APc5B461CXwCTycDHrTZCuTwcCoPT1OOaAJtwL46t3pu77pAyBUQxzj6dKFGXA/KgCZXOBnqe9JNJg4LDPcUxccD1+Y8e1Mk2biMkcZ+7/9egAaYdu/SmefxnIx6/jTXEYGRk56ZX/69RFlJOAflP60AWVkBAJ6+9PS4KMBznv0Peqa4OBzkn+tJ1dj2XpQBdM5kGT1PrT45DkZHXA49apoVBAZS2ewOP6GrcaxhgSGUYycEE/ngUATK5J4ye1PBbaSAOP1qvD83T+VTpjAA6dffpQArNhjxwKmWTHQ/nUTAdByT1zT4wNxXpg0AWwx46/hT0Y9Tz9PrTBgDnOPSkjK9x3oAtKT6f41Mj54BOPpVJTtwOeakD8DHUjrQBe3evoPrUkTFccfKeapRsMZ9BzU6vge1AGmkmBj+Qrh/iV4cS/tTeW8Cm6jQ5IwD04/lXVxSfN1ODU52yghhkd80AedfDi2aGBUnjVbhN3mEgZJB6GvTbIgsvQ4rCGmwWk7TQAjzWy4x39q29P5XcepFAEt+SsJx6Z4xXyp8VLvf4ruOfukjj619P63IFtpDzwv9a+QvHdyZfE16WzxIw/U0Af/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Standard ILO film for large B opacities in patient with silicosis or coal worker's pneumoconiosis. Conglomerate masses of silicosis or progressive massive fibrosis of coal worker's pneumoconiosis can produce the so-called angel wings.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_61_26582=[""].join("\n");
var outline_f25_61_26582=null;
var title_f25_61_26583="Cefuroxime: Drug information";
var content_f25_61_26583=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cefuroxime: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?28/55/29556?source=see_link\">",
"    see \"Cefuroxime: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/61/31701?source=see_link\">",
"    see \"Cefuroxime: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F148304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ceftin&reg;;",
"     </li>",
"     <li>",
"      Zinacef&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F148305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Cefuroxime&reg;;",
"     </li>",
"     <li>",
"      Auro-Cefuroxime;",
"     </li>",
"     <li>",
"      Ceftin&reg;;",
"     </li>",
"     <li>",
"      Cefuroxime For Injection;",
"     </li>",
"     <li>",
"      Cefuroxime For Injection, USP;",
"     </li>",
"     <li>",
"      PRO-Cefuroxime;",
"     </li>",
"     <li>",
"      ratio-Cefuroxime",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F148353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Cephalosporin (Second Generation)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F148308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Cefuroxime axetil film-coated tablets and oral suspension are not bioequivalent and are not substitutable on a mg/mg basis.  All oral doses listed are for tablet formulation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bronchitis, acute (and exacerbations of chronic bronchitis):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 250-500 mg every 12 hours for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 500-750 mg every 8 hours (complete therapy with oral dosing)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cellulitis, orbital:",
"     </b>",
"     I.V.: 1.5 g every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cholecystitis, mild-to-moderate:",
"     </b>",
"     I.V.: 1.5 g every 8 hours for 4-7 days (provided source controlled)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Gonorrhea:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Disseminated:",
"     </i>",
"     I.M., I.V.: 750 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Uncomplicated:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral: 1 g as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.M.: 1.5 g as single dose (administer in two different sites with probenecid)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Intra-abdominal infection, complicated, community-acquired, mild-to-moderate (in combination with metronidazole):",
"     </b>",
"     I.V.: 1.5 g every 8 hours for 4-7 days (provided source controlled)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lyme disease (early):",
"     </b>",
"     Oral: 500 mg twice daily for 20 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pharyngitis/tonsillitis and sinusitis:",
"     </b>",
"     Oral: 250 mg twice daily for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Skin/skin structure infection, uncomplicated:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 250-500 mg every 12 hours for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M., I.V.: 750 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pneumonia, uncomplicated:",
"     </b>",
"     I.M., I.V.: 750 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Severe or complicated infections:",
"     </b>",
"     I.M., I.V.: 1.5 g every 8 hours (up to 1.5 g every 6 hours in life-threatening infections)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Surgical prophylaxis:",
"     </b>",
"     I.V.: 1.5 g 30 minutes to 1 hour prior to procedure (if procedure is prolonged can give 750 mg every 8 hours I.M.)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Cholecystectomy:",
"     </i>",
"     I.V.: 1.5 g every 8 hours, discontinue within 24 hours unless infection outside gallbladder suspected",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Open heart:",
"     </i>",
"     I.V.: 1.5 g every 12 hours to a total of 6 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Urinary tract infection, uncomplicated:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 125-250 mg twice daily for 7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V., I.M.: 750 mg every 8 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F148329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/61/31701?source=see_link\">",
"      see \"Cefuroxime: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Cefuroxime axetil film-coated tablets and oral suspension are not bioequivalent and are not substitutable on a mg/mg basis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Children &ge;3 months to 12 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Epiglottitis:",
"     </b>",
"     <i>",
"      Oral:",
"     </i>",
"     150 mg/kg/day in 3 divided doses for 7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Acute otitis media, impetigo:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Suspension: 30 mg/kg/day (maximum: 1 g/day) in 2 divided doses for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Tablet: 250 mg every 12 hours for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      I.M., I.V.:",
"     </i>",
"     75-150 mg/kg/day divided every 8 hours (maximum dose: 6 g/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Acute bacterial maxillary sinusitis:",
"     </b>",
"     <i>",
"      Oral:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Suspension: 30 mg/kg/day in 2 divided doses for 10 days (maximum dose: 1 g/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Tablet: 250 mg twice daily for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Meningitis:",
"     </b>",
"     NOT recommended (doses of 200-240 mg/kg/day divided every 6-8 hours have been used) (maximum dose: 9 g/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Pharyngitis, tonsillitis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Suspension: 20 mg/kg/day (maximum: 500 mg/day) in 2 divided doses for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Tablet: 125 mg every 12 hours for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      I.M., I.V.:",
"     </i>",
"     75-150 mg/kg/day divided every 8 hours; maximum dose: 6 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;13 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F148309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F148310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-20 mL/minute: Administer every 12 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer every 24 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Dialyzable (25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis: Dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT): 1 g every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Cefuroxime axetil film-coated tablets and oral suspension are not bioequivalent and are not substitutable on a mg/mg basis.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F148279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed iso-osmotic solution, as sodium [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zinacef&reg;: 750 mg (50 mL); 1.5 g (50 mL) [contains sodium 4.8 mEq (111 mg) per 750 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as sodium [strength expressed as base]: 750 mg, 1.5 g, 7.5 g, 75 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zinacef&reg;: 750 mg, 1.5 g, 7.5 g [DSC] [contains sodium ~1.8 mEq (41 mg) per 750 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral, as axetil [strength expressed as base]: 125 mg/5 mL (100 mL); 250 mg/5 mL (50 mL, 100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ceftin&reg;: 125 mg/5 mL (100 mL) [contains phenylalanine 11.8 mg/5 mL; tutti frutti flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ceftin&reg;: 250 mg/5 mL (50 mL, 100 mL) [contains phenylalanine 25.2 mg/5 mL; tutti frutti flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as axetil [strength expressed as base]: 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ceftin&reg;: 250 mg, 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F148263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F148283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral suspension: Administer with food. Shake well before use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Inject deep I.M. into large muscle mass.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Inject direct I.V. over 3-5 minutes. Infuse intermittent infusion over 15-30 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F148359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, allopurinol, amifostine, anidulafungin, atracurium, aztreonam, bivalirudin, cyclophosphamide, cyclosporine, dexmedetomidine, diltiazem, docetaxel, etoposide phosphate, famotidine, fenoldopam, fentanyl, fludarabine, foscarnet, gemcitabine, granisetron, hetastarch in lactate electrolyte injection (Hextend&reg;), hydromorphone, linezolid, melphalan, meperidine, milrinone, morphine, ondansetron, pancuronium, pemetrexed, propofol, remifentanil, sargramostim, tacrolimus, teniposide, thiotepa, vecuronium.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Azithromycin, filgrastim, fluconazole, midazolam, pantoprazole, vinorelbine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Amiodarone, cisatracurium, vancomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Dimenhydrinate.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Doxapram, pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F148282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of infections caused by staphylococci, group B streptococci,",
"     <i>",
"      H. influenzae",
"     </i>",
"     (type A and B),",
"     <i>",
"      E. coli",
"     </i>",
"     ,",
"     <i>",
"      Enterobacter",
"     </i>",
"     ,",
"     <i>",
"      Salmonella",
"     </i>",
"     , and",
"     <i>",
"      Klebsiella",
"     </i>",
"     ; treatment of susceptible infections of the upper and lower respiratory tract, otitis media, urinary tract, uncomplicated skin and soft tissue, bone and joint, sepsis, uncomplicated gonorrhea, and early Lyme disease; surgical prophylaxis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F148361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cefuroxime may be confused with cefotaxime, cefprozil, deferoxamine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ceftin&reg; may be confused with Cefzil&reg;, Cipro&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zinacef&reg; may be confused with Zithromax&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ceftin [U.S., Canada] may be confused with Cefiton brand name for cefixime [Portugal]; Ceftim brand name for ceftazidime [Portugal]; Ceftime brand name for ceftazidime [Thailand]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F148351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Diarrhea (4% to 11%, duration-dependent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Diaper rash (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Alkaline phosphatase increased (2%), lactate dehydrogenase increased (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/vomiting (3% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Vaginitis (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Eosinophilia (7%), hemoglobin and hematocrit decreased (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Transaminases increased (2% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Thrombophlebitis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis, angioedema, BUN increased, chest pain, cholestasis, colitis, creatinine increased, dyspnea, erythema multiforme, fever, GI bleeding,  hemolytic anemia, hepatitis, hives, hyperbilirubinemia, hypersensitivity, interstitial nephritis, jaundice, leukopenia,  neutropenia, pain at injection site, pancytopenia, positive Coombs test, prolonged PT/INR, pseudomembranous colitis, rash, renal dysfunction, seizure, Stevens-Johnson syndrome, stomach cramps, tachycardia, thrombocytopenia (rare), tongue swelling, toxic epidermal necrolysis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Reactions reported with other cephalosporins: Agranulocytosis, aplastic anemia, asterixis, colitis, encephalopathy, hemorrhage, neuromuscular excitability, serum-sickness reactions, superinfection, toxic nephropathy",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F148286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cefuroxime, any component of the formulation, or other cephalosporins",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F148267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elevated INR: May be associated with increased INR, especially in nutritionally-deficient patients, prolonged treatment, hepatic or renal disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Penicillin allergy: Use with caution in patients with a history of penicillin allergy, especially IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; modify dosage in severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenylalanine: Some products may contain phenylalanine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suspension/tablet bioequivalence: Tablets and oral suspension are not bioequivalent; do not substitute on a mg-per-mg basis.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F148272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Cephalosporins (2nd Generation) may enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of Cefuroxime. Management:  Consider administering antacids and cefuroxime at least 2 hours apart.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May decrease the absorption of Cefuroxime. Separate oral doses by at least 2 hours.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Cephalosporins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F148300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Bioavailability is increased with food; cefuroxime serum levels may be increased if taken with food or dairy products.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F148275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5193889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Cefuroxime crosses the placenta and reaches the cord serum and amniotic fluid. Placental transfer is decreased in the presence of oligohydramnios. Several studies have failed to identify an increased teratogenic risk to the fetus following maternal cefuroxime use.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     During pregnancy, mean plasma concentrations of cefuroxime are 50% lower, the AUC is 25% lower, and the plasma half-life is shorter than nonpregnant values. At term, plasma half-life is similar to nonpregnant values and peak maternal concentrations after I.M. administration are slightly decreased. Pregnancy does not alter the volume of distribution. Cefuroxime is one of the antibiotics recommended for prophylactic use prior to cesarean delivery.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F148315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F148289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cefuroxime is excreted in breast milk. Manufacturer recommendations vary; caution is recommended if cefuroxime I.V. is given to a nursing woman and it is recommended to consider discontinuing nursing temporarily during treatment following oral cefuroxime. Nondose-related effects could include modification of bowel flora.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F148290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Some products may contain phenylalanine and/or sodium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral suspension: May be taken with food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F148288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Zinacef in D5W Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     750 mg (50 mL): $9.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Zinacef in Sterile Water Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5 g (50 mL): $16.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Cefuroxime Sodium Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5 g (1): $3.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5 g (1): $18.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 g (1): $330.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     225 g (1): $960.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     750 mg (1): $2.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Cefuroxime Sodium Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5 g (1): $6.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5 g (1): $28.47",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Cefuroxime Sodium-Dextrose Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     750 mg 4.1% (1): $10.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Zinacef Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5 g (1): $13.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5 g (1): $65.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     750 mg (1): $6.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Zinacef Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5 g (1): $13.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     750 mg (1): $7.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (Ceftin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mg/5 mL (100 mL): $97.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg/5 mL (50 mL): $73.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (Cefuroxime Axetil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mg/5 mL (100 mL): $68.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ceftin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (20): $241.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (20): $440.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Cefuroxime Axetil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (20): $87.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (20): $160.31",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F148277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor renal, hepatic, and hematologic function periodically with prolonged therapy. Monitor prothrombin time in patients at risk of prolongation during cephalosporin therapy (nutritionally-deficient, prolonged treatment, renal or hepatic disease). Observe for signs and symptoms of anaphylaxis during first dose.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F148291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alporin (KP);",
"     </li>",
"     <li>",
"      Altacef (PH);",
"     </li>",
"     <li>",
"      Anbacim (ID);",
"     </li>",
"     <li>",
"      Axacef (HK);",
"     </li>",
"     <li>",
"      Axet (PH);",
"     </li>",
"     <li>",
"      Axetine (NZ);",
"     </li>",
"     <li>",
"      Axim (HK);",
"     </li>",
"     <li>",
"      Axurocef (TW);",
"     </li>",
"     <li>",
"      Bacticef (IN);",
"     </li>",
"     <li>",
"      Bearcef (KP);",
"     </li>",
"     <li>",
"      C-Tri T (TH);",
"     </li>",
"     <li>",
"      Cefabiot (MX);",
"     </li>",
"     <li>",
"      Cefasun (IN);",
"     </li>",
"     <li>",
"      Ceflour (MY);",
"     </li>",
"     <li>",
"      Ceftil (KP);",
"     </li>",
"     <li>",
"      Cefudura (DE);",
"     </li>",
"     <li>",
"      Cefuhexal (DE);",
"     </li>",
"     <li>",
"      Cefuracet (MX);",
"     </li>",
"     <li>",
"      Cefurax (DE);",
"     </li>",
"     <li>",
"      Cefuro-Puren (DE);",
"     </li>",
"     <li>",
"      Cefurox-wolff (DE);",
"     </li>",
"     <li>",
"      Cefutil (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Cefuxime (HK, KP);",
"     </li>",
"     <li>",
"      Cefxin (SG);",
"     </li>",
"     <li>",
"      Cefzime (PH);",
"     </li>",
"     <li>",
"      Celocid (ID);",
"     </li>",
"     <li>",
"      Ceprosim (KP);",
"     </li>",
"     <li>",
"      Ceroxim (CL, IL, ZA);",
"     </li>",
"     <li>",
"      Cethixim (ID);",
"     </li>",
"     <li>",
"      Cetil (IN, PE);",
"     </li>",
"     <li>",
"      Cetoxil (MX);",
"     </li>",
"     <li>",
"      Cexil (KP);",
"     </li>",
"     <li>",
"      Cexim (HU);",
"     </li>",
"     <li>",
"      Curocef (AT, CN);",
"     </li>",
"     <li>",
"      Curoxime (PT);",
"     </li>",
"     <li>",
"      Deltrox (AR);",
"     </li>",
"     <li>",
"      Efurox (MY);",
"     </li>",
"     <li>",
"      Elobact (DE);",
"     </li>",
"     <li>",
"      Eroxmit (PH);",
"     </li>",
"     <li>",
"      Farmacef (TH);",
"     </li>",
"     <li>",
"      Fornax (PE);",
"     </li>",
"     <li>",
"      Froxime (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Furacam (EC);",
"     </li>",
"     <li>",
"      Furobioxin (MX);",
"     </li>",
"     <li>",
"      Furoxim (PH);",
"     </li>",
"     <li>",
"      Furoxime (TH);",
"     </li>",
"     <li>",
"      Gomcef (KP);",
"     </li>",
"     <li>",
"      Jectocef (PH);",
"     </li>",
"     <li>",
"      Kefezy (PH);",
"     </li>",
"     <li>",
"      Kefstar (PH);",
"     </li>",
"     <li>",
"      Kefurox (LU);",
"     </li>",
"     <li>",
"      Ketocef (HR);",
"     </li>",
"     <li>",
"      Magnaspor (TH);",
"     </li>",
"     <li>",
"      Medxime (PH);",
"     </li>",
"     <li>",
"      Neurox-250 (TH);",
"     </li>",
"     <li>",
"      Novador (MX);",
"     </li>",
"     <li>",
"      Novocef (HR);",
"     </li>",
"     <li>",
"      Olcef (KP);",
"     </li>",
"     <li>",
"      Oraxim (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Oxtercid (ID);",
"     </li>",
"     <li>",
"      Profurex (PH);",
"     </li>",
"     <li>",
"      Rucef (PH);",
"     </li>",
"     <li>",
"      Sefuxim (HK);",
"     </li>",
"     <li>",
"      Sharox-500 (ID);",
"     </li>",
"     <li>",
"      Situroxime (ID);",
"     </li>",
"     <li>",
"      Unoximed (PH);",
"     </li>",
"     <li>",
"      Vekfazolin (GR);",
"     </li>",
"     <li>",
"      Xorimax (CR, GT, HK, MY, NI, PA, PH, SG, SV);",
"     </li>",
"     <li>",
"      Xorufec (MX);",
"     </li>",
"     <li>",
"      Zamur (CR, GT, HN, NI, PA, SV, TT);",
"     </li>",
"     <li>",
"      Zegen (PH);",
"     </li>",
"     <li>",
"      Zinacef (BE, BG, CH, CL, CO, CZ, DK, EE, ES, FI, GB, GR, HU, IE, LU, MT, NL, NO, NZ, PH, PT, RU, SE, SK, TR);",
"     </li>",
"     <li>",
"      Zinat (CH);",
"     </li>",
"     <li>",
"      Zincef (KP);",
"     </li>",
"     <li>",
"      Zinnat (AE, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GT, GY, HK, HN, HR, HU, ID, IE, IL, IQ, IR, IT, JM, JO, KE, KP, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NI, NL, NZ, OM, PA, PE, PH, PK, PL, PR, PY, QA, SA, SC, SD, SL, SN, SR, SV, SY, TH, TN, TR, TW, TZ, UG, UY, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Zocef (TH);",
"     </li>",
"     <li>",
"      Zoref (PT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F148266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F148285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral (cefuroxime axetil): Increases with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely to body tissues and fluids; crosses blood-brain barrier; therapeutic concentrations achieved in CSF even when meninges are not inflamed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 33% to 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Tablet: Fasting: 37%; Following food: 52%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Children 1-2 hours; Adults: 1-2 hours; prolonged with renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: I.M.: &sim;15-60 minutes; I.V.: 2-3 minutes; Oral: Children: 3-4 hours; Adults: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (66% to 100% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abramowicz M, &ldquo;Antimicrobial Prophylaxis in Surgery,&rdquo;",
"      <i>",
"       Medical Letter on Drugs and Therapeutics, Handbook of Antimicrobial Therapy",
"      </i>",
"      , 16th ed, New York, NY: Medical Letter, 2002.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al.  &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/61/26583/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bratzler DW, Dellinger EP, Olsen KM, et al, &ldquo;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2013, 70(3):195-283.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/61/26583/abstract-text/23327981/pubmed\" id=\"23327981\" target=\"_blank\">",
"        23327981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bratzler DW and Houck PM (for the Surgical Infection Prevention Guidelines Writers Workgroup), &ldquo;Antimicrobial Prophylaxis for Surgery: An Advisory Statement From the National Surgical Infection Prevention Project,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2004, 38(12):1706-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/61/26583/abstract-text/15227616 /pubmed\" id=\"15227616 \" target=\"_blank\">",
"        15227616",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Broekhuysen J, Deger F, Douchamps J, et al, &ldquo;Pharmacokinetic Study of Cefuroxime in the Elderly,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1981, 21(6):801-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/61/26583/abstract-text/7340882/pubmed\" id=\"7340882\" target=\"_blank\">",
"        7340882",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Louvois J, Mulhall A, and Hurley R, &ldquo;Cefuroxime in the Treatment of Neonates,&rdquo;",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1982, 57(1):59-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/61/26583/abstract-text/7065695/pubmed\" id=\"7065695\" target=\"_blank\">",
"        7065695",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Douglas JG, Bax RP, and Munro JF, &ldquo;The Pharmacokinetics of Cefuroxime in the Elderly,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 1980, 6(4):543-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/61/26583/abstract-text/7430016/pubmed\" id=\"7430016\" target=\"_blank\">",
"        7430016",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gentry LO, Zeluff BJ, and Cooley DA, &ldquo;Antibiotic Prophylaxis in Open-Heart Surgery: A Comparison of Cefamandole, Cefuroxime, and Cefazolin,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 1988, 46(2):167-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/61/26583/abstract-text/3401076/pubmed\" id=\"3401076\" target=\"_blank\">",
"        3401076",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gooch WM 3rd, Blair E, Puopolo A, et al, &ldquo;Effectiveness of Five Days of Therapy With Cefuroxime Axetil Suspension for Treatment of Acute Otitis Media,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1996, 15(2):157-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/61/26583/abstract-text/8822290/pubmed\" id=\"8822290\" target=\"_blank\">",
"        8822290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mandell LA, Wunderink RG, Anzueto A, et al, &ldquo;Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2007, 44(Suppl 2):27-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/61/26583/abstract-text/17278083/pubmed\" id=\"17278083\" target=\"_blank\">",
"        17278083",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marshall WF and Blair JE, &ldquo;The Cephalosporins,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1999, 74(2):187-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/61/26583/abstract-text/10069359/pubmed\" id=\"10069359\" target=\"_blank\">",
"        10069359",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nelson JD, &ldquo;Cefuroxime: A Cephalosporin With Unique Applicability to Pediatric Practice,&rdquo;",
"      <i>",
"       Pediatr Infect Dis",
"      </i>",
"      , 1983, 2(5):394-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/61/26583/abstract-text/6356062/pubmed\" id=\"6356062\" target=\"_blank\">",
"        6356062",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Peterson CD, Lake KD, Arom KV, et al, &ldquo;Antibiotic Prophylaxis in Open-Heart Surgery Patients: Comparison of Cefamandole and Cefuroxime,&rdquo;",
"      <i>",
"       Drug Intell Clin Pharm",
"      </i>",
"      , 1987, 21(9):728-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/61/26583/abstract-text/3498617/pubmed\" id=\"3498617\" target=\"_blank\">",
"        3498617",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      ,  2010, 50(2):133-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/61/26583/abstract-text/20034345/pubmed\" id=\"20034345\" target=\"_blank\">",
"        20034345",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9230 Version 52.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D34A3220F9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_61_26583=[""].join("\n");
var outline_f25_61_26583=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148304\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148305\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148353\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148308\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148329\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148309\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148310\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682556\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148279\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148263\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148283\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148359\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148282\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148361\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148351\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148286\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148267\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298999\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148272\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148300\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148275\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5193889\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148315\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148289\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148290\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148288\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148277\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148291\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148266\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148285\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9230\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9230|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/55/29556?source=related_link\">",
"      Cefuroxime: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/61/31701?source=related_link\">",
"      Cefuroxime: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_61_26584="Myocardial dysfunction in end-stage renal disease";
var content_f25_61_26584=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Myocardial dysfunction in end-stage renal disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/61/26584/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/61/26584/contributors\">",
"     William L Henrich, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/61/26584/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/61/26584/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/61/26584/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/61/26584/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/61/26584/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular disease is an important cause of mortality in patients undergoing maintenance dialysis, accounting for almost 50 percent of deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It is an important source of morbidity, as the annual probability of hospital admission for heart failure (HF)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    myocardial ischemia is approximately 20 percent in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=see_link\">",
"     \"Patient survival and maintenance dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not surprisingly, the presence of heart failure (HF) independently predicts early mortality in end-stage renal disease as it does in nonuremic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]. In one study that used the United States Renal Data System database, long-term survival was evaluated among 310,456 incident hemodialysis patients with a first hospital admission for heart failure, fluid overload, or pulmonary edema [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/8\">",
"     8",
"    </a>",
"    ]. Five-year survival was only 12.5, 20.2, and 21.3 percent for these three groups, respectively. Increasing clinical severity of HF, as determined by the New York Heart Association classification, is also associated with increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myocardial dysfunction is common just prior to the onset of dialysis and often worsens after the initiation of dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/5,9-12\">",
"     5,9-12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HF was present in nearly 40 percent of over 4000 incident patients as reported in the United States Renal System Data Base [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective study of 432 patients found that 31 percent had evidence of HF at onset of dialysis and 25 percent of those without initial heart failure subsequently developed HF at a rate of approximately 7 percent per year [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 190 participants of the Chronic Renal Insufficiency Cohort (CRIC) study echocardiograms performed during advanced stages of CKD and after the initiation of dialysis showed a decline in the mean ejection fraction from 53 to 50 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/12\">",
"       12",
"      </a>",
"      ]. The proportion of patients with an ejection fraction &le;50 percent increased from 29 among patients with advanced CKD to 48 percent among patients with ESRD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both systolic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diastolic function may be impaired. Overall, observational studies suggest that the prevalence of heart failure is 10 to 30-fold higher among dialysis patients than in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/1,3,10,13\">",
"     1,3,10,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors for new onset HF include hypertension, older age, anemia, ischemic heart disease, and baseline systolic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/5\">",
"     5",
"    </a>",
"    ]. In another report, progressive myocardial dysfunction, as suggested by increasing left ventricular enlargement, was most pronounced within the first year of the initiation of dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/14\">",
"     14",
"    </a>",
"    ]. Enlargement occurring after the first year did not appear to be associated with a perceived reversible risk factor, such as anemia, level of blood pressure, nutrition, and mode of dialysis.",
"   </p>",
"   <p>",
"    Coronary heart disease and hypertension occur with increased frequency and are important causes of myocardial dysfunction in end-stage renal disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/49/33559?source=see_link\">",
"     \"Clinical manifestations and diagnosis of coronary heart disease in end-stage renal disease (dialysis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20202?source=see_link\">",
"     \"Hypertension in dialysis patients\"",
"    </a>",
"    .) In addition, there is evidence supporting a direct role for the uremic milieu",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an indirect role for enhanced cardiovascular calcification [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/15\">",
"     15",
"    </a>",
"    ]. Both an increase in diffuse myocardial fibrosis and a reduction in phosphocreatine have been demonstrated in uremic hearts [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Animal studies suggest that marinobufagenin, a cardiotonic steroid, may have a role in increasing fibrotic processes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The change in phosphocreatine may be mediated by disordered handling of intracellular calcium [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/17\">",
"     17",
"    </a>",
"    ]. Why these changes occur is not well understood, but secondary hyperparathyroidism may play a contributory role [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The degree of myocardial fibrosis can be blunted by the administration of an angiotensin converting enzyme (ACE) inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following is an overview of myocardial dysfunction in end-stage renal disease. Detailed discussions of these subjects are presented separately. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the marked incidence of myocardial dysfunction and poor overall cardiovascular prognosis in dialysis patients, dialysis patients should be evaluated for systolic (ie, reduced left ventricular ejection fraction)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diastolic dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11610?source=see_link\">",
"     \"Noninvasive methods for measurement of left ventricular systolic function\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=see_link\">",
"     \"Clinical manifestations and diagnosis of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines recommend that, at initiation of dialysis, all patients should undergo baseline echocardiography and electrocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/21\">",
"     21",
"    </a>",
"    ]. Echocardiography should be performed after dry weight is attained (which usually occurs after one to three months), and should be repeated routinely at three-year intervals.",
"   </p>",
"   <p>",
"    As with the general population, patients should also be re-evaluated if there are changes in cardiovascular status. This includes symptoms of heart failure, recurrent hemodialysis hypotension, consideration for a renal transplant, and post-cardiac events [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition to echocardiography, left ventricular systolic function can be evaluated with other modalities, including gated nuclear scintigraphy, ultrafast CT, contrast ventriculography, or cardiac magnetic resonance imaging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link\">",
"     \"Evaluation of the patient with suspected heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evaluation for the presence of coronary artery disease, which may underlie myocardial dysfunction in many dialysis patients, is particularly warranted. This includes those with decreased systolic function (ejection fraction less than 40 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/21\">",
"     21",
"    </a>",
"    ], and symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    signs suggestive of coronary heart disease, such as chest pain during dialysis. This assessment may include stress imaging",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    coronary angiography, the choice of which is based upon clinical",
"    <span class=\"nowrap\">",
"     symptoms/signs",
"    </span>",
"    and the presence or absence of cardiovascular risk factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/49/33559?source=see_link\">",
"     \"Clinical manifestations and diagnosis of coronary heart disease in end-stage renal disease (dialysis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Natriuretic hormones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial natriuretic peptide (ANP) is a hormone that is released from myocardial cells in the atria and, in some cases, the ventricles in response to volume expansion and possibly increased wall stress. Brain natriuretic peptide (BNP), a natriuretic hormone that is similar to ANP, was initially identified in the brain but is also present in the heart, particularly the ventricles. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The release of both ANP and BNP is increased in heart failure (HF), as ventricular cells are recruited to secrete both ANP and BNP in response to ventricular wall stretch. Therefore, the plasma concentrations of both hormones are increased in patients with asymptomatic and symptomatic left ventricular dysfunction, permitting their use in diagnosis among patients with normal renal function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although BNP is primarily cleared by the clearance receptor and neutral endopeptidase, GFR is inversely related to BNP concentrations. Thus, plasma BNP concentrations are often elevated in patients with renal insufficiency, whether or not they have clinically diagnosed HF.",
"   </p>",
"   <p>",
"    Therefore, we do NOT use plasma BNP for the diagnosis or management of HF in patients with renal failure, with or without dialysis. The main value would be a low plasma BNP, which would exclude left ventricular dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    N-Terminal pro-BNP (NT-pro-BNP), an inactive fragment released in a 1:1 ratio with BNP, is cleared by the kidney and its plasma concentration is elevated by renal failure alone and minimally removed by hemodialysis. There are insufficient data to establish clear cut-off values for NT-proBNP in this setting, and elevated levels may reflect various clinical abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, as with cTnT, increased NT-pro-BNP levels may have prognostic significance. A few studies that compared the accuracy of NT-pro-BNP and cTnT in predicting outcomes in dialysis patients have had conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/23-28\">",
"     23-28",
"    </a>",
"    ]. The best designed prospective study found that increased NT-pro-BNP levels were significantly associated with increased mortality and left ventricular systolic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/29\">",
"     29",
"    </a>",
"    ]. In an analysis of 150 asymptomatic hemodialysis patients, baseline levels of NT-pro-BNP and cTNT levels were correlated with echocardiographic variables and all-cause and cardiovascular mortality. NT-pro-BNP levels independently correlate with low midwall fractional shortening, a measure of poor systolic function. At a median follow-up of 24 months, there was a strong relationship between increasing NT-pro-BNP levels with all-cause (hazard ratio of 1.54, 4.78, and 4.03 for increasing quartiles) and cardiovascular mortality (HRs of 2.99, 10.95, and 8.54, respectively). By comparison, increasing cTnT levels had a weaker relationship with all-cause (HRs of 1.54, 2.32, and 3.39) and cardiovascular mortality (HRs of 0.81, 2.12, and 2.14).",
"   </p>",
"   <p>",
"    At present, we do NOT use NT-pro-BNP levels for prognostic information given individual variability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     LEFT VENTRICULAR HYPERTROPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left ventricular hypertrophy (LVH) is a common finding in mild renal disease and end-stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/29,30\">",
"     29,30",
"    </a>",
"    ], with some claiming an incidence of nearly 75 to 80 percent in dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/29,31\">",
"     29,31",
"    </a>",
"    ]. In those with relatively mild renal disease, a cross-sectional study reported a progressive increase of 40 to 80 percent in the incidence of LVH as renal dysfunction decreased from normal to near normal levels to end-stage disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LVH is usually diagnosed by echocardiography, with the definition being a left ventricular mass index &ge;134 and &ge;110",
"    <span class=\"nowrap\">",
"     g/m2",
"    </span>",
"    body surface area in men and women, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18247?source=see_link\">",
"     \"Definition and pathogenesis of left ventricular hypertrophy in hypertension\"",
"    </a>",
"    .) In the general population, the presence of LVH (on electrocardiogram or echocardiography) is important clinically because it is associated with increases in the incidence of heart failure, ventricular arrhythmias, death following myocardial infarction, decreased LV ejection fraction, sudden cardiac death, aortic root dilation, and a cerebrovascular event. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17959?source=see_link\">",
"     \"Clinical implications and treatment of left ventricular hypertrophy in hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    LVH is also a major risk factor for cardiovascular morbidity and mortality in patients with end-stage renal disease. Among those who have LVH, two-thirds die from HF or sudden death, while one-third die from a noncardiovascular event. Worsening of LVH is also a strong predictor of sudden death and arrhythmias, which is also associated with increased QT interval and dispersal [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/29,32\">",
"     29,32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Heart failure'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H11\">",
"     'Arrhythmias'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Increased levels of natriuretic peptides, particularly brain natriuretic peptides, are associated with increased LV hypertrophy and LV mass index in patients with and without ESRD. Among patients with ESRD, elevated levels of brain natriuretic peptide appear to correlate with adverse cardiovascular outcomes, although the exact role for these peptides in assessing cardiovascular prognosis is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to left ventricular mass [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/34\">",
"     34",
"    </a>",
"    ], left ventricular geometry also may be a determinant of prognosis. One study found that, in patients with left ventricular dilatation and normal systolic function, a high LV cavity volume (&gt;120",
"    <span class=\"nowrap\">",
"     mL/m2)",
"    </span>",
"    and a low mass-to-volume ratio (&lt;1.8",
"    <span class=\"nowrap\">",
"     mL/m2)",
"    </span>",
"    were independently associated with late mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/35\">",
"     35",
"    </a>",
"    ]. Thus, an increase in LV mass is associated with mortality only when the cavity volume is normal, whereas an increase in cavity volume is associated with mortality only when there is cavity dilation.",
"   </p>",
"   <p>",
"    Hypertension (particularly the systolic blood pressure) and increasing age are the major risk factors for LVH in dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/30,36\">",
"     30,36",
"    </a>",
"    ], but chronic volume overload, anemia, and perhaps the increase in cardiac index induced by the arteriovenous fistula created for hemodialysis access also may contribute. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/21/6486?source=see_link\">",
"     \"Anemia and left ventricular hypertrophy in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Prevention and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The poor prognosis associated with LVH in patients with renal failure may be improved by reducing left ventricular mass toward normal [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/37\">",
"     37",
"    </a>",
"    ]. Some degree of regression can be achieved by control of hypertension and by correction of anemia with erythropoietic stimulating agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20202?source=see_link\">",
"     \"Hypertension in dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/21/6486?source=see_link\">",
"     \"Anemia and left ventricular hypertrophy in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies in nonuremic hypertensive subjects suggest that, at equivalent blood pressure control, angiotensin converting enzyme inhibitors and calcium channel blockers reduce left ventricular mass more rapidly and perhaps more effectively than most other antihypertensive drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17959?source=see_link\">",
"     \"Clinical implications and treatment of left ventricular hypertrophy in hypertension\"",
"    </a>",
"    .) It is not clear if this observation applies to the patient with renal failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/21/6486?source=see_link\">",
"     \"Anemia and left ventricular hypertrophy in chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20202?source=see_link\">",
"     \"Hypertension in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Limited data have evaluated the efficacy of antihypertensive therapy in normotensive hemodialysis patients with increased left ventricular mass [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. This was best examined in a study of 46 normotensive hemodialysis patients with mildly increased left ventricular mass who were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    (2.5 mg three times per week) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/39\">",
"     39",
"    </a>",
"    ]. At one year, no significant benefit was observed with active therapy.",
"   </p>",
"   <p>",
"    Partial correction of anemia with erythropoietin presumably acts by improving tissue oxygen delivery, thereby allowing cardiac output (which is increased in anemia) and therefore cardiac work to fall toward normal. These changes have been associated with a 10 to 30 percent reduction in left ventricular mass index. This is discussed in detail separately, particularly the effects on the left ventricular mass index of near-normal and normal hemoglobin levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41257?source=see_link\">",
"     \"Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/21/6486?source=see_link\">",
"     \"Anemia and left ventricular hypertrophy in chronic kidney disease\"",
"    </a>",
"    .) However, attention must also be paid to the frequent elevation in blood pressure following erythropoietin, an effect that may partially counteract the benefit associated with the elevation in hematocrit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8436?source=see_link\">",
"     \"Hypertension following erythropoietin in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Kidney transplantation is also associated with regression of left ventricular hypertrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. As an example, one prospective study of 24 dialysis patients evaluated changes in hypertrophy by echocardiography at 3, 6, and 12 months post-transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/40\">",
"     40",
"    </a>",
"    ]. In addition to a significant decrease in blood pressure load at 12 months, the incidence of LVH decreased from 75 to 52 percent. There was also a significant decrease in left ventricular dilatation, and systolic dysfunction normalized in all patients after 12 months. It is unclear if removing the uremic milieu, improving the blood pressure load, or both were significant factors underlying this improvement.",
"   </p>",
"   <p>",
"    An additional reversible cause of LVH among patients with ESRD may include abnormalities of calcium phosphate homeostasis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17738?source=see_link\">",
"     \"Vascular calcification in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     HEART FAILURE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Either systolic or diastolic dysfunction can lead to clinically evident HF, even when the patient is at or near \"dry weight.\" Myocardial disease can also reduce cardiac reserve, making the patient more vulnerable to episodes of hypotension during dialysis. In addition, overt left ventricular hypertrophy is very common.",
"   </p>",
"   <p>",
"    The clinicopathologic features of dialysis patients with heart failure without coronary artery disease are poorly described. This was evaluated in a Japanese study in which endomyocardial biopsies were performed in 40 patients with dilated cardiomyopathy and without coronary artery disease and in a control group of 50 nondialysis patients with idiopathic dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/43\">",
"     43",
"    </a>",
"    ]. Severe myocyte hypertrophy and extensive fibrosis were characteristic of the dialysis group, which resembled the dilated phase of hypertrophic cardiomyopathy. Increasing fibrosis correlated with a decreased survival rate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30777?source=see_link\">",
"     \"Definition and classification of the cardiomyopathies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19465?source=see_link\">",
"     \"Causes of dilated cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemodialysis-induced myocardial stunning, which is defined as hemodialysis-induced segmental left ventricular dysfunction without heart disease, is common and may be associated with an adverse prognosis. In a study of 70 hemodialysis patients, significant myocardial stunning during hemodialysis was noted at baseline in 64 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/44\">",
"     44",
"    </a>",
"    ]. At 12-month follow-up, survival was significantly lower in those with stunning and, among those who survived, the left ventricular ejection fraction was markedly lower at rest and during hemodialysis. A second study demonstrated a much lower prevalence of hemodialysis-induced left ventricular dysfunction of 27 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/45\">",
"     45",
"    </a>",
"    ]. The difference in prevalence between studies may have been due to differences in the study population (including a lower percentage of patients with diabetes, known cardiovascular disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    left ventricular hypertrophy in the latter study) or to differences in the echocardiographic method of evaluation.",
"   </p>",
"   <p>",
"    The underlying cause of stunning in this setting is unknown.",
"   </p>",
"   <p>",
"    The epidemiology and clinical features associated with heart failure in dialysis patients as well as the evaluation of such patients are discussed above and in detail separately. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3\">",
"     'Evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of heart failure in dialysis patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/12/9416?source=see_link\">",
"     \"Therapy of heart failure in hemodialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ARRHYTHMIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular and atrial arrhythmias are additional manifestations of myocardial dysfunction in end-stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Ventricular arrhythmias and sudden death",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of ventricular",
"    <span class=\"nowrap\">",
"     tachycardia/fibrillation",
"    </span>",
"    is a significant source of morbidity and mortality, such as sudden death and cardiac arrest, in dialysis patients. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11288?source=see_link\">",
"     \"Evaluation of sudden cardiac arrest and sudden cardiac death in dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/36/15945?source=see_link\">",
"     \"Treatment and prevention of sudden cardiac arrest in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other than dosing with renal failure, additional issues surrounding ventricular arrhythmias and their management are largely the same in patients with and without end-stage renal disease. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important and as yet unresolved issue is the incidence, morbidity, and mortality associated with atrial fibrillation (AF) among dialysis patients. Published data are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/46-49\">",
"     46-49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 488 patients (mean age 67 years), AF was noted in 27 percent, with 3.5, 9.6, and 13.9 percent having paroxysmal, persistent, and permanent AF, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/46\">",
"       46",
"      </a>",
"      ]. On multivariate analysis, AF was significantly associated with age, increased duration of dialysis, and LA dilatation.",
"     </li>",
"     <li>",
"      In a single center study of 190 hemodialysis patients (mean age 60 years), AF was identified in 13.6 percent, most of whom (9.4 percent) had chronic AF [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second single center study of 256 hemodialysis patients reported that 12.1 percent had AF at dialysis initiation while, among 225 patients initially in sinus rhythm, 28 subsequently developed AF during a mean followup of 24 months (12.4 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An analysis of 63,884 US hemodialysis patients showed a prevalence of chronic AF of 7 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/49\">",
"       49",
"      </a>",
"      ]. Atrial fibrillation was associated with age greater than 60 years, male sex, Caucasian race, body mass index greater than 25",
"      <span class=\"nowrap\">",
"       kg/m2,",
"      </span>",
"      coronary artery disease and heart failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This is a much higher prevalence than expected for ages 60 to 69 (1 to 3 percent in the general population) (",
"    <a class=\"graphic graphic_figure graphicRef77268 \" href=\"UTD.htm?2/14/2286\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26584/abstract/50\">",
"     50",
"    </a>",
"    ]. At least two factors may contribute to the increase in prevalence of AF in patients with end-stage renal disease: more comorbidities that predispose to AF; and a greater likelihood of detecting paroxysmal AF because of monitoring during dialysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=see_link\">",
"     \"Epidemiology of and risk factors for atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antithrombotic therapy in patients with chronic kidney disease or end stage renal disease who have atrial fibrillation is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39721?source=see_link\">",
"     \"Management of thromboembolic risk in patients with atrial fibrillation and chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1437836\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Heart failure (HF) independently predicts early mortality in end-stage renal disease. The increasing clinical severity of HF is also associated with increased mortality in such patients. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for new onset HF include hypertension, older age, anemia, ischemic heart disease, and baseline systolic dysfunction. Other contributors to HF include the uremic milieu and enhanced cardiovascular calcification. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dialysis patients should be evaluated for systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic dysfunction. All patients should undergo baseline echocardiography and electrocardiography. Echocardiography should be performed after dry weight is attained, and should be repeated routinely at three-year intervals. Patients should be re-evaluated if there are changes in cardiovascular status. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation for the presence of coronary artery disease is warranted in selected patients including those with decreased systolic function (ejection fraction less than 40 percent), and symptoms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      signs suggestive of coronary heart disease, such as chest pain during dialysis. This assessment may include stress imaging",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      coronary angiography. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do NOT use plasma brain natriuretic hormone (BNP) for the diagnosis or management of HF in patients with renal failure, with or without dialysis. This is because plasma BNP concentrations are often elevated in patients with renal insufficiency, whether or not they have clinically diagnosed HF. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Natriuretic hormones'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Left ventricular hypertrophy (LVH) is a major risk factor for cardiovascular morbidity and mortality in patients with end-stage renal disease. Left ventricular hypertrophy (LVH) is usually diagnosed by echocardiography. Left ventricular geometry may also be a determinant of prognosis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Left ventricular hypertrophy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Regression of LVH can be achieved by control of hypertension, correction of anemia with erythropoietic stimulating agents, and possibly correction of abnormalities of calcium phosphate homeostasis. Kidney transplantation is also associated with regression of LVH. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Prevention and management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The development of ventricular arrhythmias is a significant source of morbidity and mortality in dialysis patients. The management of ventricular arrhythmias is largely the same in patients with and without end-stage renal disease. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Ventricular arrhythmias and sudden death'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is a higher prevalence of atrial fibrillation (AF) among dialysis patients. Contributing factors include a high incidence of predisposing comorbidities and a greater likelihood of detecting paroxysmal AF because of monitoring during dialysis.(See",
"      <a class=\"local\" href=\"#H13\">",
"       'Atrial fibrillation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/1\">",
"      U.S. Renal Data System: USRDS 2008 annual data report. The National Institutes of Health. 2008. Am J Kidney Dis 2009; 1(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/2\">",
"      Venkatesan J, Henrich WL. Anemia, hypertension, and myocardial dysfunction in end-stage renal disease. Semin Nephrol 1997; 17:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/3\">",
"      Churchill DN, Taylor DW, Cook RJ, et al. Canadian Hemodialysis Morbidity Study. Am J Kidney Dis 1992; 19:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/4\">",
"      Trespalacios FC, Taylor AJ, Agodoa LY, et al. Heart failure as a cause for hospitalization in chronic dialysis patients. Am J Kidney Dis 2003; 41:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/5\">",
"      Harnett JD, Foley RN, Kent GM, et al. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 1995; 47:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/6\">",
"      Zoccali C, Benedetto FA, Tripepi G, et al. Left ventricular systolic function monitoring in asymptomatic dialysis patients: a prospective cohort study. J Am Soc Nephrol 2006; 17:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/7\">",
"      Postorino M, Marino C, Tripepi G, et al. Prognostic value of the New York Heart Association classification in end-stage renal disease. Nephrol Dial Transplant 2007; 22:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/8\">",
"      Banerjee D, Ma JZ, Collins AJ, Herzog CA. Long-term survival of incident hemodialysis patients who are hospitalized for congestive heart failure, pulmonary edema, or fluid overload. Clin J Am Soc Nephrol 2007; 2:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/9\">",
"      Parfrey PS, Harnett JD, Griffiths SM, et al. Congestive heart failure in dialysis patients. Arch Intern Med 1988; 148:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/10\">",
"      Stack AG, Bloembergen WE. A cross-sectional study of the prevalence and clinical correlates of congestive heart failure among incident US dialysis patients. Am J Kidney Dis 2001; 38:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/11\">",
"      McCullough PA. Cardiovascular disease in chronic kidney disease from a cardiologist's perspective. Curr Opin Nephrol Hypertens 2004; 13:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/12\">",
"      Bansal N, Keane M, Delafontaine P, et al. A Longitudinal Study of Left Ventricular Function and Structure from CKD to ESRD: The CRIC Study. Clin J Am Soc Nephrol 2013; 8:355.",
"     </a>",
"    </li>",
"    <li>",
"     Collins, AJ. Impact of congestive heart failure and other cardiac diseases on patient outcomes. Kidney Int Suppl 2002; 53.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/14\">",
"      Foley RN, Parfrey PS, Kent GM, et al. Long-term evolution of cardiomyopathy in dialysis patients. Kidney Int 1998; 54:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/15\">",
"      London GM. Cardiovascular calcifications in uremic patients: clinical impact on cardiovascular function. J Am Soc Nephrol 2003; 14:S305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/16\">",
"      Mall G, Rambausek M, Neumeister A, et al. Myocardial interstitial fibrosis in experimental uremia--implications for cardiac compliance. Kidney Int 1988; 33:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/17\">",
"      Raine AE, Seymour AM, Roberts AF, et al. Impairment of cardiac function and energetics in experimental renal failure. J Clin Invest 1993; 92:2934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/18\">",
"      Elkareh J, Periyasamy SM, Shidyak A, et al. Marinobufagenin induces increases in procollagen expression in a process involving protein kinase C and Fli-1: implications for uremic cardiomyopathy. Am J Physiol Renal Physiol 2009; 296:F1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/19\">",
"      Amann K, Ritz E, Wiest G, et al. A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 1994; 4:1814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/20\">",
"      Smogorzewski M, Massry SG. Uremic cardiomyopathy: role of parathyroid hormone. Kidney Int Suppl 1997; 62:S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/21\">",
"      K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/22\">",
"      Booth J, Pinney J, Davenport A. N-terminal proBNP--marker of cardiac dysfunction, fluid overload, or malnutrition in hemodialysis patients? Clin J Am Soc Nephrol 2010; 5:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/23\">",
"      Sommerer C, Beimler J, Schwenger V, et al. Cardiac biomarkers and survival in haemodialysis patients. Eur J Clin Invest 2007; 37:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/24\">",
"      Fern&aacute;ndez-Reyes MJ, Mon C, Heras M, et al. Predictive value of troponin T levels for ischemic heart disease and mortality in patients on hemodialysis. J Nephrol 2004; 17:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/25\">",
"      Apple FS, Murakami MM, Pearce LA, Herzog CA. Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. Clin Chem 2004; 50:2279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/26\">",
"      Satyan S, Light RP, Agarwal R. Relationships of N-terminal pro-B-natriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients. Am J Kidney Dis 2007; 50:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/27\">",
"      Roberts MA, Srivastava PM, Macmillan N, et al. B-type natriuretic peptides strongly predict mortality in patients who are treated with long-term dialysis. Clin J Am Soc Nephrol 2008; 3:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/28\">",
"      Wang AY, Lai KN. Use of cardiac biomarkers in end-stage renal disease. J Am Soc Nephrol 2008; 19:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/29\">",
"      Stewart GA, Gansevoort RT, Mark PB, et al. Electrocardiographic abnormalities and uremic cardiomyopathy. Kidney Int 2005; 67:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/30\">",
"      Harnett JD, Kent GM, Barre PE, et al. Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients. J Am Soc Nephrol 1994; 4:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/31\">",
"      Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol 2001; 12:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/32\">",
"      Paoletti E, Specchia C, Di Maio G, et al. The worsening of left ventricular hypertrophy is the strongest predictor of sudden cardiac death in haemodialysis patients: a 10 year survey. Nephrol Dial Transplant 2004; 19:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/33\">",
"      Joffy S, Rosner MH. Natriuretic peptides in ESRD. Am J Kidney Dis 2005; 46:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/34\">",
"      Mallamaci F, Zoccali C, Parlongo S, et al. Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2002; 40:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/35\">",
"      Foley RN, Parfrey PS, Harnett JD, et al. The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 1995; 5:2024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/36\">",
"      Zoccali C, Benedetto FA, Tripepi G, Mallamaci F. Cardiac consequences of hypertension in hemodialysis patients. Semin Dial 2004; 17:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/37\">",
"      Foley RN, Parfrey PS, Kent GM, et al. Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol 2000; 11:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/38\">",
"      Wang AY, Li PK, Lui SF, Sanderson JE. Angiotensin converting enzyme inhibition for cardiac hypertrophy in patients with end-stage renal disease: what is the evidence? Nephrology (Carlton) 2004; 9:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/39\">",
"      Yu WC, Lin YP, Lin IF, et al. Effect of ramipril on left ventricular mass in normotensive hemodialysis patients. Am J Kidney Dis 2006; 47:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/40\">",
"      Ferreira SR, Mois&eacute;s VA, Tavares A, Pacheco-Silva A. Cardiovascular effects of successful renal transplantation: a 1-year sequential study of left ventricular morphology and function, and 24-hour blood pressure profile. Transplantation 2002; 74:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/41\">",
"      Rigatto C, Foley RN, Kent GM, et al. Long-term changes in left ventricular hypertrophy after renal transplantation. Transplantation 2000; 70:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/42\">",
"      De Lima JJ, Vieira ML, Viviani LF, et al. Long-term impact of renal transplantation on carotid artery properties and on ventricular hypertrophy in end-stage renal failure patients. Nephrol Dial Transplant 2002; 17:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/43\">",
"      Aoki J, Ikari Y, Nakajima H, et al. Clinical and pathologic characteristics of dilated cardiomyopathy in hemodialysis patients. Kidney Int 2005; 67:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/44\">",
"      Burton JO, Jefferies HJ, Selby NM, McIntyre CW. Hemodialysis-induced cardiac injury: determinants and associated outcomes. Clin J Am Soc Nephrol 2009; 4:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/45\">",
"      Assa S, Hummel YM, Voors AA, et al. Hemodialysis-induced regional left ventricular systolic dysfunction: prevalence, patient and dialysis treatment-related factors, and prognostic significance. Clin J Am Soc Nephrol 2012; 7:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/46\">",
"      Genovesi S, Pogliani D, Faini A, et al. Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am J Kidney Dis 2005; 46:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/47\">",
"      V&aacute;zquez E, S&aacute;nchez-Perales C, Borrego F, et al. Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. Am Heart J 2000; 140:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/48\">",
"      Vazquez E, Sanchez-Perales C, Garcia-Garcia F, et al. Atrial fibrillation in incident dialysis patients. Kidney Int 2009; 76:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/49\">",
"      Wetmore JB, Mahnken JD, Rigler SK, et al. The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaid-eligible dialysis patients. Kidney Int 2012; 81:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26584/abstract/50\">",
"      Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285:2370.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1846 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-95F309B6B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_61_26584=[""].join("\n");
var outline_f25_61_26584=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1437836\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Natriuretic hormones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      LEFT VENTRICULAR HYPERTROPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Prevention and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HEART FAILURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ARRHYTHMIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Ventricular arrhythmias and sudden death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1437836\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1846\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1846|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/14/2286\" title=\"figure 1\">",
"      Prevalence of atrial fibrillation with age",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/21/6486?source=related_link\">",
"      Anemia and left ventricular hypertrophy in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41257?source=related_link\">",
"      Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19465?source=related_link\">",
"      Causes of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17959?source=related_link\">",
"      Clinical implications and treatment of left ventricular hypertrophy in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/49/33559?source=related_link\">",
"      Clinical manifestations and diagnosis of coronary heart disease in end-stage renal disease (dialysis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=related_link\">",
"      Clinical manifestations and diagnosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30777?source=related_link\">",
"      Definition and classification of the cardiomyopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18247?source=related_link\">",
"      Definition and pathogenesis of left ventricular hypertrophy in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=related_link\">",
"      Epidemiology of and risk factors for atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11288?source=related_link\">",
"      Evaluation of sudden cardiac arrest and sudden cardiac death in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8436?source=related_link\">",
"      Hypertension following erythropoietin in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20202?source=related_link\">",
"      Hypertension in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39721?source=related_link\">",
"      Management of thromboembolic risk in patients with atrial fibrillation and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11610?source=related_link\">",
"      Noninvasive methods for measurement of left ventricular systolic function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=related_link\">",
"      Patient survival and maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/12/9416?source=related_link\">",
"      Therapy of heart failure in hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/36/15945?source=related_link\">",
"      Treatment and prevention of sudden cardiac arrest in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17738?source=related_link\">",
"      Vascular calcification in chronic kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_61_26585="Initial surgical management of melanoma of the skin and unusual sites";
var content_f25_61_26585=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial surgical management of melanoma of the skin and unusual sites",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/61/26585/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/61/26585/contributors\">",
"     Michael Stone, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/61/26585/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/61/26585/contributors\">",
"     Michael B Atkins, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/61/26585/contributors\">",
"     Martin Weiser, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/61/26585/contributors\">",
"     Hensin Tsao, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/61/26585/contributors\">",
"     Russell S Berman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/61/26585/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/61/26585/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/61/26585/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/61/26585/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper surgical management is critical for establishing the diagnosis, staging, and providing the optimal treatment of primary cutaneous melanoma.",
"   </p>",
"   <p>",
"    The goals of surgery include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Histologic confirmation of the diagnosis of melanoma, which ideally has been established through an appropriately planned biopsy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22009?source=see_link\">",
"       \"Pathologic characteristics of melanoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Obtaining complete and accurate microstaging of the primary tumor to guide therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42488?source=see_link\">",
"       \"Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Appropriate margin excision of the primary site to minimize the risk of local recurrence without compromising additional staging maneuvers (eg, sentinel lymph node biopsy potentially is less accurate after wide margin excision).",
"     </li>",
"     <li>",
"      Optimal functional outcome and cosmetic results.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The surgical principles for the management of primary cutaneous melanomas, as well as those arising in mucous membranes, subungual, and plantar regions, are discussed here. Surgery also is an important component in the management of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Regional lymph nodes (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26664?source=see_link\">",
"       \"Evaluation and treatment of regional lymph nodes in melanoma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Local recurrences (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34007?source=see_link\">",
"       \"Cutaneous melanoma: Management of local recurrence\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      In transit metastases (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27081?source=see_link\">",
"       \"Cutaneous melanoma: Management of in transit metastases\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Distant metastatic disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/8/2183?source=see_link\">",
"       \"Surgical management of metastatic melanoma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ocular melanomas (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/59/8122?source=see_link\">",
"       \"Ocular melanoma\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INITIAL BIOPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An excisional biopsy with a 1 to 2 mm rim of normal-appearing skin is the optimal technique for lesions suspected to be melanomas.",
"   </p>",
"   <p>",
"    An excisional biopsy should be performed with consideration of definitive surgery in mind, should the diagnosis of melanoma be confirmed. As such, the incision should be oriented along Langer's lines of stress on the trunk, and parallel to the long axis of the extremity for extremity lesions. Such an incision facilitates the subsequent closure of a wide local excision and minimizes the need for skin grafting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40264?source=see_link\">",
"     \"Skin biopsy techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For large lesions, a punch or incisional biopsy permits the diagnosis of melanoma to be made in most cases. However, an incisional biopsy may not accurately assess tumor thickness if the thickest portion of the lesion is not sampled [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Superficial shave biopsies are never appropriate for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The lesion is likely to be inadequately excised, with residual tumor remaining at both the radial and deep margins.",
"     </li>",
"     <li>",
"      Because only the superficial portion of the tumor is removed, shave biopsies results underestimate tumor thickness, a critical prognostic factor and determinant of treatment.",
"     </li>",
"     <li>",
"      Fibrosis and scarring at the base of the biopsy site may obscure residual melanoma, making it impossible for a pathologist to identify tumor and accurately measure its thickness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     WIDE LOCAL EXCISION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definitive surgical treatment for primary cutaneous melanoma is a wide local excision down to the deep fascia. The recommended width of the normal tissue around the lesion has progressively decreased as a result of multiple large clinical trials that have examined the impact of the surgical margin on the local recurrence rate (",
"    <a class=\"graphic graphic_table graphicRef73371 \" href=\"UTD.htm?3/55/3965\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The thickness of the melanoma is a key factor in determining the stage of the lesion and the recommended margin of normal tissue to be resected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42488?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Thin melanomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several large clinical trials have studied the optimal resection margins for patients with thin (T1,T2) primary melanomas (",
"    <a class=\"graphic graphic_table graphicRef50225 graphicRef74203 \" href=\"UTD.htm?32/8/32910\">",
"     table 2A-B",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a World Health Organization (WHO) trial, 612 patients with melanomas &lt;2.0 mm thick were randomly assigned to wide local excision with a 3 cm margin or a narrower excision with a 1 cm margin [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/2-4\">",
"       2-4",
"      </a>",
"      ]. At 12 year follow-up, survival rates were similar (87 versus 85 percent), and the local recurrence rate for all patients was 1.8 percent. There were four local recurrences in patients with lesions 1.1 to 2.0 mm thick in the 1 cm margin group, compared to none in the 3 cm margin group, a difference that was not statistically significant. Based upon these results, the WHO recommended the use of 1 cm margins for patients with melanomas &le;1 mm thick and made no recommendation for thicker melanomas. However, in a subsequent report with additional follow-up, the 3 cm margin group had a local recurrence rate of 1 percent (",
"      <a class=\"graphic graphic_table graphicRef60305 \" href=\"UTD.htm?11/10/11435\">",
"       table 3",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/2\">",
"       2",
"      </a>",
"      ]. Two-thirds of the patients who developed a local recurrence died.",
"     </li>",
"     <li>",
"      In a trial conducted by the Swedish Melanoma Study Group, 989 patients with melanomas 0.8 to 2 mm thick were randomly assigned to 2 cm or 5 cm resection margins [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/5\">",
"       5",
"      </a>",
"      ]. At a median follow-up of 11 years, the rate of local recurrence for all patients was less than 1 percent and was similar in both groups. There were no differences between the groups in either overall or disease-free survival.",
"     </li>",
"     <li>",
"      A third trial sponsored by the French Cooperative Group consisted of 362 patients with melanomas &le;2 mm in thickness, who were randomly assigned to 2 cm versus 5 cm margins [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/6\">",
"       6",
"      </a>",
"      ]. There was no difference between the groups in the risk of local recurrence or in overall survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these results, our approach is to resect melanomas &lt;1 mm thick (T1) with a 1 cm margin of normal tissue. For melanomas 1 to 2 mm thick (T2 lesions), we use a 2 cm margin of normal tissue if this is feasible without the need for a skin graft; a 1 cm margin may be adequate if anatomically constrained based upon the location of the lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Intermediate thickness melanomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;For primary melanomas between 2 and 4 mm thick (T3), clinical trials have not demonstrated a benefit of excision margins &gt;2 cm. Thus, we suggest a 2 cm margin in this setting.",
"   </p>",
"   <p>",
"    The clinical trial data supporting this approach include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a multicenter European trial that enrolled patients from 1992 to 2004, 936 patients with a resected melanoma greater than 2 mm thick were randomly assigned to have either a 2 cm or 4 cm resection margin [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/7\">",
"       7",
"      </a>",
"      ]. The study was originally designed to include 2000 patients, but the trial was terminated early when accrual slowed. After a median follow-up of 6.7 years, there was no statistically significant difference in either recurrence-free or overall survival (hazard ratios 0.98 and 1.00).",
"     </li>",
"     <li>",
"      The Melanoma Intergroup Trial randomly assigned 468 patients with intermediate thickness (1 to 4 mm) melanomas to 2 cm or 4 cm excision margins [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/8-10\">",
"       8-10",
"      </a>",
"      ]. At a median follow-up of eight years, the rates of overall survival and local recurrence were not significantly decreased with the 2 cm excision margin (80 versus 84 percent with a 4 cm margin and 0.8 versus 1.7 percent, respectively). On multivariate analysis, statistically significant independent predictors of local recurrence included tumor thickness and ulceration, but not the excision margin. Patients treated with the 2 cm excision margin had a shorter hospital stay and required skin grafting less frequently (11 versus 46 percent).",
"     </li>",
"     <li>",
"      In a third trial, a higher locoregional recurrence rate (local and nodal recurrence, in transit metastases) was observed in a British trial that randomly assigned 900 patients with lesions &ge;2 mm thick to 1 cm or 3 cm margins [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/11\">",
"       11",
"      </a>",
"      ]. At a median follow-up of 60 months, the risk of locoregional recurrence was significantly higher with 1 cm margins (hazard ratio [HR] 1.26), but the difference in melanoma-specific survival did not reach the level of statistical significance (HR 1.24, 95% CI 0.96-1.61). The authors concluded that 1 cm surgical margins should be restricted to patients with tumor thickness &lt;2 mm, and that thicker melanomas require excision margins that exceed 1 cm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Thick melanomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;For thick melanomas (ie, those &gt;4 mm), we also suggest an excision margin of 2 cm. There is no evidence that margins &gt;2 cm decrease the incidence of local recurrence. In this group, the outcome depends upon the presence of regional",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    distant disease.",
"   </p>",
"   <p>",
"    Data about the optimal approach in this setting is more limited:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the British trial involving 900 patients, 243 patients (27 percent) had lesions &gt;4 mm thick [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/11\">",
"       11",
"      </a>",
"      ]. Overall, that trial observed an increased risk of local recurrence with 1 cm surgical margins compared to 3 cm (hazard ratio [HR] 1.26). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Intermediate thickness melanomas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The only other extensive series of data for patients with thick (&ge;4 mm) primary melanomas comes from a retrospective review of 278 patients with a median tumor thickness of 6 mm [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/12\">",
"       12",
"      </a>",
"      ]. There was no correlation between the width of resection (&gt;2 cm versus &lt;2 cm) and local recurrence or overall survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No study has directly compared 2 cm with 3 cm margins for patients with thick primary melanoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     In situ melanomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with in situ melanomas, there are no data from randomized trials to define the optimal extent of surgical resection. A 1992 NIH consensus conference recommended the routine use of 0.5 cm margins for in situ melanomas, although margins &gt;5 mm may be required for in situ lentigo maligna melanoma based upon histologic evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/1\">",
"     1",
"    </a>",
"    ]. However, margins up to 1 cm may be required for complete clearance in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/13\">",
"     13",
"    </a>",
"    ]. Guidelines from the American Academy of Dermatology in 2011 recommend a resection margin of 0.5 to 1.0 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21982963\">",
"    <span class=\"h2\">",
"     Management of muscular fascia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine extension of surgery to include the muscular fascia during a wide local excision of cutaneous melanomas of the extremities or trunk (&ge;1 mm thick) does not appear to offer any benefit in terms of long-term local disease control and is not recommended.",
"   </p>",
"   <p>",
"    A single institution, retrospective review of 964 cases of melanoma &ge;1 cm thick, including 278 (29 percent) who underwent resection of the muscular fascia, found no decrease in the rate of local recurrence when the muscular fascia was resected [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/15\">",
"     15",
"    </a>",
"    ]. Resection of the fascia was associated with an increase in the incidence of in transit and regional lymph node metastases. Whether this reflects an effect on the barrier to lymphatic spread or simply a patient selection bias is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Experimental approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mohs microsurgery (MMS) has been evaluated in patients with melanomas in difficult locations and for superficial lesions of large diameter (eg, lentigo maligna). Although one series suggests that MMS effectively controls the primary tumor site [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/16\">",
"     16",
"    </a>",
"    ], longer follow-up will be required before this approach can be widely used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/63/17400?source=see_link\">",
"     \"Mohs surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In another experimental approach, the topical immune modifier",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    has been used to treat lentigo maligna [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. As an example, a role for this approach was suggested in a series of 30 cases in which three months of daily treatment achieved complete regression in over 90 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/17\">",
"     17",
"    </a>",
"    ]. This approach remains experimental and should not be used outside a protocol setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22009?source=see_link&amp;anchor=H4#H4\">",
"     \"Pathologic characteristics of melanoma\", section on 'In situ melanoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13690?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment and prognosis of basal cell carcinoma\", section on 'Imiquimod'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     REGIONAL LYMPH NODES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision of whether or not to surgically stage regional lymph nodes is based upon the risk of recurrence.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients in whom the regional lymph nodes are clinically negative and the primary melanoma has a low risk of recurrence due to lack of adverse pathologic features (stage IA without ulceration and with &lt;1",
"      <span class=\"nowrap\">",
"       mitosis/mm",
"       <sup>",
"        2",
"       </sup>",
"       ),",
"      </span>",
"      we recommend omitting lymphatic mapping with sentinel lymph node biopsy.",
"     </li>",
"     <li>",
"      For patients with clinically negative nodes and a primary melanoma at intermediate or high risk for lymph node metastasis, lymphatic mapping with sentinel lymph node biopsy is recommended. This includes melanomas &gt;1 mm thick, and melanomas &lt;1mm thick but with adverse primary tumor features (eg, ulceration or mitotic rate &ge;1",
"      <span class=\"nowrap\">",
"       mitosis/mm",
"       <sup>",
"        2",
"       </sup>",
"       ).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The indications for sentinel lymph node biopsy of the regional nodes and the incorporation of the results into the subsequent management of patients with cutaneous melanoma are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26664?source=see_link\">",
"     \"Evaluation and treatment of regional lymph nodes in melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ADJUVANT IMMUNOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of adjuvant immunotherapy with interferon following staging is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44711?source=see_link&amp;anchor=H2#H2\">",
"     \"Adjuvant immunotherapy for melanoma\", section on 'Clinical trials'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SKIN OF HEAD AND NECK",
"    </span>",
"    &nbsp;&mdash;&nbsp;The skin of the head and neck accounts for 15 to 30 percent of all primary melanomas, despite the fact that this region accounts for only 9 percent of the total surface area of the body [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Multiple factors may contribute to this anatomic predilection for the skin of the head and neck, including higher levels of sun exposure and a melanocyte content of the skin that is two- to threefold higher than other regions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link\">",
"     \"Risk factors for the development of melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Surgical management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melanomas of the face and scalp are associated with higher rates of local recurrence and regional lymph node disease than those arising on extremity or trunk sites.",
"   </p>",
"   <p>",
"    The recommendations for surgical margins during wide local excision are the same as for other cutaneous melanomas. These recommendations were derived from trials in which most patients had extremity or truncal melanomas. In the head and neck, such margins are not always attainable and may result in significant functional and cosmetic disability. Although skin grafts on the face are avoided whenever possible, the appropriate excision margins for the degree of tumor thickness should not be compromised solely because of cosmetic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Wide local excision'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Intraoperative frozen section analysis may be helpful when tissue conservation is important. However, the use of frozen section analysis carries a small but real risk of a false negative report [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/25\">",
"     25",
"    </a>",
"    ]. Thus, frozen section analysis should be used judiciously and only by surgeons and pathologists with experience in its use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Regional nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The parotid and cervical lymphatics are the most common sites of spread for melanomas of the head and neck.",
"   </p>",
"   <p>",
"    In contrast to the widespread acceptance of lymphatic mapping and sentinel lymph node biopsy for extremity and truncal melanomas, the role of this technique in cutaneous melanomas of the head and neck is evolving. The use of this approach has been limited by the complexity of lymphatic drainage patterns and the frequent need to remove sentinel nodes from the parotid gland, thereby risking damage to the facial nerve. A sentinel node can be identified in approximately 95 percent of patients with low false negative rates when appropriate techniques are utilized [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26664?source=see_link\">",
"     \"Evaluation and treatment of regional lymph nodes in melanoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/5/15450?source=see_link&amp;anchor=H10#H10\">",
"     \"Imaging studies in melanoma\", section on 'Lymph node imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prognostic implications of a positive sentinel lymph node biopsy in patients with a melanoma of the head and neck are similar to those in other areas of the body. This was illustrated by a multicenter series involving 614 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/27\">",
"     27",
"    </a>",
"    ]. Ten percent of patients had melanoma involving at least one lymph node. Multivariate analysis found that a positive sentinel lymph node biopsy was the strongest predictor for subsequent relapse (hazard ratio [HR] 2.81). Other independent prognostic factors associated with recurrent disease included tumor ulceration (HR 2.34) and location of the tumor on the scalp (HR 1.94).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Adjuvant RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant radiation therapy (RT) is used for situations in which the risk of and morbidity from local or regional recurrence may be substantial or if there is a very high risk of locoregional recurrence. However, the role of RT has not been established in clinical trials.",
"   </p>",
"   <p>",
"    We suggest RT for patients with head and neck melanomas if satisfactory margins cannot be achieved without significant morbidity. Some centers recommend routine postoperative RT for those with palpable lymph nodes or the finding of extracapsular extension following wide local excision and neck dissection. Patients are excluded from RT if lesions are close to the eye or central nervous system. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8713?source=see_link&amp;anchor=H9#H9\">",
"     \"Role of radiation therapy in the management of melanoma\", section on 'Regionally metastatic melanoma: irradiation of high-risk nodal basins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Desmoplastic and neurotropic melanomas are more common in the head and neck region than in other areas. These melanomas have a higher risk of local recurrence, making postoperative local radiation an important consideration in their management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8713?source=see_link&amp;anchor=H7#H7\">",
"     \"Role of radiation therapy in the management of melanoma\", section on 'Adjuvant RT of the primary site'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DESMOPLASTIC MELANOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desmoplastic melanoma is a rare variant that comprises less than 5 percent of melanoma cases. Although pure desmoplastic melanomas are often locally aggressive, the prognosis appears to be better than other cutaneous melanomas of the same stage [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/28-35\">",
"     28-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathologic features of desmoplastic melanoma and correlation with other prognostic factors are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22009?source=see_link&amp;anchor=H14#H14\">",
"     \"Pathologic characteristics of melanoma\", section on 'Desmoplastic melanoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical features of pure desmoplastic melanoma and differences from nondesmoplastic melanoma are illustrated by a series of publications from the Sydney Melanoma Unit [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/30,34,36,37\">",
"     30,34,36,37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with desmoplastic melanoma were older (median 61 versus 46 years) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/30,37\">",
"       30,37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Desmoplastic melanomas were more common in the head and neck region, where they comprised 37 percent of cases. The local recurrence rate was 11 percent, which is substantially higher than reported in surgical series for other cutaneous melanomas. A possible contributing factor is inadequate local excision, which, as noted above, is more common with head and neck melanomas [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/30\">",
"       30",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Skin of head and neck'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Desmoplastic melanomas were more frequently amelanotic (44 versus 7 percent with other cutaneous melanomas), which may have contributed to delays in diagnosis and presentation with more advanced disease [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Desmoplastic melanomas were thicker and more deeply invasive, with a median Breslow thickness of 2.5 mm. The Clark's level was III, IV, or V in 95 percent of cases. Only 29 percent of patients had stage I disease, in contrast to 80 percent of cutaneous melanomas overall [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Despite the thickness of these lesions, regional lymph node involvement was uncommon, with only 4 to 7 percent of patients having stage III disease at presentation [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/30,37\">",
"       30,37",
"      </a>",
"      ]. Tumor thickness, older age, and ulceration of the primary tumor were associated with an increased risk of lymph node involvement [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The overall prognosis was better with desmoplastic melanomas compared with patients with other types of melanoma at the same stage (eg, five-year survival rate 90 versus 79 percent for patients with stage I and stage II disease) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pure desmoplastic melanomas had a longer time to recurrence, compared with those where pathology showed a mixed desmoplastic and nondesmoplastic appearance [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some desmoplastic melanomas surround or directly invade nerves. An analysis of a group of 128 patients with this neurotropic variant from the Sydney Melanoma Unit found a median Breslow thickness of 4 mm, and all but one patient had Clark level IV or V primary tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/34\">",
"     34",
"    </a>",
"    ]. The local recurrence rates following surgery alone or surgery plus adjuvant RT were 7 and 6 percent, respectively.",
"   </p>",
"   <p>",
"    The initial management of patients with desmoplastic melanoma is wide local excision. Adjuvant radiation therapy may be indicated to reduce the risk of local recurrence, particularly when there is a question about the adequacy of surgical margins or there is a significant neurotropic component to the tumor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8713?source=see_link&amp;anchor=H7#H7\">",
"     \"Role of radiation therapy in the management of melanoma\", section on 'Adjuvant RT of the primary site'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     UNUSUAL SITES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although melanomas are most frequent in sun-exposed areas of the skin, these tumors may arise at a number of other sites (eg, nail bed, mucosal surfaces, eye). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/59/8122?source=see_link\">",
"     \"Ocular melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cutaneous and noncutaneous melanomas differ in their epidemiology, even though they have a shared cell of origin. Noncutaneous melanomas tend to present at an older age and to be diagnosed at a more advanced stage [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Although both cutaneous and ocular melanomas share a common environmental risk factor (ultraviolet radiation), this may not be the case for all mucosal melanomas [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/38,40\">",
"     38,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Melanomas at these unusual sites generally carry a worse prognosis than those arising in the common cutaneous locations. Early diagnosis is the key to proper treatment and improved survival for patients with these unusual variants.",
"   </p>",
"   <p>",
"    The rarity of these melanomas has precluded large randomized trials upon which to base treatment decision. For tumors at all of these sites, wide local excision when technically feasible offers the best chance for prolonged disease-free survival. Radiation therapy may decrease the incidence of local recurrences in carefully selected patients, although no impact on survival has been demonstrated. Radiation therapy may also be an alternative to control local disease when a complete resection is not feasible.",
"   </p>",
"   <p>",
"    Adjuvant immunotherapy with high-dose interferon alfa is recommended for patients with cutaneous melanoma and resected positive regional lymph nodes. Randomized clinical trials, however, are not available to address the value of adjuvant immunotherapy for patients with acral and mucosal melanoma. This approach might be considered in carefully selected patients who have undergone a potentially curative resection, have no serious coexisting illness, and have the potential for long-term survival excluding their risk of melanoma related mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44711?source=see_link&amp;anchor=H2#H2\">",
"     \"Adjuvant immunotherapy for melanoma\", section on 'Clinical trials'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with systemic metastases originating in an acral or mucosal site are generally treated similarly to those with melanoma arising in the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8328?source=see_link\">",
"     \"Cytotoxic chemotherapy for metastatic melanoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7625?source=see_link\">",
"     \"Interleukin-2 and other immunotherapies for advanced melanoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=see_link\">",
"     \"Molecularly targeted therapy for metastatic melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, there is a higher risk of c-kit mutations in patients with mucosal and to a lesser extent acral lentiginous melanomas. Given the observed efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    and other c-kit inhibitors in patients with c-kit mutant tumors, all patients with stage IV disease from these primary sites should have their tumors tested for c-kit mutations. If mutations are detected, these patients should be considered for enrolment on clinical trials with agents targeting c-Kit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=see_link&amp;anchor=H100473013#H100473013\">",
"     \"Molecularly targeted therapy for metastatic melanoma\", section on 'Kit inhibition'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Acral melanomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acral melanomas, which occur on subungual sites and the palms and soles, are usually lentiginous [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. In one series, 28 percent of these lesions were unpigmented [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These melanomas are often misdiagnosed and associated with significant delays in diagnosis. As a result, tumors in these less visible body areas are often significantly thicker at the time of diagnosis than those occurring in more highly visible areas and are associated with a poorer prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22009?source=see_link\">",
"     \"Pathologic characteristics of melanoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42488?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Subungual",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subungual melanoma arises from the nail matrix and accounts for 0.7 to 3.5 percent of all melanoma cases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. This disorder often presents as a brown or black linear streak in the nail (longitudinal melanonychia), with 70 percent of subungual melanomas occurring on the thumb or great toe (",
"    <a class=\"graphic graphic_picture graphicRef64134 \" href=\"UTD.htm?42/33/43536\">",
"     picture 1",
"    </a>",
"    ). In some cases, pigment also involves periungual skin, a finding assigned the term &ldquo;Hutchinson&rsquo;s sign.&rdquo; Advanced lesions may demonstrate complete destruction of the nail apparatus (",
"    <a class=\"graphic graphic_picture graphicRef75881 graphicRef52821 \" href=\"UTD.htm?13/39/13944\">",
"     picture 2A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In addition to melanoma, longitudinal melanonychia occurs in other conditions, including benign nevi of the nail matrix and the multiple linear streaks that are common in people with dark skin (",
"    <a class=\"graphic graphic_picture graphicRef64603 \" href=\"UTD.htm?27/6/27745\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef73554 \" href=\"UTD.htm?5/31/5627\">",
"     table 4",
"    </a>",
"    ). However, patients with a solitary, widening, irregularly shaped, or irregularly pigmented streak in the nail should undergo biopsy of the nail matrix to evaluate for melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subungual melanomas involving the toes can be managed easily with digital amputation at the metatarsal-phalangeal joint. If the first toe is involved, complete amputation should be avoided when oncologically feasible because of the importance of the toe in balance.",
"   </p>",
"   <p>",
"    Whenever possible, subungual melanomas of the fingers should be resected at the distal interphalangeal joint to preserve function [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/50\">",
"     50",
"    </a>",
"    ]. Melanomas located more proximally on the fingers can often be managed with wide local excision of soft tissue, skin grafts, or local flaps for soft tissue coverage.",
"   </p>",
"   <p>",
"    As with other melanomas, increasing tumor thickness and the presence of ulceration in the tumor are associated with a worse prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/51\">",
"     51",
"    </a>",
"    ]. As an example, in one series of 93 patients with subungual melanomas, the five-year survival rates for patients with stage I or II tumors were 74 and 40 percent, respectively (",
"    <a class=\"graphic graphic_table graphicRef50225 graphicRef74203 \" href=\"UTD.htm?32/8/32910\">",
"     table 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42488?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Plantar/palmar",
"    </span>",
"    &nbsp;&mdash;&nbsp;For melanomas arising on the sole of the foot or the palm of the hand, excisions are almost never closed primarily due to the lack of surplus skin. Skin grafts can be performed, but some weight-bearing areas may require more substantial soft tissue coverage. One approach is to allow the excision wound to granulate before skin grafting, either through dressing changes or continuous vacuum devices. Alternatively, rotation, advancement, or free flaps may be used.",
"   </p>",
"   <p>",
"    The prognosis for patients with plantar melanoma is inferior to that of melanomas on the leg of comparable thickness. This was illustrated by a series of 51 Caucasians with plantar melanoma and 239 controls with stage I melanomas of the leg [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26585/abstract/53\">",
"     53",
"    </a>",
"    ]. The five-year disease-free survival rates were significantly worse for patients with plantar melanomas compared to those with primary leg lesions (82 versus 95 percent for lesions &lt;1.5 mm, 51 versus 71 percent for lesions 1.5 to 3.49 mm, and 0 versus 46 percent for lesion &ge;3.5 mm thick).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Mucosal melanomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucosal melanomas can occur at a variety of sites, including the head and neck, anorectal regional, female genital tract, and urinary tract. The presentation and management of these lesions is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4010?source=see_link\">",
"     \"Mucosal melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SURVEILLANCE AFTER SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The issues surrounding surveillance after initial surgical management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35065?source=see_link&amp;anchor=H7#H7\">",
"     \"Staging work-up and surveillance after treatment of melanoma\", section on 'Surveillance after treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/8/39042?source=see_link\">",
"       \"Patient information: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/6/28772?source=see_link\">",
"       \"Patient information: Melanoma treatment; localized melanoma (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper surgical resection is critical for the initial management of both cutaneous melanomas and melanomas arising in other sites in order to maximize the chances of long-term survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Cutaneous melanoma",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An excisional biopsy with a 1 to 2 mm rim of normal-appearing tissue should be used for lesions suspected to be a melanoma. When an excisional biopsy is not technically feasible, an incisional or punch biopsy can provide a definitive diagnosis. Shave biopsies are to be discouraged when a melanoma is suspected. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Initial biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once a diagnosis of melanoma has been established, surgical excision with an adequate margin of normal tissue is required. The recommended width of surrounding local normal tissue is determined by thickness of the primary tumor. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Wide local excision'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For melanomas &lt;1 mm thick (T1) (",
"      <a class=\"graphic graphic_table graphicRef50225 graphicRef74203 \" href=\"UTD.htm?32/8/32910\">",
"       table 2A-B",
"      </a>",
"      ), our approach is to resect with a 1 cm margin of normal tissue. We recommend that wider margins not be used (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Wider margins have not resulted in an improved survival or a decreased incidence of local recurrence. We recommend that margins &lt;1 cm not be used (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). The efficacy of narrow margins has not been adequately assessed. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Thin melanomas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For melanomas 1 to 2 mm thick (T2) our approach is to resect with a 2 cm margin of normal tissue. We suggest not using wider margins (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). More extensive resection margins have not been shown to improve survival or decrease the frequency of local recurrence. We suggest not using margins &lt;2 cm (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Narrower margins have been associated with an increased frequency of local recurrence in intermediate thickness melanomas. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Intermediate thickness melanomas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For melanomas 2 to 4 mm thick (T3), we recommend resection with a 2 cm margin of normal tissue rather than a wider margin, since more extensive resection margins have not been shown to improve survival or decrease the frequency of local recurrence (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We recommend not using margins less than 2 cm since narrower margins have been associated with an increased frequency of local recurrence in intermediate thickness melanomas (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Intermediate thickness melanomas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For melanomas &gt;4 mm thick (T4), our approach is to use a 2 cm margin of normal tissue. We suggest not using wider resection margins (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). There is no evidence that wider margins decrease the incidence of local recurrence or improve overall survival. We recommend not using resection margins &lt;2 cm (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Narrower margins have been associated with an increased frequency of local recurrence in this setting. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Thick melanomas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For in situ melanomas, we suggest a 0.5 cm margin of normal tissue (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The incidence of local recurrence in this setting is extremely low, and there are no data to support either a wider or narrower excision margin. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'In situ melanomas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with cutaneous melanoma arising in the skin of the head and neck area, the same principles of wide local excision and margins of normal tissue should be applied. If anatomic considerations preclude an adequate resection margin or if the lesion is considered to be at particularly high risk of local recurrence (desmoplastic melanoma), we suggest adjuvant radiation therapy postoperatively (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Wide local excision'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lymphatic mapping and sentinel lymph node biopsy are indicated in the initial management of melanomas with a thickness &ge;1 mm, or high risk features such as ulceration or mitoses",
"      <span class=\"nowrap\">",
"       &ge;1/mm",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      in otherwise healthy patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26664?source=see_link\">",
"       \"Evaluation and treatment of regional lymph nodes in melanoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Melanomas in unusual sites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melanomas arising in subungual or",
"    <span class=\"nowrap\">",
"     plantar/palmar",
"    </span>",
"    sites or on mucous membranes are generally associated with a poorer",
"    <strong>",
"     prognosi",
"    </strong>",
"    s than cutaneous melanomas. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Unusual sites'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients without evidence of regional or disseminated metastases, we recommend wide local excision when technically feasible (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). This approach offers the best chance for prolonged disease-free survival. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Wide local excision'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Unusual sites'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In carefully selected patients, radiation therapy may be an alternative to control local disease when a complete resection is not feasible. Radiation therapy may also decrease the incidence of local recurrences in carefully selected patients, although no impact on survival has been demonstrated. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Unusual sites'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/1\">",
"      NIH Consensus conference. Diagnosis and treatment of early melanoma. JAMA 1992; 268:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/2\">",
"      Cascinelli N. Margin of resection in the management of primary melanoma. Semin Surg Oncol 1998; 14:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/3\">",
"      Veronesi U, Cascinelli N, Adamus J, et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med 1988; 318:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/4\">",
"      Veronesi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg 1991; 126:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/5\">",
"      Cohn-Cedermark G, Rutqvist LE, Andersson R, et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer 2000; 89:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/6\">",
"      Khayat D, Rixe O, Martin G, et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer 2003; 97:1941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/7\">",
"      Gillgren P, Drzewiecki KT, Niin M, et al. 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. Lancet 2011; 378:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/8\">",
"      Balch CM, Urist MM, Karakousis CP, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg 1993; 218:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/9\">",
"      Karakousis CP, Balch CM, Urist MM, et al. Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial. Ann Surg Oncol 1996; 3:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/10\">",
"      Balch CM, Soong S, Ross MI, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 2000; 7:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/11\">",
"      Thomas JM, Newton-Bishop J, A'Hern R, et al. Excision margins in high-risk malignant melanoma. N Engl J Med 2004; 350:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/12\">",
"      Heaton KM, Sussman JJ, Gershenwald JE, et al. Surgical margins and prognostic factors in patients with thick (&gt;4mm) primary melanoma. Ann Surg Oncol 1998; 5:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/13\">",
"      Kunishige JH, Brodland DG, Zitelli JA. Surgical margins for melanoma in situ. J Am Acad Dermatol 2012; 66:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/14\">",
"      Bichakjian CK, Halpern AC, Johnson TM, et al. Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. J Am Acad Dermatol 2011; 65:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/15\">",
"      Grotz TE, Glorioso JM, Pockaj BA, et al. Preservation of the deep muscular fascia and locoregional control in melanoma. Surgery 2013; 153:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/16\">",
"      Temple CL, Arlette JP. Mohs micrographic surgery in the treatment of lentigo maligna and melanoma. J Surg Oncol 2006; 94:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/17\">",
"      Naylor MF, Crowson N, Kuwahara R, et al. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol 2003; 149 Suppl 66:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/18\">",
"      Powell AM, Robson AM, Russell-Jones R, Barlow RJ. Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up. Br J Dermatol 2009; 160:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/19\">",
"      Goldsmith HS. Melanoma: an overview. CA Cancer J Clin 1979; 29:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/20\">",
"      Gibbs P, Robinson WA, Pearlman N, et al. Management of primary cutaneous melanoma of the head and neck: The University of Colorado experience and a review of the literature. J Surg Oncol 2001; 77:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/21\">",
"      Golger A, Young DS, Ghazarian D, Neligan PC. Epidemiological features and prognostic factors of cutaneous head and neck melanoma: a population-based study. Arch Otolaryngol Head Neck Surg 2007; 133:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/22\">",
"      Lentsch EJ, Myers JN. Melanoma of the head and neck: current concepts in diagnosis and management. Laryngoscope 2001; 111:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/23\">",
"      Glat PM, Longaker MT, Jelks EB, et al. Periorbital melanocytic lesions: excision and reconstruction in 40 patients. Plast Reconstr Surg 1998; 102:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/24\">",
"      Hudson DA, Krige JE, Grobbelaar AO, et al. Melanoma of the face: the safety of narrow excision margins. Scand J Plast Reconstr Surg Hand Surg 1998; 32:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/25\">",
"      Zitelli JA, Moy RL, Abell E. The reliability of frozen sections in the evaluation of surgical margins for melanoma. J Am Acad Dermatol 1991; 24:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/26\">",
"      de Rosa N, Lyman GH, Silbermins D, et al. Sentinel node biopsy for head and neck melanoma: a systematic review. Otolaryngol Head Neck Surg 2011; 145:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/27\">",
"      Leong SP, Accortt NA, Essner R, et al. Impact of sentinel node status and other risk factors on the clinical outcome of head and neck melanoma patients. Arch Otolaryngol Head Neck Surg 2006; 132:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/28\">",
"      Pawlik TM, Ross MI, Prieto VG, et al. Assessment of the role of sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma. Cancer 2006; 106:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/29\">",
"      Livestro DP, Muzikansky A, Kaine EM, et al. Biology of desmoplastic melanoma: a case-control comparison with other melanomas. J Clin Oncol 2005; 23:6739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/30\">",
"      Quinn MJ, Crotty KA, Thompson JF, et al. Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients. Cancer 1998; 83:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/31\">",
"      Hawkins WG, Busam KJ, Ben-Porat L, et al. Desmoplastic melanoma: a pathologically and clinically distinct form of cutaneous melanoma. Ann Surg Oncol 2005; 12:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/32\">",
"      Lens MB, Newton-Bishop JA, Boon AP. Desmoplastic malignant melanoma: a systematic review. Br J Dermatol 2005; 152:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/33\">",
"      Posther KE, Selim MA, Mosca PJ, et al. Histopathologic characteristics, recurrence patterns, and survival of 129 patients with desmoplastic melanoma. Ann Surg Oncol 2006; 13:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/34\">",
"      Chen JY, Hruby G, Scolyer RA, et al. Desmoplastic neurotropic melanoma: a clinicopathologic analysis of 128 cases. Cancer 2008; 113:2770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/35\">",
"      Skelton HG, Smith KJ, Laskin WB, et al. Desmoplastic malignant melanoma. J Am Acad Dermatol 1995; 32:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/36\">",
"      Sassen S, Shaw HM, Colman MH, et al. The complex relationships between sentinel node positivity, patient age, and primary tumor desmoplasia: analysis of 2303 melanoma patients treated at a single center. Ann Surg Oncol 2008; 15:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/37\">",
"      Murali R, Shaw HM, Lai K, et al. Prognostic factors in cutaneous desmoplastic melanoma: a study of 252 patients. Cancer 2010; 116:4130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/38\">",
"      McLaughlin CC, Wu XC, Jemal A, et al. Incidence of noncutaneous melanomas in the U.S. Cancer 2005; 103:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/39\">",
"      Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998; 83:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/40\">",
"      Chiu NT, Weinstock MA. Melanoma of oronasal mucosa. Population-based analysis of occurrence and mortality. Arch Otolaryngol Head Neck Surg 1996; 122:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/41\">",
"      Kim KB, Sanguino AM, Hodges C, et al. Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer 2004; 100:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/42\">",
"      Kuchelmeister C, Schaumburg-Lever G, Garbe C. Acral cutaneous melanoma in caucasians: clinical features, histopathology and prognosis in 112 patients. Br J Dermatol 2000; 143:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/43\">",
"      Slingluff CL Jr, Vollmer R, Seigler HF. Acral melanoma: a review of 185 patients with identification of prognostic variables. J Surg Oncol 1990; 45:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/44\">",
"      Phan A, Touzet S, Dalle S, et al. Acral lentiginous melanoma: a clinicoprognostic study of 126 cases. Br J Dermatol 2006; 155:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/45\">",
"      Metzger S, Ellwanger U, Stroebel W, et al. Extent and consequences of physician delay in the diagnosis of acral melanoma. Melanoma Res 1998; 8:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/46\">",
"      Hemo Y, Gutman M, Klausner JM. Anatomic site of primary melanoma is associated with depth of invasion. Arch Surg 1999; 134:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/47\">",
"      Levit EK, Kagen MH, Scher RK, et al. The ABC rule for clinical detection of subungual melanoma. J Am Acad Dermatol 2000; 42:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/48\">",
"      Park KG, Blessing K, Kernohan NM. Surgical aspects of subungual malignant melanomas. The Scottish Melanoma Group. Ann Surg 1992; 216:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/49\">",
"      Haneke E, Baran R. Longitudinal melanonychia. Dermatol Surg 2001; 27:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/50\">",
"      Heaton KM, el-Naggar A, Ensign LG, et al. Surgical management and prognostic factors in patients with subungual melanoma. Ann Surg 1994; 219:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/51\">",
"      Finley RK 3rd, Driscoll DL, Blumenson LE, Karakousis CP. Subungual melanoma: an eighteen-year review. Surgery 1994; 116:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/52\">",
"      O'Leary JA, Berend KR, Johnson JL, et al. Subungual melanoma. A review of 93 cases with identification of prognostic variables. Clin Orthop Relat Res 2000; :206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26585/abstract/53\">",
"      Dwyer PK, Mackie RM, Watt DC, Aitchison TC. Plantar malignant melanoma in a white Caucasian population. Br J Dermatol 1993; 128:115.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7620 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-782CD78CC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_61_26585=[""].join("\n");
var outline_f25_61_26585=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INITIAL BIOPSY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      WIDE LOCAL EXCISION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Thin melanomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Intermediate thickness melanomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Thick melanomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      In situ melanomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21982963\">",
"      Management of muscular fascia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Experimental approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      REGIONAL LYMPH NODES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ADJUVANT IMMUNOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SKIN OF HEAD AND NECK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Surgical management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Regional nodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Adjuvant RT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DESMOPLASTIC MELANOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      UNUSUAL SITES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Acral melanomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Subungual",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Plantar/palmar",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Mucosal melanomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SURVEILLANCE AFTER SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Cutaneous melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Melanomas in unusual sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7620\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7620|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/33/43536\" title=\"picture 1\">",
"      Subungual melanoma - finger",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/31/26098\" title=\"picture 2A\">",
"      Subungual melanoma - advanced",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/43/36531\" title=\"picture 2B\">",
"      Subungual melanoma - advanced on thumb",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/6/27745\" title=\"picture 3\">",
"      Longitudinal melanonychia - thumbs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7620|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/55/3965\" title=\"table 1\">",
"      Rand trials marg width melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/61/8157\" title=\"table 2A\">",
"      Melanoma 7th TNM staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/20/35149\" title=\"table 2B\">",
"      Melanoma 7th TNM stage group",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/10/11435\" title=\"table 3\">",
"      WHO thin melanoma trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/31/5627\" title=\"table 4\">",
"      Causes of longitudinal melanonychia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44711?source=related_link\">",
"      Adjuvant immunotherapy for melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27081?source=related_link\">",
"      Cutaneous melanoma: Management of in transit metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34007?source=related_link\">",
"      Cutaneous melanoma: Management of local recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8328?source=related_link\">",
"      Cytotoxic chemotherapy for metastatic melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26664?source=related_link\">",
"      Evaluation and treatment of regional lymph nodes in melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/5/15450?source=related_link\">",
"      Imaging studies in melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7625?source=related_link\">",
"      Interleukin-2 and other immunotherapies for advanced melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/63/17400?source=related_link\">",
"      Mohs surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=related_link\">",
"      Molecularly targeted therapy for metastatic melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4010?source=related_link\">",
"      Mucosal melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/59/8122?source=related_link\">",
"      Ocular melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22009?source=related_link\">",
"      Pathologic characteristics of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/8/39042?source=related_link\">",
"      Patient information: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/6/28772?source=related_link\">",
"      Patient information: Melanoma treatment; localized melanoma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=related_link\">",
"      Risk factors for the development of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8713?source=related_link\">",
"      Role of radiation therapy in the management of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40264?source=related_link\">",
"      Skin biopsy techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35065?source=related_link\">",
"      Staging work-up and surveillance after treatment of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/8/2183?source=related_link\">",
"      Surgical management of metastatic melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13690?source=related_link\">",
"      Treatment and prognosis of basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42488?source=related_link\">",
"      Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_61_26586="Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder";
var content_f25_61_26586=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/61/26586/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/61/26586/contributors\">",
"     Siamak Daneshmand, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/61/26586/contributors\">",
"     Thomas M Becker, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/61/26586/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/61/26586/contributors\">",
"     Derek Raghavan, MD, PhD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/61/26586/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/61/26586/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/61/26586/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bladder cancer is the most common malignancy involving the urinary system and the ninth most common malignancy worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/1\">",
"     1",
"    </a>",
"    ]. Urothelial (transitional cell) carcinoma is the predominant histologic type in the United States and Western Europe, where it accounts for approximately 90 percent of bladder cancers. In other areas of the world, such as the Middle East, nonurothelial histologies are more frequent, at least in part to the prevalence of schistosomiasis.",
"   </p>",
"   <p>",
"    Studies of urothelial bladder cancer have identified multiple risk factors, the most important of which are cigarette smoking and various occupational exposures. Numerous other factors have also been identified that may play an etiologic role in some cases of urothelial cancer, although interpretation of the evidence is frequently confounded by exposure to tobacco use.",
"   </p>",
"   <p>",
"    The epidemiology and risk factors associated with urothelial cancer of the bladder will be reviewed here. Nonurothelial bladder cancer is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40409?source=see_link\">",
"     \"Nonurothelial bladder cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Incidence and prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2008, there were an estimated 386,000 new cases of bladder cancer worldwide, with bladder cancer causing approximately 150,000 deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/2\">",
"     2",
"    </a>",
"    ]. In the United States, there are estimated to be approximately 73,000 cases and 15,000 deaths each year due to bladder cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/3\">",
"     3",
"    </a>",
"    ]. In developed regions such as North America and Europe, this is predominantly urothelial carcinoma.",
"   </p>",
"   <p>",
"    From 1985 to 2005 the number of bladder cancers diagnosed in the United States increased by over 50 percent, while from 1975 to 1996 the five-year survival rate for those diagnosed with bladder cancer increased from 75 to 81 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Mortality rates in several western European countries have shown similar downward trends over the last two decades, but are still increasing in some eastern European countries [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many bladder cancer patients do not die of their disease but do experience multiple recurrences. As a consequence, there are a relatively large number of people alive with a history of bladder cancer. In middle-aged and elderly men, bladder cancer is the second most prevalent malignancy after prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Geographic distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Geographically, there is a wide variation in the incidence of urothelial cancer of the bladder with western Europe and North America having the highest incidence and eastern Europe and Asian countries having the lowest rates [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/6\">",
"     6",
"    </a>",
"    ]. Even within the United States there are substantial regional differences in the incidence of bladder cancer, with the highest incidence in the Northeast and with Hawaii and Utah having less than one-half the incidence [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/5\">",
"     5",
"    </a>",
"    ]. These differences are only slightly attenuated after controlling for smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Age, sex, and race",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bladder cancer is typically diagnosed in older individuals, with a median age at diagnosis of 69 years in men and 71 in women [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The incidence increases with age from 142 to 296 per 100,000 in men aged 65 to 69 years and 85 and over, respectively, and from 33 to 74 per 100,000 in women in the same age groups. The age of onset is younger in current smokers than in never smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/12\">",
"     12",
"    </a>",
"    ]. Although extremely rare, bladder cancer can be seen in children and young adults, where it usually presents with low-grade, non-invasive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are racial and ethnic variations in bladder cancer incidence. In the United States, white males have the highest risk with roughly twice the incidence seen in African-American and Hispanic men [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/14\">",
"     14",
"    </a>",
"    ]. Postulated explanations for these racial and ethnic differences include variations in acetylator phenotypes among different",
"    <span class=\"nowrap\">",
"     racial/ethnic",
"    </span>",
"    groups and occupational differences among minorities that influence exposure to industrial carcinogens [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Occupational carcinogen exposure'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H32\">",
"     'Detoxification of carcinogens'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition to differences in incidence, sex and race also affect the stage at presentation and prognosis. Although the overall incidence of bladder cancer is lower in women and African-Americans, these groups have more advanced stage tumors at presentation compared to white men [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Environmental exposures account for most cases of bladder cancer. The surface epithelium (urothelium) that lines the mucosal surfaces of the entire urinary tract is exposed to potential carcinogens that are either excreted in the urine or activated from precursors in the urine by hydrolyzing enzymes. This \"field cancerization\" effect is one hypothesis to explain the multifocal occurrence that is a characteristic feature of urothelial carcinomas of both the urinary bladder and the upper urinary tract [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/16-19\">",
"     16-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in the majority of cases, multifocal urothelial carcinomas are monoclonal [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/18,20-22\">",
"     18,20-22",
"    </a>",
"    ]. This supports their presumed origin from a single genetically altered cell, which then spreads through the urothelium via intraluminal seeding or intraepithelial migration. This is referred to as the monoclonality hypothesis.",
"   </p>",
"   <p>",
"    Although the monoclonality hypothesis appears to conflict with field cancerization, both mechanisms are probably operative in urothelial carcinogenesis, as has been shown with squamous carcinogenesis in the oral cavity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=see_link\">",
"     \"Epidemiology and risk factors for head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ENVIRONMENTAL RISK FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Chemical carcinogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemical carcinogenesis is believed to be responsible for much of the burden of bladder cancer, including the increased risk associated with cigarette smoke as well as various industrial exposures. The relationship of bladder cancer to chemical carcinogens was initially suggested by the high incidence of bladder cancer in workers with particular chemical exposures. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Occupational carcinogen exposure'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Subsequent epidemiologic and laboratory studies have identified a large number of chemical compounds thought to be carcinogenic. Most are aromatic amines, such as 2-naphthylamine, benzidine and their precursors or derivatives. Other well-characterized carcinogenic chemicals include 4-aminobiphenyl, 4-nitrobiphenyl, and 2-amino-1-naphthol [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. The long latent period between exposure and the development of TCC, combined with exposures to multiple compounds, has complicated studies attempting to identify specific carcinogens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cigarette smoke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cigarette smoking is the most important factor contributing to the overall incidence of urothelial cancer in western countries. The carcinogenic compounds present in cigarettes that are responsible for bladder cancer have not been definitively identified. There are over 60 known carcinogens and reactive oxygen species present, including 4-aminobiphenyl (4-ABP), polycyclic aromatic hydrocarbons, N-nitroso compounds and unsaturated aldehydes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relationship between smoking and the risk of bladder cancer is illustrated by a prospective analysis in the National Institutes of Health-AARP Diet and Health Study Cohort [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/28\">",
"     28",
"    </a>",
"    ]. This database included over 465,000 individuals followed from 1995 to 2006 in the United States. For current smokers, there was a significant increase in the risk of bladder cancer for both men and women (multivariate adjusted hazard ratios [HRs] 3.89 and 4.65, respectively). Although there was an attenuation of risk in former smokers, the risk remained significantly elevated (HRs 2.14 and 2.52 for men and women, respectively). There was a small, but statistically significant increase in the incidence of bladder cancer among men who smoked a pipe or cigars but not cigarettes (HR 1.29).",
"   </p>",
"   <p>",
"    In this analysis, the population attributable risk was 50 and 52 percent for men and women, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/28\">",
"     28",
"    </a>",
"    ]. Compared to prospective cohort studies from earlier time periods [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/29,30\">",
"     29,30",
"    </a>",
"    ], the percentage of cases attributable to cigarette smoking has remained constant in men despite a decrease the overall incidence of smoking, while the percentage has increased in women, presumably reflecting the increase in cigarette smoking among women [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/28\">",
"     28",
"    </a>",
"    ]. Increases in the content of specific carcinogens such as beta naphthylamine in cigarettes were postulated as contributing to these changes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Smoking cessation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although smoking cessation decreases the risk of bladder cancer, the available data suggest that the risk does not reach background levels even after 20 years or more [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/28,29,31\">",
"     28,29,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a meta-analysis of 11 case-control studies, there was a rapid decrease in risk of bladder cancer for those who quit smoking. The decrease in excess risk was more than 30 percent after one to four years, and over 60 percent 25 years after cessation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/29\">",
"     29",
"    </a>",
"    ]. Even after 25 years, however, the risk of bladder cancer had not reached the level of never smokers. Smoking cessation also appears to decrease the recurrence rate for patients with non-muscle-invasive bladder cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approaches to smoking cessation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/34997?source=see_link\">",
"     \"Patterns of tobacco use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Second hand smoke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to second hand smoke in women appears to be a risk factor for the development of bladder cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of second hand smoke was illustrated by a study from Los Angeles County that included 148 individuals with bladder cancer and 292 controls, all of whom were never smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/34\">",
"     34",
"    </a>",
"    ]. Women who lived with two or more smokers during childhood had a threefold increased risk of bladder cancer compared to those without a childhood exposure to second hand smoke, while women with a domestic partner who smoked for 10 or more years had a twofold increased risk compared to those without such exposure. These associations were not observed in male never smokers.",
"   </p>",
"   <p>",
"    Levels of environmental carcinogens were compared in those with exposure to second hand smoke by directly quantifying 4-aminobiphenyl (4-ABP) hemoglobin adducts, which are established biomarkers of 4-ABP exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/34\">",
"     34",
"    </a>",
"    ]. Mean levels of 4-ABP adducts were highest in those women with current exposure to environmental smoke and lowest in those with no history of exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Occupational carcinogen exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between workplace exposure to various chemical carcinogens and an increased risk of urothelial cancer was first noted over a century ago. Such exposures are thought to account for approximately 10 to 20 percent of bladder cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. For workers with substantial industrial exposure, the risk may be elevated as much as 200-fold compared to matched controls without such chemical carcinogen exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/37\">",
"     37",
"    </a>",
"    ]. The risk of death from bladder cancer appears to be elevated for more than 30 years after cessation of exposure to occupational carcinogens [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occupations that have been linked to an increased risk of bladder cancer include metal workers, painters, rubber industry workers, leather workers, textile and electrical workers, miners, cement workers, transport operators, excavating-machine operators, and jobs that involve manufacture of carpets, paints, plastics, and industrial chemicals [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/23,39,40\">",
"     23,39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bladder cancer also has been associated with exposure to paint components, polycyclic aromatic hydrocarbons (PAHs), and diesel exhausts [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. In a cohort study that included more than 58,000 men in Netherlands, investigators found only \"marginal\" evidence for increased risk of bladder cancer due to diesel exhaust, although this risk was more pronounced in current smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/41\">",
"     41",
"    </a>",
"    ]. In a meta-analysis of 35 studies reviewing occupational exposure to diesel exhaust, the summary relative risk (RR) of developing bladder cancer was 1.13 (95% CI 1-1.27) with a positive dose response relation (RR 1.44 for high diesel exposure) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Firefighters are exposed to a variety of potential chemical carcinogens at the scene of a fire and its aftermath, as well as at the firehouse. Potential carcinogenic compounds include benzene, polyaromatic hydrocarbons, and diesel exhausts, among others. Although some individual studies found a modest increase in the risk of developing bladder cancer among firefighters [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/41,43,44\">",
"     41,43,44",
"    </a>",
"    ], two meta-analyses could not identify clear evidence that employment as a firefighter was associated with an increased risk of bladder cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Carcinogenic compounds have also been identified in hair dyes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/47\">",
"     47",
"    </a>",
"    ]. Numerous epidemiologic studies have investigated the relationship between occupational exposure to hair dye use and the risk of bladder cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/48-52\">",
"     48-52",
"    </a>",
"    ]. As an example, a fivefold increase in risk of bladder cancer was observed in subjects who worked for 10 or more years as hairdressers or barbers in a population based case-control study of 1514 incident cases of bladder cancer in Los Angeles [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/52\">",
"     52",
"    </a>",
"    ]. Changes in hair dye formulations and the widespread implementation of safety measures appear to have decreased this risk [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This increase in risk does not appear to extend to personal users of such hair dyes. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Other factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Drinking water",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Chlorination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chlorination is the most common process by which drinking water is decontaminated for use by the general population. Trihalomethanes (THMs) are formed as a by-product when chlorine or bromine is used to disinfect water for drinking and may have adverse health effects at high concentrations. Many governments now set limits on the maximum level permissible in drinking water.",
"   </p>",
"   <p>",
"    Several epidemiologic studies have investigated a possible relationship between chlorination of drinking water and the risk of bladder cancer. A meta-analysis that included six case-control and two cohort studies with more than 6000 bladder cancer cases and 10,000 controls in total showed that long-term consumption of chlorinated drinking water was associated with an increased risk of bladder cancer in men (odds ratio [OR] 1.4, 95% CI 1.1-1.9) and a nonsignificant increase in women (OR = 1.2, 95% CI 0.7-1.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further evidence supporting this hypothesis comes from a study suggesting that ozonation decreases the concentration of THMs and reduces the risk of bladder cancer associated with the chlorination of drinking water [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Arsenic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple epidemiologic studies have established a link between high concentrations of arsenic in drinking water and the subsequent development of bladder cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. This relationship has been most clearly defined in areas of Chile and Taiwan, where subsequent removal of arsenic from drinking water sources led to a decline in the incidence of bladder cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/56\">",
"     56",
"    </a>",
"    ]. Although the precise mechanism by which arsenic induces bladder cancer is unknown, it probably acts by causing chromosomal alterations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from Taiwan indicate that bladder cancer cases in high arsenic areas are associated with more aggressive disease and a poorer prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/59\">",
"     59",
"    </a>",
"    ]. However, multivariate analysis suggested that the prognosis was similar when corrected for stage and grade.",
"   </p>",
"   <p>",
"    The relationship of arsenic in drinking water to bladder cancer and other malignancies is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8730?source=see_link&amp;anchor=H11#H11\">",
"     \"Arsenic exposure and poisoning\", section on 'Cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Fluid intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increase in total fluid intake may dilute excreted urinary carcinogens and reduce contact time with the urothelium. In the Health Professional Follow-up Study involving almost 48,000 participants over a period of 10 years, multivariate analysis found that total daily fluid intake was inversely associated with the risk of bladder cancer (relative risk [RR] 0.51, 95% CI 0.32-0.80 for daily fluid intake &gt;2.5 L per day compared to &lt;1.3 L per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional evidence supporting a relationship between the extent of urothelial exposure to potential carcinogens and the risk of bladder cancer comes from a case control study of 884 individuals with bladder cancer and 996 controls [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/61\">",
"     61",
"    </a>",
"    ]. An increased frequency of urination, particularly nocturia, was associated with a significantly decreased risk of bladder cancer. Other epidemiologic studies however have not confirmed this association [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Aristolochic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consumption of Chinese herbs that contain aristolochic acid or prescription of aristolochic acid have been associated with an increased incidence of urinary tract infections, including urothelial malignancies of the bladder, ureter, and renal pelvis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6933?source=see_link&amp;anchor=H3#H3\">",
"     \"Nephropathy induced by aristolochic acid (AA) containing herbs\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Chemoprevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recognition that environmental factors are responsible for most cases of lung cancer provides an opportunity to minimize the incidence of bladder cancer by blocking these changes. A variety of approaches are being studied, but none has been shown to effectively decrease the incidence of bladder cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35367?source=see_link\">",
"     \"Chemoprevention of bladder cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MISCELLANEOUS RISK FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Chronic cystitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with recurrent or chronic bladder infections and those who have an ongoing source of bladder inflammation (eg, prolonged indwelling catheters in the setting of spinal cord injury, bladder calculi, gonorrhea, neurogenic bladder, spina bifida) have a higher risk of bladder cancer compared to the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/63-66\">",
"     63-66",
"    </a>",
"    ]. In this setting, there is a substantially higher incidence of nonurothelial cancers, especially squamous cell carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40409?source=see_link\">",
"     \"Nonurothelial bladder cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic urinary tract infections are thought to contribute to bladder carcinogenesis by several mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Repeated chronic irritation can lead to metaplastic changes, then dysplasia, and finally carcinoma.",
"     </li>",
"     <li>",
"      Chronic infection predisposes to obstructive uropathy, bacterial superinfection, and the production of nitrosamines in the acidic urine environment. Nitrosamines are capable of inducing bladder cancer in animal models [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/67,68\">",
"       67,68",
"      </a>",
"      ]. In addition, the bacteria themselves are capable of activating N-nitroso compounds to nitric oxide radicals, which can produce oxidative damage to tissues and DNA.",
"     </li>",
"     <li>",
"      Inflammatory cells, including neutrophils, eosinophils, and macrophages, are also rich sources of reactive oxygen species that are produced by endogenous enzymatic reactions. Local infiltration of these cells into the bladder mucosa provides angiogenic and lymphangiogenic growth factors, cytokines, and proteases, all of which may enhance tumor progression [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/69\">",
"       69",
"      </a>",
"      ]. In addition, the proinflammatory signals that target the elimination of infection in the acute phase subsequently switch their function from the killing of the intruder to tissue healing, thereby providing further growth opportunities for incipient tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Genetic variations in the genes involved in the inflammatory response (eg, single nucleotide polymorphisms in the interleukin-6 gene [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/71\">",
"       71",
"      </a>",
"      ]) may alter their expression and function, potentially affecting the risk of developing bladder cancer in the setting of chronic inflammation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H368026843\">",
"    <span class=\"h2\">",
"     Human papillomavirus infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have suggested that there is a relationship between human papillomavirus (HPV) infection and urothelial bladder cancer. A meta-analysis that included data from 52 studies and 2855 cases of bladder cancer found that the prevalence of HPV was 17 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/72\">",
"     72",
"    </a>",
"    ]. Most of these were associated with high-risk serotypes of HPV, especially HPV 16.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Upper urinary tract cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urothelial cancers of the renal pelvis and ureter are thought to be due to the same etiologic factors as urothelial cancer of the bladder. Thus, it is not surprising that patients with urothelial cancer of the upper urinary tract are at high risk for the subsequent development of urothelial cancer of the urinary bladder as well as contralateral upper urinary tract malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/73,74\">",
"     73,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The magnitude of this effect was illustrated by a series of 82 patients who had complete resection of a urothelial cancer of the renal pelvis or ureter. In this series, urothelial carcinoma of the bladder was subsequently diagnosed in 36 (44 percent) at a median interval of 14 months [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/73\">",
"     73",
"    </a>",
"    ]. The bladder tumors were frequently multifocal (mean 2.1 per patient). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/45/1754?source=see_link\">",
"     \"Malignancies of the renal pelvis and ureter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of various risk factors for bladder recurrence or contralateral upper tract recurrence was illustrated in a series of 223 patients with documented primary upper urinary tract TCC, who had been managed definitively by either complete surgical extirpation or endoscopic resection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/17\">",
"     17",
"    </a>",
"    ]. Recurrent bladder tumors and contralateral upper urinary tract tumors were identified in 31 and 6 percent, respectively. Multiplicity of the initial upper urinary tract tumor was a risk factor for recurrence in the bladder.",
"   </p>",
"   <p>",
"    The high frequency of bladder cancer in patients with urothelial cancer of the upper urinary tract requires that patients who have received definitive therapy for upper urinary tract urothelial cancer undergo close surveillance for primary tumors arising in the bladder as well as the contralateral upper urinary tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Bladder augmentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Augmentation cystoplasty is occasionally used to treat neurogenic bladder, and may also be undertaken if the bladder does not develop to a sufficient size to allow for continence.",
"   </p>",
"   <p>",
"    Patients who undergo a bladder augmentation procedure (including both ileocystoplasty and gastrocystoplasty) appear to be at increased risk for the subsequent development of urothelial cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]. The cumulative risk is estimated to be about 1 percent, with a latent period of less than 20 years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These cancers may arise in the residual bladder urothelium or in the intestinal mucosa of the augmented bladder. Tumors have included urothelial carcinomas, adenocarcinomas, and at least one case of signet cell carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of this increased risk, patients who undergo bladder augmentation procedures require close long-term follow up, including annual cystoscopy beginning 10 years after the bladder augmentation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Iatrogenic",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have shown an increased risk of bladder cancer following pelvic radiation for cervical, ovarian, prostate, and testicular cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/79-84\">",
"     79-84",
"    </a>",
"    ]. However, this relationship has not been observed in all studies and the magnitude of the risk appears to be small [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/85,86\">",
"     85,86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with a history of prior pelvic radiation who do develop urothelial cancer appear to have more advanced tumors with poorer survival than age- and stage-matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/83,87-89\">",
"     83,87-89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    have up to a nine-fold increase in risk of developing bladder cancer, with a latency period that is generally less than 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/90-92\">",
"     90-92",
"    </a>",
"    ]. The risk of bladder cancer in patients receiving cyclophosphamide as an antitumor or immunosuppressive agent is illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 145 patients receiving chronic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      therapy for Wegener's granulomatosis between 1967 and 1993, urothelial cancer of the bladder developed in seven (5 percent) at a median follow-up of 8.5 years [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/91\">",
"       91",
"      </a>",
"      ]. Six of these patients had received cumulative doses exceeding 100 grams with a cumulative duration of cyclophosphamide therapy of 2.7 years; all had episodes of gross hematuria during cyclophosphamide treatment. The duration and extent of cyclophosphamide exposure is far greater than current regimens used in Wegener's granulomatosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link&amp;anchor=H11#H11\">",
"       \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Choice of cyclophosphamide regimen'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A series of more than 6000 two-year survivors of non-Hodgkin lymphoma found a 4.5-fold increased risk of bladder cancer following therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/90\">",
"       90",
"      </a>",
"      ]. The absolute risk depended upon the cumulative dose, and was greatest in those receiving &ge;50 grams of cyclophosphamide [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/90\">",
"       90",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Acrolein, a urinary metabolite of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , is thought to be responsible for both hemorrhagic cystitis as well as bladder cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/93\">",
"     93",
"    </a>",
"    ]. The uroprotectant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"     mesna",
"    </a>",
"    inactivates urinary acrolein and can lower the subsequent risk of hemorrhagic cystitis as well as bladder cancer when used in conjunction with cyclophosphamide [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/94\">",
"     94",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23161?source=see_link&amp;anchor=H10#H10\">",
"     \"Cystitis in patients with cancer\", section on 'Chemotherapy-induced cystitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Analgesics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phenacetin, an analgesic that was widely used until the third quarter of the 20th century, has been linked to an increased risk of TCC, particularly of the renal pelvis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. In the late 1980s, it was recognized as a carcinogen and removed from analgesic compounds in the United States and Europe, and largely replaced by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , which does not increase the bladder cancer risk.",
"   </p>",
"   <p>",
"    A number of studies have documented a decrease in the risk of bladder cancer with regular use of any non-steroidal anti-inflammatory drug [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/97,98\">",
"     97,98",
"    </a>",
"    ], suggesting a protective effect by inhibition of the inflammatory and proliferative response, although others have found no association [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relationship between analgesics and urinary tract malignancy is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1012?source=see_link&amp;anchor=H2#H2\">",
"     \"Urinary tract malignancy and atherosclerotic disease in patients with chronic analgesic abuse\", section on 'Urinary tract malignancy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35335?source=see_link\">",
"     \"Risk factors for and pathogenesis of analgesic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H185945766\">",
"    <span class=\"h3\">",
"     Thiazolidinediones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thiazolidinediones are oral hypoglycemic agents indicated in the treatment of diabetes mellitus. However, long term use appears to be associated with an increased risk of bladder cancer. Whether this represents a class effect or not is unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=see_link&amp;anchor=H12774482#H12774482\">",
"     \"Thiazolidinediones in the treatment of diabetes mellitus\", section on 'Bladder cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A cohort study involving over 59,000 patients identified from the United Kingdom Health Improvement Network demonstrated that compared to the use of sulfonylureas, administration of thiazolidinediones for three to four years, four to five years, or more than five years was associated with a significantly increased risk of bladder cancer (HR 1.15, 1.40, and 1.72, respectively, p-trend=0.006) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/100\">",
"       100",
"      </a>",
"      ]. The increased risk was seen with both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"       pioglitazone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"       rosiglitazone",
"      </a>",
"      , although the overall incidence of bladder cancer was small (0.3 percent among patients taking either agent).",
"     </li>",
"     <li>",
"      A separate 2012 meta-analysis also showed an increased risk of bladder cancer among patients with type 2 diabetes using these agents, although it was only seen with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"       pioglitazone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/101\">",
"       101",
"      </a>",
"      ]. Using data from four randomized trials, there was statistically nonsignificant increased risk among users compared to nonusers, although the overall incidence was small (0.3 versus 0.2%, RR 1.45, 95% CI 0.75-2.83). In addition, a second analysis using data from six cohort studies showed similar findings, although the risk was statistically significant (RR 1.15, 95% CI 1.04-1.26). Of note, the risk of bladder cancer was increased among users of pioglitazone (RR 1.22, 95% CI 1.07-1.39) but not",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"       rosiglitazone",
"      </a>",
"      (RR 0.87, 95% CI 0.34-2.23). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other factors have been postulated as risk factors for bladder cancer. The available evidence for these suggests that these factors either are not associated with causing urothelial cancer or the increased risk is relatively small.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Air pollution &mdash; Air pollution has been postulated to increase the risk of bladder cancer, but studies have given conflicting results. A case-control study from Spain found a 30 percent increased risk of bladder cancer in individuals who lived for more than 40 years in a city with a population &gt;100,000, presumably secondary to emissions of polycyclic aromatic hydrocarbons and diesel from industries near the residence [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/102\">",
"       102",
"      </a>",
"      ]. Other studies have not documented an excess in cancers related to air pollution compared with the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/103\">",
"       103",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Artificial sweeteners &mdash; Large doses of artificial sweeteners, including saccharin and cyclamates induce bladder tumors in rats [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/104\">",
"       104",
"      </a>",
"      ]. The extremely high levels of the compounds, the timing of exposure during the perinatal period, and the lack of reproducibility in primate studies make the relevance of these findings unclear. Multiple case-control studies failed to show a definitive association between saccharin use and bladder cancer risk [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/105,106\">",
"       105,106",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Coffee and tea &mdash; A possible association of coffee and tea consumption with bladder cancer has been studied in numerous epidemiologic investigations. Although caffeine is a potentially mutagenic substance in vitro, studies have been inconsistent and have failed to demonstrate a significant relationship between regular use of coffee and bladder cancer. A meta-analysis that included 34 case-control and three follow-up studies found that coffee consumption increased the risk of urinary tract cancer by approximately 20 percent, while tea consumption was not associated with an increased risk [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/107\">",
"       107",
"      </a>",
"      ]. Although normal coffee consumption is unlikely to be associated with an increased risk of bladder cancer when adjusted for smoking, consumption of large amounts (7 to 10 cups a day) may cause a slightly increased risk [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/108,109\">",
"       108,109",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hair dyes &mdash; Although exposure to chemical carcinogens in hair stylists has been linked to an increased risk of bladder cancer, a 2005 meta-analysis based upon ten studies did not identify an increased risk of bladder cancer in personal users of permanent hair dyes [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/110\">",
"       110",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Occupational carcinogen exposure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     GENETIC EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carcinogenesis within the urothelium is the result of complex interactions involving oncogenes, tumor suppressor genes, and amplification or overexpression of normal genes that encode for growth factors or their receptors. These genetic abnormalities may directly modify the risk of developing bladder cancer or alter its natural history, and such factors may act alone or in concert with extrinsic factors.",
"   </p>",
"   <p>",
"    Alternatively, genetic factors may indirectly affect the risk of bladder cancer by activating carcinogen precursors or by detoxifying carcinogens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Heredity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple epidemiologic studies have looked at the role of genetic factors as risk factors for the development of bladder cancer.",
"   </p>",
"   <p>",
"    In most studies, there has been a small increase in risk in relatives of those with bladder cancer and the risk that appears to be greatest in those whose affected relatives were diagnosed before age 60 years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/111-114\">",
"     111-114",
"    </a>",
"    ]. Although the risk is increased in never smokers, there appears to be an interaction with smoking and a larger increase in risk has been observed in smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The possible relationship of heredity to the development of bladder cancer is illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A case control study from the M D Anderson Cancer Center analyzed 713 bladder cancer patients and 658 controls [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/114\">",
"       114",
"      </a>",
"      ]. Probands who had smoked and who had a positive family history for bladder cancer had a five-fold increased risk of developing bladder cancer. In an associated analysis of families of this cohort, the risk of bladder cancer was increased nearly seven-fold in relatives of patients who had been diagnosed with bladder cancer between ages 40 and 65 years who had a history of smoking, compared to never smokers with a negative family history.",
"     </li>",
"     <li>",
"      In the Swedish Family History Cancer Database from 1958 to 1996, bladder cancer was identified in a parent offspring pair in 65 families [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/112\">",
"       112",
"      </a>",
"      ]. The risk of bladder cancer was elevated in offspring of parents with bladder cancer (standardized incidence ratios [SIRs] 1.35 and 2.29 in sons and daughters respectively). The highest risk was observed in brothers of patients diagnosed before age 45 (SIR 7.3), suggesting an X-linked inheritance.",
"     </li>",
"     <li>",
"      The Spanish Bladder Cancer Study analyzed 1158 patients with newly diagnosed bladder cancer and 1244 controls [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/115\">",
"       115",
"      </a>",
"      ]. There was a nonsignificant increase in the risk of bladder cancer in patients with a positive family history odds ratio (OR 2.34, 95% CI 0.95-5.77). An interaction with extrinsic factors was suggested by the observation that the risk was significantly increased in slow N-acetyltransferase-2 (NAT2) acetylators (OR = 4.76, 95% CI 1.25-18.09), but not rapid or intermediate NAT-2 acetylators (OR 1.17, 95% CI 0.17-7.86) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/115\">",
"       115",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Oncogene and tumor suppressor genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of oncogenes and tumor suppressor genes may play a role in the pathogenesis of bladder cancer.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The p53 tumor suppressor gene expresses a transcription factor that regulates the cell cycle. Over one-half of bladder tumors contain a mutation in the TP53 gene [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/19,116,117\">",
"       19,116,117",
"      </a>",
"      ]. However, there is significant discordance between mutations in the p53 gene and protein alterations detectable by immunohistochemistry. A meta-analysis of 168 studies assessing the prognostic value of p53 overexpression showed a significant, although, weak association with the overall risk of recurrence and mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/118\">",
"       118",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The retinoblastoma gene (RB) encodes a nuclear phosphoprotein that indirectly controls the cell division process. Alterations of the RB gene have been associated with bladder cancer progression [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/116,119-123\">",
"       116,119-123",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other genes that may be involved in the initiation of bladder cancer or its subsequent progression include p16 [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/124-126\">",
"       124-126",
"      </a>",
"      ], matrix metalloproteinases [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/127\">",
"       127",
"      </a>",
"      ], and genes involved in folate metabolism (methylene-tetrahydrofolate reductase and methionine synthase) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/128,129\">",
"       128,129",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Activation of carcinogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most arylamines require in vivo activation to acquire carcinogenic potential, and several metabolic pathways have been identified. Genetic factors that regulate these metabolic steps may serve to modify the risk of developing bladder cancer after occupational or environmental exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/130\">",
"     130",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, a series of P450 cytochrome enzymes (CYP1A2, CYP2D6, and CYP3A4) are involved in N-oxidation to N-hydroxylated metabolites, the initial step of arylamine activation. These enzymes are polymorphic in the general population, meaning that there are variants with slightly different molecular structures and biologic activities. High levels of enzymatic activity may facilitate the formation of activated arylamine metabolites, and predispose to bladder carcinogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/131-134\">",
"     131-134",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Case-control studies suggest that cigarette smokers with a genotype consistent with extensive metabolic activators have a significantly higher incidence of bladder cancer compared to controls [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/135\">",
"     135",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Detoxification of carcinogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differences in the endogenous mechanisms responsible for metabolizing chemical carcinogens may contribute to an altered risk of bladder cancer in response to such agents.",
"   </p>",
"   <p>",
"    Acetylation can detoxify aromatic amines, which are known bladder cancer carcinogens. There are two known N-acetyltransferase genes (NAT1 and NAT2), which are important acetylating enzymes. The NAT2 enzyme is polymorphic and variations in the activity of NAT2 have been implicated as risk factors in the pathogenesis of bladder cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/136\">",
"     136",
"    </a>",
"    ]. Two normal NAT2 alleles allow for rapid acetylation and 'fast' deactivation of carcinogens. In contrast, 'slow' acetylators, who have two altered NAT2 alleles, appear to be at increased risk for bladder cancer when exposed to cigarette smoke or occupational aromatic amines [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/137\">",
"     137",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Cigarette smoke'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H12\">",
"     'Occupational carcinogen exposure'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A meta-analysis of 22 case-control studies found an increased risk of bladder cancer among NAT2 slow acetylators compared to rapid acetylators (relative risk 1.4, 95% CI 1.2-1.6). Using the predominantly male European study population and assuming a 2.5-fold increased risk of bladder cancer from smoking, the authors estimated that the population attributable risk was 35 percent for slow acetylators who had ever smoked and 13 percent for rapid acetylators who had ever smoked.",
"   </p>",
"   <p>",
"    Another enzyme that may detoxify carcinogens in urine is glutathione S transferase M1 (GSTM1) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/138\">",
"     138",
"    </a>",
"    ]. About half of the Caucasians in the United States have a deletion of both GSTM1 alleles with no enzymatic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/139\">",
"     139",
"    </a>",
"    ]. Epidemiologic data suggest that a deficiency of GSTM1 is also associated with an increased bladder cancer risk [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/138,140\">",
"     138,140",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further evidence in support of a role of both NAT2 and GSTM1 come from studies of genetic studies that have identified an increased risk of bladder cancer with polymorphisms in both of these genes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/61/26586/abstract/141\">",
"     141",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urothelial carcinoma of the bladder is the most frequent urinary tract malignancy, accounting for approximately 90 percent of bladder cancers in the United States and Western Europe. Urothelial cancer is about three times more common in men than women and is primarily seen in older individuals. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Epidemiologic studies have identified various chemical carcinogens that are believed to be responsible for most cases of TCC. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Chemical carcinogenesis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cigarette smoke is responsible for approximately one-half of cases of urothelial cancer in both men and women. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Cigarette smoke'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Occupational exposure to various chemical carcinogens is estimated to contribute approximately 20 percent of the bladder cancer burden. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Occupational carcinogen exposure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genetic effects may play a direct role in the initiation and progression of TCC. Genetic factors may also modify the risk associated with exogenous agents, either through the activation or detoxification of potential carcinogens. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Activation of carcinogens'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H32\">",
"       'Detoxification of carcinogens'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/1\">",
"      Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol 2009; 27:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/2\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/3\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/4\">",
"      Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/5\">",
"      Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/6\">",
"      Pelucchi C, Bosetti C, Negri E, et al. Mechanisms of disease: The epidemiology of bladder cancer. Nat Clin Pract Urol 2006; 3:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/7\">",
"      Feldman AR, Kessler L, Myers MH, Naughton MD. The prevalence of cancer. Estimates based on the Connecticut Tumor Registry. N Engl J Med 1986; 315:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/8\">",
"      Vercelli M, Quaglia A, Parodi S, Crosignani P. Cancer prevalence in the elderly. ITAPREVAL Working Group. Tumori 1999; 85:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/9\">",
"      Michaud DS, Clinton SK, Rimm EB, et al. Risk of bladder cancer by geographic region in a U.S. cohort of male health professionals. Epidemiology 2001; 12:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/10\">",
"      Lynch CF, Cohen MB. Urinary system. Cancer 1995; 75:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/11\">",
"      Scosyrev E, Noyes K, Feng C, Messing E. Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer 2009; 115:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/12\">",
"      Hinotsu S, Akaza H, Miki T, et al. Bladder cancer develops 6 years earlier in current smokers: analysis of bladder cancer registry data collected by the cancer registration committee of the Japanese Urological Association. Int J Urol 2009; 16:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/13\">",
"      Linn JF, Sesterhenn I, Mostofi FK, Schoenberg M. The molecular characteristics of bladder cancer in young patients. J Urol 1998; 159:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/14\">",
"      Howe HL, Wu X, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer 2006; 107:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/15\">",
"      Schulz MR, Loomis D. Occupational bladder cancer mortality among racial and ethnic minorities in 21 states. Am J Ind Med 2000; 38:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/16\">",
"      Rabbani F, Perrotti M, Russo P, Herr HW. Upper-tract tumors after an initial diagnosis of bladder cancer: argument for long-term surveillance. J Clin Oncol 2001; 19:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/17\">",
"      Kang CH, Yu TJ, Hsieh HH, et al. The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract. Cancer 2003; 98:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/18\">",
"      Jones TD, Wang M, Eble JN, et al. Molecular evidence supporting field effect in urothelial carcinogenesis. Clin Cancer Res 2005; 11:6512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/19\">",
"      Hartmann A, Schlake G, Zaak D, et al. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res 2002; 62:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/20\">",
"      Hafner C, Knuechel R, Stoehr R, Hartmann A. Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies. Int J Cancer 2002; 101:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/21\">",
"      Sidransky D, Frost P, Von Eschenbach A, et al. Clonal origin bladder cancer. N Engl J Med 1992; 326:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/22\">",
"      Louhelainen J, Wijkstr&ouml;m H, Hemminki K. Allelic losses demonstrate monoclonality of multifocal bladder tumors. Int J Cancer 2000; 87:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/23\">",
"      Kogevinas M, 't Mannetje A, Cordier S, et al. Occupation and bladder cancer among men in Western Europe. Cancer Causes Control 2003; 14:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/24\">",
"      Vineis P, Pirastu R. Aromatic amines and cancer. Cancer Causes Control 1997; 8:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/25\">",
"      Steineck G, Plato N, Norell SE, Hogstedt C. Urothelial cancer and some industry-related chemicals: an evaluation of the epidemiologic literature. Am J Ind Med 1990; 17:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/26\">",
"      Hoffman D, Masuda Y, Wynder EL. Alpha-naphthylamine and beta-naphthylamine in cigarette smoke. Nature 1969; 221:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/27\">",
"      Hecht SS. Cigarette smoking: cancer risks, carcinogens, and mechanisms. Langenbecks Arch Surg 2006; 391:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/28\">",
"      Freedman ND, Silverman DT, Hollenbeck AR, et al. Association between smoking and risk of bladder cancer among men and women. JAMA 2011; 306:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/29\">",
"      Brennan P, Bogillot O, Cordier S, et al. Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. Int J Cancer 2000; 86:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/30\">",
"      Brennan P, Bogillot O, Greiser E, et al. The contribution of cigarette smoking to bladder cancer in women (pooled European data). Cancer Causes Control 2001; 12:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/31\">",
"      Samanic C, Kogevinas M, Dosemeci M, et al. Smoking and bladder cancer in Spain: effects of tobacco type, timing, environmental tobacco smoke, and gender. Cancer Epidemiol Biomarkers Prev 2006; 15:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/32\">",
"      Chen CH, Shun CT, Huang KH, et al. Stopping smoking might reduce tumour recurrence in nonmuscle-invasive bladder cancer. BJU Int 2007; 100:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/33\">",
"      Skipper PL, Tannenbaum SR, Ross RK, Yu MC. Nonsmoking-related arylamine exposure and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 2003; 12:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/34\">",
"      Jiang X, Yuan JM, Skipper PL, et al. Environmental tobacco smoke and bladder cancer risk in never smokers of Los Angeles County. Cancer Res 2007; 67:7540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/35\">",
"      Jung I, Messing E. Molecular mechanisms and pathways in bladder cancer development and progression. Cancer Control 2000; 7:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/36\">",
"      Cole P, Hoover R, Friedell GH. Occupation and cancer of the lower urinary tract. Cancer 1972; 29:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/37\">",
"      CASE RA, HOSKER ME, McDONALD DB, PEARSON JT. Tumours of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry. I. The role of aniline, benzidine, alpha-naphthylamine, and beta-naphthylamine. Br J Ind Med 1954; 11:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/38\">",
"      Pira E, Piolatto G, Negri E, et al. Bladder cancer mortality of workers exposed to aromatic amines: a 58-year follow-up. J Natl Cancer Inst 2010; 102:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/39\">",
"      Gaertner RR, Trpeski L, Johnson KC, Canadian Cancer Registries Epidemiology Research Group. A case-control study of occupational risk factors for bladder cancer in Canada. Cancer Causes Control 2004; 15:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/40\">",
"      Smailyte G, Kurtinaitis J, Andersen A. Mortality and cancer incidence among Lithuanian cement producing workers. Occup Environ Med 2004; 61:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/41\">",
"      Zeegers MP, Swaen GM, Kant I, et al. Occupational risk factors for male bladder cancer: results from a population based case cohort study in the Netherlands. Occup Environ Med 2001; 58:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/42\">",
"      Boffetta P, Dosemeci M, Gridley G, et al. Occupational exposure to diesel engine emissions and risk of cancer in Swedish men and women. Cancer Causes Control 2001; 12:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/43\">",
"      Ma F, Fleming LE, Lee DJ, et al. Mortality in Florida professional firefighters, 1972 to 1999. Am J Ind Med 2005; 47:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/44\">",
"      Youakim S. Risk of cancer among firefighters: a quantitative review of selected malignancies. Arch Environ Occup Health 2006; 61:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/45\">",
"      LeMasters GK, Genaidy AM, Succop P, et al. Cancer risk among firefighters: a review and meta-analysis of 32 studies. J Occup Environ Med 2006; 48:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/46\">",
"      Haas NS, Gochfeld M, Robson MG, Wartenberg D. Latent health effects in firefighters. Int J Occup Environ Health 2003; 9:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/47\">",
"      Ames BN, Kammen HO, Yamasaki E. Hair dyes are mutagenic: identification of a variety of mutagenic ingredients. Proc Natl Acad Sci U S A 1975; 72:2423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/48\">",
"      Henley SJ, Thun MJ. Use of permanent hair dyes and bladder-cancer risk. Int J Cancer 2001; 94:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/49\">",
"      Hartge P, Hoover R, Altman R, et al. Use of hair dyes and risk of bladder cancer. Cancer Res 1982; 42:4784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/50\">",
"      Czene K, Tiikkaja S, Hemminki K. Cancer risks in hairdressers: assessment of carcinogenicity of hair dyes and gels. Int J Cancer 2003; 105:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/51\">",
"      La Vecchia C, Tavani A. Hair dyes and bladder cancer: an update. Eur J Cancer Prev 2001; 10:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/52\">",
"      Gago-Dominguez M, Castelao JE, Yuan JM, et al. Use of permanent hair dyes and bladder-cancer risk. Int J Cancer 2001; 91:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/53\">",
"      Villanueva CM, Fern&aacute;ndez F, Malats N, et al. Meta-analysis of studies on individual consumption of chlorinated drinking water and bladder cancer. J Epidemiol Community Health 2003; 57:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/54\">",
"      Chevrier C, Junod B, Cordier S. Does ozonation of drinking water reduce the risk of bladder cancer? Epidemiology 2004; 15:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/55\">",
"      Marshall G, Ferreccio C, Yuan Y, et al. Fifty-year study of lung and bladder cancer mortality in Chile related to arsenic in drinking water. J Natl Cancer Inst 2007; 99:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/56\">",
"      Tsai SM, Wang TN, Ko YC. Cancer mortality trends in a blackfoot disease endemic community of Taiwan following water source replacement. J Toxicol Environ Health A 1998; 55:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/57\">",
"      Chen CJ, Chuang YC, You SL, et al. A retrospective study on malignant neoplasms of bladder, lung and liver in blackfoot disease endemic area in Taiwan. Br J Cancer 1986; 53:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/58\">",
"      Moore LE, Smith AH, Eng C, et al. Arsenic-related chromosomal alterations in bladder cancer. J Natl Cancer Inst 2002; 94:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/59\">",
"      Chen CH, Chiou HY, Hsueh YM, et al. Clinicopathological characteristics and survival outcome of arsenic related bladder cancer in taiwan. J Urol 2009; 181:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/60\">",
"      Michaud DS, Spiegelman D, Clinton SK, et al. Fluid intake and the risk of bladder cancer in men. N Engl J Med 1999; 340:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/61\">",
"      Silverman DT, Alguacil J, Rothman N, et al. Does increased urination frequency protect against bladder cancer? Int J Cancer 2008; 123:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/62\">",
"      Lai MN, Wang SM, Chen PC, et al. Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Natl Cancer Inst 2010; 102:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/63\">",
"      Bejany DE, Lockhart JL, Rhamy RK. Malignant vesical tumors following spinal cord injury. J Urol 1987; 138:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/64\">",
"      Delnay KM, Stonehill WH, Goldman H, et al. Bladder histological changes associated with chronic indwelling urinary catheter. J Urol 1999; 161:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/65\">",
"      Groah SL, Weitzenkamp DA, Lammertse DP, et al. Excess risk of bladder cancer in spinal cord injury: evidence for an association between indwelling catheter use and bladder cancer. Arch Phys Med Rehabil 2002; 83:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/66\">",
"      Michaud DS, Platz EA, Giovannucci E. Gonorrhoea and male bladder cancer in a prospective study. Br J Cancer 2007; 96:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/67\">",
"      Matanoski GM, Elliott EA. Bladder cancer epidemiology. Epidemiol Rev 1981; 3:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/68\">",
"      Magee PN, Barnes JM. Carcinogenic nitroso compounds. Adv Cancer Res 1967; 10:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/69\">",
"      Schoppmann SF, Birner P, St&ouml;ckl J, et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 2002; 161:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/70\">",
"      Nathan C. Points of control in inflammation. Nature 2002; 420:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/71\">",
"      Leibovici D, Grossman HB, Dinney CP, et al. Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol 2005; 23:5746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/72\">",
"      Li N, Yang L, Zhang Y, et al. Human papillomavirus infection and bladder cancer risk: a meta-analysis. J Infect Dis 2011; 204:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/73\">",
"      Raman JD, Sosa RE, Vaughan ED Jr, Scherr DS. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma. Urology 2007; 69:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/74\">",
"      Matsui Y, Utsunomiya N, Ichioka K, et al. Risk factors for subsequent development of bladder cancer after primary transitional cell carcinoma of the upper urinary tract. Urology 2005; 65:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/75\">",
"      Castellan M, Gosalbez R, Perez-Brayfield M, et al. Tumor in bladder reservoir after gastrocystoplasty. J Urol 2007; 178:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/76\">",
"      Soergel TM, Cain MP, Misseri R, et al. Transitional cell carcinoma of the bladder following augmentation cystoplasty for the neuropathic bladder. J Urol 2004; 172:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/77\">",
"      Shaw J, Lewis MA. Bladder augmentation surgery--what about the malignant risk? Eur J Pediatr Surg 1999; 9 Suppl 1:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/78\">",
"      Baydar DE, Allan RW, Castellan M, et al. Anaplastic signet ring cell carcinoma arising in gastrocystoplasty. Urology 2005; 65:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/79\">",
"      Hoffman M, Roberts WS, Cavanagh D. Second pelvic malignancies following radiation therapy for cervical cancer. Obstet Gynecol Surv 1985; 40:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/80\">",
"      Sella A, Dexeus FH, Chong C, et al. Radiation therapy-associated invasive bladder tumors. Urology 1989; 33:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/81\">",
"      Kleinerman RA, Boice JD Jr, Storm HH, et al. Second primary cancer after treatment for cervical cancer. An international cancer registries study. Cancer 1995; 76:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/82\">",
"      Boorjian S, Cowan JE, Konety BR, et al. Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol 2007; 177:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/83\">",
"      Sandhu JS, Vickers AJ, Bochner B, et al. Clinical characteristics of bladder cancer in patients previously treated with radiation for prostate cancer. BJU Int 2006; 98:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/84\">",
"      Travis LB, Curtis RE, Storm H, et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997; 89:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/85\">",
"      M&uuml;ller AC, Ganswindt U, Bamberg M, Belka C. Risk of second malignancies after prostate irradiation? Strahlenther Onkol 2007; 183:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/86\">",
"      Chrouser K, Leibovich B, Bergstralh E, et al. Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer. J Urol 2005; 174:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/87\">",
"      Bostrom PJ, Soloway MS, Manoharan M, et al. Bladder cancer after radiotherapy for prostate cancer: detailed analysis of pathological features and outcome after radical cystectomy. J Urol 2008; 179:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/88\">",
"      Shah SK, Lui PD, Baldwin DD, Ruckle HC. Urothelial carcinoma after external beam radiation therapy for prostate cancer. J Urol 2006; 175:2063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/89\">",
"      Yee DS, Shariat SF, Lowrance WT, et al. Impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancer. J Urol 2010; 183:1751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/90\">",
"      Travis LB, Curtis RE, Glimelius B, et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 1995; 87:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/91\">",
"      Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996; 124:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/92\">",
"      O'Keane JC. Carcinoma of the urinary bladder after treatment with cyclophosphamide. N Engl J Med 1988; 319:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/93\">",
"      Pedersen-Bjergaard J, Ersb&oslash;ll J, Hansen VL, et al. Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. N Engl J Med 1988; 318:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/94\">",
"      Habs MR, Schm&auml;hl D. Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium 2-mercaptoethane sulfonate (mesna) and disodium 2,2'-dithio-bis-ethane sulfonate (dimesna). Cancer 1983; 51:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/95\">",
"      Piper JM, Tonascia J, Matanoski GM. Heavy phenacetin use and bladder cancer in women aged 20 to 49 years. N Engl J Med 1985; 313:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/96\">",
"      Porp&aacute;czy P, Schramek P. Analgesic nephropathy and phenacetin-induced transitional cell carcinoma - analysis of 300 patients with long-term consumption of phenacetin-containing drugs. Eur Urol 1981; 7:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/97\">",
"      Fortuny J, Kogevinas M, Zens MS, et al. Analgesic and anti-inflammatory drug use and risk of bladder cancer: a population based case control study. BMC Urol 2007; 7:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/98\">",
"      Blumentals WA, Foulis PR, Schwartz SW, Mason TJ. Analgesic therapy and the prevention of bladder cancer. Urol Oncol 2004; 22:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/99\">",
"      Genkinger JM, De Vivo I, Stampfer MJ, et al. Nonsteroidal antiinflammatory drug use and risk of bladder cancer in the health professionals follow-up study. Int J Cancer 2007; 120:2221.",
"     </a>",
"    </li>",
"    <li>",
"     Mamtani R, Haynes K, Bilker WB, et al. Long-term therapy with thiazolidinediones and the risk of bladder cancer: A cohort study. J Clin Oncol 30, 2012 (suppl; abstr 1503).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/101\">",
"      Colmers IN, Bowker SL, Majumdar SR, Johnson JA. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ 2012; 184:E675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/102\">",
"      Casta&ntilde;o-Vinyals G, Cantor KP, Malats N, et al. Air pollution and risk of urinary bladder cancer in a case-control study in Spain. Occup Environ Med 2008; 65:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/103\">",
"      Soll-Johanning H, Bach E. Occupational exposure to air pollution and cancer risk among Danish urban mail carriers. Int Arch Occup Environ Health 2004; 77:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/104\">",
"      Sontag JM. Experimental identification of genitourinary carcinogens. Urol Clin North Am 1980; 7:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/105\">",
"      Armstrong BK. Saccharin/cyclamates: epidemiological evidence. IARC Sci Publ 1985; :129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/106\">",
"      Morrison AS. Advances in the etiology of urothelial cancer. Urol Clin North Am 1984; 11:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/107\">",
"      Zeegers MP, Tan FE, Goldbohm RA, van den Brandt PA. Are coffee and tea consumption associated with urinary tract cancer risk? A systematic review and meta-analysis. Int J Epidemiol 2001; 30:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/108\">",
"      Sala M, Cordier S, Chang-Claude J, et al. Coffee consumption and bladder cancer in nonsmokers: a pooled analysis of case-control studies in European countries. Cancer Causes Control 2000; 11:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/109\">",
"      Zeegers MP, Dorant E, Goldbohm RA, van den Brandt PA. Are coffee, tea, and total fluid consumption associated with bladder cancer risk? Results from the Netherlands Cohort Study. Cancer Causes Control 2001; 12:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/110\">",
"      Takkouche B, Etminan M, Montes-Mart&iacute;nez A. Personal use of hair dyes and risk of cancer: a meta-analysis. JAMA 2005; 293:2516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/111\">",
"      Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 1994; 86:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/112\">",
"      Plna K, Hemminki K. Familial bladder cancer in the National Swedish Family Cancer Database. J Urol 2001; 166:2129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/113\">",
"      Aben KK, Witjes JA, Schoenberg MP, et al. Familial aggregation of urothelial cell carcinoma. Int J Cancer 2002; 98:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/114\">",
"      Lin J, Spitz MR, Dinney CP, et al. Bladder cancer risk as modified by family history and smoking. Cancer 2006; 107:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/115\">",
"      Murta-Nascimento C, Silverman DT, Kogevinas M, et al. Risk of bladder cancer associated with family history of cancer: do low-penetrance polymorphisms account for the increase in risk? Cancer Epidemiol Biomarkers Prev 2007; 16:1595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/116\">",
"      Shariat SF, Tokunaga H, Zhou J, et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 2004; 22:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/117\">",
"      Sidransky D, Von Eschenbach A, Tsai YC, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991; 252:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/118\">",
"      Malats N, Bustos A, Nascimento CM, et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 2005; 6:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/119\">",
"      Cote RJ, Dunn MD, Chatterjee SJ, et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998; 58:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/120\">",
"      Cordon-Cardo C, Wartinger D, Petrylak D, et al. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst 1992; 84:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/121\">",
"      Grossman HB, Liebert M, Antelo M, et al. p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 1998; 4:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/122\">",
"      Lipponen PK, Liukkonen TJ. Reduced expression of retinoblastoma (Rb) gene protein is related to cell proliferation and prognosis in transitional-cell bladder cancer. J Cancer Res Clin Oncol 1995; 121:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/123\">",
"      Quentin T, Henke C, Korabiowska M, et al. Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression. Anticancer Res 2004; 24:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/124\">",
"      Li L, Yang T, Lian X. Effects of exogenous wild-type P16 gene transfection on the expression of cell cycle-related proteins in bladder cancer cell line. Cancer Invest 2005; 23:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/125\">",
"      Benedict WF, Lerner SP, Zhou J, et al. Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer. Oncogene 1999; 18:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/126\">",
"      Friedrich MG, Blind C, Milde-Langosch K, et al. Frequent p16/MTS1 inactivation in early stages of urothelial carcinoma of the bladder is not associated with tumor recurrence. Eur Urol 2001; 40:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/127\">",
"      Kader AK, Shao L, Dinney CP, et al. Matrix metalloproteinase polymorphisms and bladder cancer risk. Cancer Res 2006; 66:11644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/128\">",
"      Lin J, Spitz MR, Wang Y, et al. Polymorphisms of folate metabolic genes and susceptibility to bladder cancer: a case-control study. Carcinogenesis 2004; 25:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/129\">",
"      Papathoma AS, Petraki C, Grigorakis A, et al. Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer. Anticancer Res 2000; 20:2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/130\">",
"      Mommsen S, Aagaard J, Sell A. An epidemiological case-control study of bladder cancer in males from a predominantly rural district. Eur J Cancer Clin Oncol 1982; 18:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/131\">",
"      Branch RA, Chern HD, Adedoyin A, et al. The procarcinogen hypothesis for bladder cancer: activities of individual drug metabolizing enzymes as risk factors. Pharmacogenetics 1995; 5 Spec No:S97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/132\">",
"      Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF. Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci U S A 1989; 86:7696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/133\">",
"      Kaisary A, Smith P, Jaczq E, et al. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res 1987; 47:5488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/134\">",
"      Bryant MS, Vineis P, Skipper PL, Tannenbaum SR. Hemoglobin adducts of aromatic amines: associations with smoking status and type of tobacco. Proc Natl Acad Sci U S A 1988; 85:9788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/135\">",
"      Kaderlik KR, Kadlubar FF. Metabolic polymorphisms and carcinogen-DNA adduct formation in human populations. Pharmacogenetics 1995; 5 Spec No:S108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/136\">",
"      Hein DW. N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene 2006; 25:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/137\">",
"      Okkels H, Sigsgaard T, Wolf H, Autrup H. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Cancer Epidemiol Biomarkers Prev 1997; 6:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/138\">",
"      Bell DA, Taylor JA, Paulson DF, et al. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst 1993; 85:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/139\">",
"      Yu MC, Ross RK, Chan KK, et al. Glutathione S-transferase M1 genotype affects aminobiphenyl-hemoglobin adduct levels in white, black and Asian smokers and nonsmokers. Cancer Epidemiol Biomarkers Prev 1995; 4:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/140\">",
"      Garc&iacute;a-Closas M, Malats N, Silverman D, et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 2005; 366:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/61/26586/abstract/141\">",
"      Dong LM, Potter JD, White E, et al. Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA 2008; 299:2423.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2957 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8BB6C55152-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_61_26586=[""].join("\n");
var outline_f25_61_26586=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Incidence and prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Geographic distribution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Age, sex, and race",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ETIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ENVIRONMENTAL RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Chemical carcinogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cigarette smoke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Second hand smoke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Occupational carcinogen exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Drinking water",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Chlorination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Arsenic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Fluid intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Aristolochic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Chemoprevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MISCELLANEOUS RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Chronic cystitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H368026843\">",
"      Human papillomavirus infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Upper urinary tract cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Bladder augmentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Iatrogenic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Radiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Analgesics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H185945766\">",
"      - Thiazolidinediones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      GENETIC EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Heredity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Oncogene and tumor suppressor genes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Activation of carcinogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Detoxification of carcinogens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8730?source=related_link\">",
"      Arsenic exposure and poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35367?source=related_link\">",
"      Chemoprevention of bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23161?source=related_link\">",
"      Cystitis in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=related_link\">",
"      Epidemiology and risk factors for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=related_link\">",
"      Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/45/1754?source=related_link\">",
"      Malignancies of the renal pelvis and ureter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6933?source=related_link\">",
"      Nephropathy induced by aristolochic acid (AA) containing herbs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40409?source=related_link\">",
"      Nonurothelial bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/34997?source=related_link\">",
"      Patterns of tobacco use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35335?source=related_link\">",
"      Risk factors for and pathogenesis of analgesic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=related_link\">",
"      Thiazolidinediones in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1012?source=related_link\">",
"      Urinary tract malignancy and atherosclerotic disease in patients with chronic analgesic abuse",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_61_26587="Causes of lumbosacral plexopathy";
var content_f25_61_26587=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F52765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F52765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of lumbosacral plexopathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Diabetic amyotrophy (diabetic lumbosacral radiculoplexus neuropathy)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Idiopathic lumbosacral radiculoplexus neuropathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Primary neoplastic invasion/compression",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Metastatic cancer",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Benign neoplasms",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Radiation plexopathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ischemic plexopathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Retroperitoneal hematoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Arterial (pseudo) aneurysm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Trauma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Obstetric (antepartum, intrapartum, postpartum)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vasculitides",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Connective tissue disorders",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sarcoidosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Amyloidosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Infection (eg, human immunodeficiency virus, Epstein-Barr virus, cytomegalovirus, varicella zoster virus, Lyme disease, syphilis)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Abscess (eg, tuberculosis, salmonella)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Heroin injection",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_61_26587=[""].join("\n");
var outline_f25_61_26587=null;
var title_f25_61_26588="Rx crypto mening non-HIV";
var content_f25_61_26588=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F77297&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F77297&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antifungal treatment recommendations for cryptococcal meningoencephalitis in non-human immunodeficiency virus-infected and nontransplant patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Regimen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Duration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Induction therapy",
"       </td>",
"       <td>",
"        AmBd (0.7-1.0 mg/kg per day) plus flucytosine (100 mg/kg per day)",
"       </td>",
"       <td>",
"        &ge;4 weeks*&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AmBd (0.7-1.0 mg/kg per day)&Delta;",
"       </td>",
"       <td>",
"        &ge;6 weeks*&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liposomal AmB (3-4 mg/kg per day) or ABLC (5 mg/kg per day) combined with flucytosine, if possible&loz;",
"       </td>",
"       <td>",
"        &ge;4 weeks*&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AmBd (0.7 mg/kg per day) plus flucytosine (100 mg/kg per day)&sect;",
"       </td>",
"       <td>",
"        2 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consolidation therapy",
"       </td>",
"       <td>",
"        Fluconazole (400-800 mg per day)&yen;",
"       </td>",
"       <td>",
"        8 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maintenance therapy",
"       </td>",
"       <td>",
"        Fluconazole (200 mg per day)&bull;",
"       </td>",
"       <td>",
"        6-12 months",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ABLC: amphotericin B lipid complex; AmB: amphotericin B; AmBd: amphotericin B deoxycholate.",
"     <br>",
"      * Four weeks are reserved for patients with meningitis who have no neurological complications, who have no significant underlying diseases or immunosuppression, and for whom the cerebrospinal fluid culture performed at the end of 2 weeks of treatment does not yield viable yeasts; during the second 2 weeks, lipid formulations of AmB may be substituted for AmBd.",
"      <br>",
"       &bull; Fluconazole is given at 200 mg per day to prevent relapse after induction therapy, and consolidation therapy is recommended.",
"       <br>",
"        &Delta; For flucytosine-intolerant patients.",
"        <br>",
"         &loz; For AmBd-intolerant patients.",
"         <br>",
"          &sect; For patients who have a low risk of therapeutic failure. Low risk is defined as an early diagnosis by history, no uncontrolled underlying condition or severe immunocompromised state, and an excellent clinical response to initial 2-week antifungal combination course.",
"          <br>",
"           &yen; A higher dosage of fluconazole (800 mg per day) is recommended if the 2-week induction regimen was used and if there is normal renal function.",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Perfect, JR, Disnukes, WE, Dromer, F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010; 50:291. Copyright &copy; 2010 University of Chicago Press.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.journals.uchicago.edu/\">",
"      file://www.journals.uchicago.edu/",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_61_26588=[""].join("\n");
var outline_f25_61_26588=null;
var title_f25_61_26589="Rd for multiple myeloma";
var content_f25_61_26589=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F56451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F56451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Lenalidomide (Revlimid) plus dexamethasone (Rd) for multiple myeloma",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: 28 days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Lenalidomide",
"        </strong>",
"        *",
"       </td>",
"       <td>",
"        25 mg by mouth",
"       </td>",
"       <td>",
"        Do not break, chew, or open the capsules.",
"       </td>",
"       <td>",
"        Daily for days 1 through 21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Dexamethasone",
"        </strong>",
"       </td>",
"       <td>",
"        40 mg by mouth, once weekly",
"       </td>",
"       <td>",
"        Take with food (after meals or with food or milk) in the morning.",
"       </td>",
"       <td>",
"        Days 1, 8, 15, and 22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreament considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        LOW or VERY LOW",
"        <sup>",
"         [2]",
"        </sup>",
"        . Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Routine primary prophylaxis with G-CSF is not indicated (rate of febrile neutropenia &lt;20 percent). The use of prophylactic antimicrobials is controversial. Refer to UpToDate topics on \"Treatment of the complications of multiple myeloma\" and \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Antithrombotic prophylaxis:",
"        </strong>",
"        The risk of thrombosis in patients with multiple myeloma treated with the RD regimen is &gt;10 percent",
"        <sup>",
"         [1]",
"        </sup>",
"        . Routine antithrombotic prophylaxis is warranted. Refer to UpToDate topic on \"Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        Patients with renal insufficiency experience more neutropenia with the use of lenalidomide",
"        <sup>",
"         [3]",
"        </sup>",
"        . Dose adjustment is recommended for patients with CrCl &lt;60 mL/min",
"        <sup>",
"         [2]",
"        </sup>",
"        . Suggested initial doses for patients with renal insufficiency are: for patients with CrCl 30 to 60 mL/min, start at 10 mg every 24 hours. For patients with CrCl &lt;30 mL/min not requiring dialysis, start at 15 mg every 48 hours. For patients with CrCl &lt;30 mL/min requiring dialysis, start at 5 mg once daily. On dialysis days, administer the dose following dialysis. At this time, studies have not been conducted in patients with hepatic impairment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess CBC with differential, electrolytes, renal function, liver function, and M protein prior to starting each cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose modifications for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        If platelets are &lt;30,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        or ANC is &lt;1000 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        , hold lenalidomide and follow CBC weekly. Lenalidomide may be resumed at a reduced dose (15 mg daily) once the platelet count rises above 30,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        and the ANC is above 1000 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        <sup>",
"         [2]",
"        </sup>",
"        . If several doses are held, reduce lenalidomide dose to 5 mg less than the previous dose.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Non-hematological toxicity:",
"        </strong>",
"        For grade 3 or 4 nonhematologic toxicity thought to be due to lenalidomide, hold treatment and restart at a reduced dose (5 mg less than previous dose) when toxicity has resolved to less than grade 2",
"        <sup>",
"         [2]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     G-CSF: granulocyte colony-stimulating factors; CrCl: creatinine clearance; CBC: complete blood count; ANC: absolute neutrophil count.",
"     <br/>",
"     * In the United States, the use of lenalidomide is subject to the RevAssist program (",
"     <a href=\"file://www.REVLIMID.com\" target=\"_blank\">",
"      www.REVLIMID.com",
"     </a>",
"     ) developed in an attempt to minimize the potential for pregnancy among patients taking this medication and associated birth defects.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Rajkumar SV, et al. Lancet Oncol 2010; 11:29.",
"      </li>",
"      <li>",
"       Lenalidomide capsule. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on January 6, 2012).",
"      </li>",
"      <li>",
"       Niesvizky R, et al. Br J Haematol 2007; 138:640.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_61_26589=[""].join("\n");
var outline_f25_61_26589=null;
var title_f25_61_26590="Monitoring type1 GD A";
var content_f25_61_26590=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57808%7EPEDS%2F68614&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57808%7EPEDS%2F68614&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Mimimum recommended initial assessment and monitoring recommendations for patients with nonneuronopathic Gaucher disease - part 1*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Initial assessment",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Frequency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Not receiving ERT",
"       </td>",
"       <td class=\"subtitle2\">",
"        Receiving ERT, has not achieved goals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Physical examination",
"       </td>",
"       <td>",
"        Every 6 months",
"       </td>",
"       <td>",
"        Every 6 to 12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Blood tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hemoglobin",
"       </td>",
"       <td>",
"        Every 12 months",
"       </td>",
"       <td>",
"        Every 3 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Platelets",
"       </td>",
"       <td>",
"        Every 12 months",
"       </td>",
"       <td>",
"        Every 3 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chitotriodase, TRAP, ACE, HDL",
"       </td>",
"       <td>",
"        Every 12 months",
"       </td>",
"       <td>",
"        Every 3 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Beta-glucosidase and mutation analysis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Antibody sample",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Not necessary",
"       </td>",
"       <td>",
"        Optional sample after six months of therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum immunoelectrophoresis",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Every 12-24 months in patients &gt;50 years",
"       </td>",
"       <td>",
"        Every 12-24 months in patients &gt;50 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Radiographs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"3\">",
"        Visceral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Spleen volume (MRI or US)",
"       </td>",
"       <td>",
"        Every 12-24 months",
"       </td>",
"       <td>",
"        Every 12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Liver volume (MRI or US)",
"       </td>",
"       <td>",
"        Every 12-24 months",
"       </td>",
"       <td>",
"        Every 12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"3\">",
"        Skeletal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\" colspan=\"3\">",
"        MRI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Spine (sagittal T1-weighted)",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Every 24 months",
"       </td>",
"       <td class=\"sublist_other\">",
"        Every 12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Femora (coronal T1- and T2- weighted)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Every 24 months (T1- and T2-weighted)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Every 12 month (T1 and T2-weighted)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\" colspan=\"3\">",
"        Plain radiographs",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Children: pelvis, long bones, spine",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Every 12-24 months",
"       </td>",
"       <td class=\"sublist_other\">",
"        Every 12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Adult: lateral spine; AP of entire Femora",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Every 12-24 months",
"       </td>",
"       <td class=\"sublist_other\">",
"        Every 12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        DEXA spine and hips",
"       </td>",
"       <td>",
"        Every 12-24 months",
"       </td>",
"       <td>",
"        Every 12 months",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    (This table is continued).",
"    <div class=\"footnotes\">",
"     ERT: enzyme replacement therapy; TRAP: tartrate resistant acid phosphatase; ACE: angiotensin converting enzyme; HDL: high density lipoprotein; MRI: magnetic resonance imaging; US: ultrasonography; DEXA: dual energy X-ray absorptiometry.",
"     <br>",
"      * The entire assessment should be performed at baseline and every 12 to 24 months in patients who are receiving ERT and have achieved therapeutic goals (DEXA should be performed every 24 months in these patients); the entire assessment also should be performed at the time of dosage change or the development of a significant complication.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       To be stored and tested only if clinically indicated.",
"       <br>",
"        &Delta; Only in children.",
"        <br>",
"         <span class=\"lozenge\">",
"          &loz;",
"         </span>",
"         Sites not included here should be evaluated if symptoms develop.",
"         <br>",
"          &sect; Plain radiographs of the spine only when patient is symptomatic (eg, back pain), disease is severe, there is poor growth or kyphosis.",
"          <br>",
"           &yen; Optional in absence of new symptoms or evidence of disease progression.",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Mimimum recommended initial assessment and monitoring recommendations for patients with nonneuronopathic Gaucher disease - part 2*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Initial assessment",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Not receiving ERT",
"       </td>",
"       <td class=\"subtitle2\">",
"        Receiving ERT, has not achieved goals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"3\">",
"        Cardiopulmonary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\" colspan=\"3\">",
"        Children:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Forced vital capacity",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"5\">",
"        Repeat if abnormal at baseline or if symptoms develop",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"5\">",
"        Repeat if abnormal at baseline or if symptoms develop",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Peak expiratory flow rate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        High resolution chest radiograph",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Echochardiography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Electrocardiogram",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\" colspan=\"3\">",
"        Adults (&gt;18 years):",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Electrocardiogram",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        <p>",
"         Every 12-24 months for those with borderline or above normal pulmonary pressures at baseline",
"        </p>",
"        <p>",
"         Consider repeating every 2-3 years if baseline is normal",
"        </p>",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Chest radiograph",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Doppler echocardiogram (right ventricular systolic pressure)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"3\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Pain",
"       </td>",
"       <td>",
"        Every 12 months",
"       </td>",
"       <td>",
"        Every 6-12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Quality of life",
"       </td>",
"       <td>",
"        Every 12 months",
"       </td>",
"       <td>",
"        Every 12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Additional tests",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        White blood count, prothrombin time, activated partial thromboplastin time, iron, iron binding capacity, ferritin, vitamin B12, aspartate aminotransferase, and/or alanine aminotransferase; alkaline phosphatase; calcium, phosphorous, albumin, total protein, total and direct bilirubin; hepatitis profile, serum immunoelectrophoresis.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ERT: enzyme replacement therapy.",
"     <br>",
"      * The entire assessment should be performed every 12 to 24 months in patients who are receiving ERT and have achieved therapeutic goals (DEXA should be performed every 24 months in these patients); the entire assessment also should be performed at the time of dosage change or the development of a significant complication.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Additional tests to be considered and followed appropriately depending upon patient's age and clinical status.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Grabowski GA, Andria G, Baldellou A, et al. Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements. Eur J Pediatr 2004; 163:58.",
"       </li>",
"       <li>",
"        Baldellou A, Andria G, Campbell PE, et al. Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring. Eur J Pediatr 2004; 163:67.",
"       </li>",
"       <li>",
"        Charrow J, Andersson HC, Kaplan P, et al. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J Pediatr 2004; 144:112.",
"       </li>",
"       <li>",
"        Weinreb NJ, Aggio MC, Andersson HC, et al. Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin Hematol 2004; 41:15.",
"       </li>",
"       <li>",
"        Rosenbloom BE, Weinreb NJ, Zimran A, et al. Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood 2005; 105:4569.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_61_26590=[""].join("\n");
var outline_f25_61_26590=null;
var title_f25_61_26591="Gomco on glans";
var content_f25_61_26591=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Foreskin resected Gomco clamp remains on glans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 376px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David G Weismiller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_61_26591=[""].join("\n");
var outline_f25_61_26591=null;
